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Cholesterol is essential for normal neuronal function, but high blood cholesterol is a 
risk factor for Alzheimer’s disease (AD). Astrocytes undertake the bulk of cholesterol 
synthesis in the brain; however, under stress conditions neurons can also synthesise 
cholesterol. Previous work showed that the neuronal DNA damage response is 
associated with lower cognitive function at the earliest stages of AD neuropathology, 
and this is associated with reduced expression of genes for cholesterol biosynthetic 
enzymes. The hypothesis for this study was that cholesterol dysregulation in neurons 
and astrocytes contributes to dementia and to the progression of AD. This study 
sought to determine the changes in expression of cholesterol biosynthetic enzymes 
in neurons and astrocytes with AD progression in post-mortem human tissue and in 
human neuronal and astrocytic monocultures.  
Expression of HMG CoA reductase (HMGCR), the rate-limiting enzyme for 
cholesterol synthesis, and Sterol Regulatory Element Binding-Protein 2 (SREBP2), a 
key transcription factor regulating expression of cholesterol biosynthetic enzymes 
was examined by immunohistochemistry in the temporal cortex (Brodmann area 
21/22) in an ageing population-based sample derived from a sub-cohort (n=99) of 
the Cognitive Function and Ageing Study (CFAS). Expression of HMGCR was 
predominantly associated with cortical pyramidal neurons within the cortex, although 
HMGCR expression was also associated with cells morphologically resembling 
astrocytes and oligodendrocytes in the cortex and white matter border regions of 
some cases. Quantification by determining HMGCR percentage immunoreactivity 
demonstrated population variation in HMGCR expression but no significant 
association with dementia status, AD neuropathology, oxidative DNA damage or 
neuroinflammation. SREBP2 was localised to neurons and astrocytes in temporal 
cortex and white matter regions. 
Further work in post-mortem human tissue determined the expression of four key 
genes (HMGCR, CYP46A1, ABCA1 and SREBP2) involved with cholesterol 
biosynthesis and metabolism; in neuronal and astrocyte cell populations isolated 
from temporal cortex tissue by laser capture microdissection, from a sub-set of cases 
that included all Braak and Braak neurofibrillary tangle stages (n=32). Staging for tau 
pathology correlated with changes in neuronal gene expression of HMGCR, 
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SREBP2 and ABCA1. Cholesterol concentration per mg of tissue was also 
determined in temporal cortex tissue using the Amplex Red cholesterol assay 
(n=63). Variation in tissue cholesterol concentration showed no significant 
association with dementia status, AD neuropathology, oxidative DNA damage or 
neuroinflammation. Furthermore, variation in HMGCR immunoreactivity and 
cholesterol biosynthetic gene expression in enriched samples of neurons and 
astrocytes isolated from temporal cortex did not correlate with temporal cortex 
cholesterol concentration. When tissue cholesterol concentration was categorically 
divided into tertiles and modelled using logistic regression analysis, moderate 
(OR:1.58, 95% CI: 0.39-6.43) and high (OR:1.44, 95% CI: 0.35-5.85) tissue 
cholesterol concentration was associated with dementia. However, the confidence 
intervals around these estimates were wide, indicating a high degree of uncertainty 
around the estimate. 
In vitro work carried out in human neurons (LUHMES) and astrocytes (primary 
human foetal astrocytes) to determine the changes in expression of these genes in 
response to acute and a more chronic oxidative stress via a single and double 
exposure to H2O2. Both in vitro astrocytes and neurons expressed genes involved in 
cholesterol biosynthesis during neuronal proliferation, differentiation and in a post-
mitotic state. Single and double exposure to 50 μM of H2O2 led to oxidative DNA 
damage in neurons and astrocytes, which persisted for 24 hrs and 96 hrs 
respectively. Preliminary data from stress experiments showed that the four key 
genes involved in cholesterol biosynthesis and metabolism (HMGCR, ABCA1, 
SREBP2 and APOE) were expressed in both cell types following a single and double 
exposure to H2O2. However; due to the COVID-19 pandemic, these experiments 
could not be completed.  
In conclusion, this study has demonstrated that neurons possess the machinery to 
carry out de novo cholesterol biosynthesis in vivo and in vitro. Changes in gene 
expression of key regulators of cholesterol biosynthesis and metabolism alter with 
increasing tau pathology. However, these changes do not translate to changes in 
tissue cholesterol levels. This suggests that whilst there may be some dysregulation 
of cholesterol biosynthetic gene expression with increasing tau pathology, brain 
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cholesterol itself is not altered by AD neuropathology and the association of altered 
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HMGCR - β hydroxy-β-methyl glutaryl Co A Reductase 
HPRT1 – Phosphoribosyl transferase 1 
HRP - Horseradish Peroxidase 
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IgG - Immunoglobulin G 
IHC - Immunohistochemistry 
IHD - Ischaemic Heart Disease 
IL-1β - Interleukin-1β 
IL-6 - Interleukin -6 
INSIG-1 - Insulin-Induced Gene 1 
INSIG-2 - Insulin-Induced Gene 2 
IPSCs - induced pluripotent stem cells  
JT - Jonckheere-Terpstra 
KS - Kolmogorov-Smirnov 
KW - Kruskal-Wallis 
LCM - laser capture microdissection 
LDH - Lactate dehydrogenase 
LDL - low density lipoprotein 
LOAD - Late-Onset Alzheimer’s Disease 
LRP1 - Low density lipoprotein receptor-related protein 1 
LUHMES - Lund human mesencephalic cells 
LXR-α - liver X receptor-α 
MAP - Microtubule Associated Protein 
MAP2 – Microtubule Associated Protein 2 
MCI - Mild Cognitive Impairment 
MDA - Malondialdehyde 
mRNA - Messenger Ribonucleic acid 
MST - Minimum Spanning Tree 
MW - Mann-Whitney 
NADPH - Nicotinamide Adenine Dinucleotide Phosphate 
NDRG2 - N-myc downstream regulated gene 2 
NFT - Neurofibrillary Tangles 
NMDA - N-methyl-D-aspartate 
NTC - Non-Template Control 
OR - Odds Ratio 
PBS - Phosphate Buffered Saline 
PBS-T - Phosphate buffered Saline-Tween 
PCR - Polymerase Chain Reaction 
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PET - Positron Emission Tomography 
PHF - Paired Helical Filaments 
pLo - Poly-L-Ornithine hydrobromide 
PMD - Post-mortem delay 
Prx3 - peroxiredoxin-3 
PSEN - Presenilin 
PSP - Progressive Supranuclear Palsy 
qRT-PCR - quantitative real-time PCR 
RGC - Retinal Ganglion Cells 
RIN - RNA Integrity Number  
ROS - Reactive Oxygen Species 
RT - Room Temperature 
SCAP - SREBP Cleavage-Activating Protein 
SDS - Sodium Dodecyl Sulphate 
SEM - standard error of the mean 
SNP - single nucleotide polymorphism 
SREBP - Sterol Regulatory Element-Binding Proteins 
TAE - Tris-acetate-Ethylenediaminetetraacetic acid 
TBS - Tris-buffered Saline 
TCx - Temporal Cortex  
TDP-43 - Transactive Response DNA-Binding Protein 43 
TEMED - Tetramethyl ethylenediamine 
Tet - Tetracycline 
TNF-α - Tumour Necrosis Factor Alpha 
TREM2- Trigger Receptor Expressed on Myeloid Cells 2 
Trx2 - Thioredoxin-2 
TTa - Tetracycline-controlled Trans activator 
WHO - World Health Organisation 
X-XOD - Xanthine Oxidase  







1.0 Introduction to Alzheimer’s disease and cholesterol in the brain 
 
1.1.1 Dementia 
Dementia is a clinical syndrome that is characterised by a significant decline in 
cognition causing an interference with the independence of the individual in everyday 
activities (Gale, Acar and Daffner, 2018).  According to a report published by the 
World Health Organisation (WHO) in April 2016, there are approximately 45.7 million 
people in the world who have dementia (WHO 2016). This shows that dementia is 
becoming an ever-increasing burden on society, especially as the ageing population 
increases. According to the American Psychiatric Association (APA) dementia is 
classified as a major neurocognitive disorder (DSM V) (American Psychological 
Association (APA), 2013).   
The multiple pathological causes for dementia can be categorised into two broad 
categories: non-neurodegenerative and neurodegenerative. Non-neurodegenerative 
causes of dementia include: nutrient deficiency such as vitamin B12, thiamine and 
folic acid; toxic causes such as exposure to lead, arsenic or pesticides; metabolic 
causes such as hypothyroidism, chronic uraemia and hypercortisolism; and vascular 
dementia (Gale, Acar and Daffner, 2018). Vascular dementia accounts for 
approximately one third of all dementias with several causes of which stroke and 
cerebral amyloid angiopathy are major contributors (O’Brien et al., 2003; Gale, Acar 
and Daffner, 2018). Cerebral amyloid angiopathy (CAA) is the accumulation of 
amyloid proteins in cerebral blood vessels causing micro-bleeds and lobar 
haemorrhages (Xiong et al., 2018).   
Neurodegenerative causes of dementia include frontotemporal lobar degeneration 
(also known as frontotemporal dementia (FTD)), dementia with Lewy bodies and 
Alzheimer’s disease (Gale, Acar and Daffner, 2018). FTD is characterised by the 
degeneration of the frontal and temporal lobes resulting in changes in behaviour and 
language and pathologically abnormal accumulations of tau and transactive 
response DNA binding protein 43 (TDP-43) (Finger, 2016). Dementia with Lewy 
bodies is characterised by the accumulation of alpha-synuclein aggregates within the 
brain and is the second most common cause of dementia (Finger, 2016; Gale, Acar 
and Daffner, 2018). Alzheimer’s disease is characterised by the accumulation of 
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neuritic plaques and neurofibrillary tangles and it is the most common cause of 
dementia (Hebert et al., 2013).  
1.1.2 Alzheimer’s Disease 
The first recorded description of the symptoms of Alzheimer’s disease (AD) was 
reported by Alois Alzheimer in 1907, where a 51-year old woman who had been 
admitted into an insane asylum in Munich portrayed a rapid loss of memory, 
disorientation and changes in her behaviour  (Stelzmann, Norman Schnitzlein and 
Reed Murtagh, 1995). Post mortem analysis of her brain using Bielschowsky’s silver 
staining method showed that abnormal neurofibrils were present in the atrophic brain 
alongside minute miliary foci which were deposited in the upper layers of the cortex 
(Stelzmann, Norman Schnitzlein and Reed Murtagh, 1995). These observations 
were later characterised to be neurofibrillary tau tangles (neurofibrils) and β-amyloid 
plaques (Aβ) (minute miliary foci) and are considered the classical hallmarks of the 
disease.  
Since characterisation of the classical pathological hallmarks described by 
Alzheimer, new evidence has elucidated further neuropathologies observed in AD. 
Neuropathological assessment of AD patient brains has shown moderate atrophy in 
association cortex, limbic lobe structures and hippocampus followed by atrophy of 
the gyri within the frontal and temporal cortices (Perl, 2010). This atrophy can lead to 
the enlargement of the lateral ventricles within the frontal and temporal lobes and a 
decrease in brain weight, this atrophy is attributed to white matter loss (Piguet et al., 
2009). These observations are not specific to AD but help in cases where other 
macroscopic changes associated with other neurodegenerative disease are not 
present (Deture and Dickson, 2019).  
A definitive diagnosis of AD is based on microscopic evaluation of post-mortem 
tissue. Alongside the presence of classical AD pathologies, such as senile plaques 
formed from aggregated amyloid peptide and neurofibrillary tangles formed for 
hyperphosphorylation of tau. Other cellular pathologies such CAA, granulovacuolar 
degeneration, Hirano bodies, neuroinflammation, gliosis and synaptic loss are also 
associated with AD (Perl, 2010; Deture and Dickson, 2019). Granulovacuolar 
degeneration are intraneuronal vacuoles found in the cytoplasm of pyramidal 
neurons of the hippocampus. The small vacuoles measure approximately 2-4 μm in 
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diameter and contain a dense basophilic granule (Ball and Lo, 1977). Recent studies 
have shown that the abundance of granulovacuolar bodies correlates to 
neurofibrillary tangle density  suggesting that the presence of these vacuoles may be 
a cellular response to neuronal damage (Hou et al., 2018). Hirano bodies are rod-like 
structures localised to neuronal dendrites within the hippocampus and formed from 
F-actin and actin proteins. The exact role Hirano bodies play in AD pathogenesis is 
unclear however, recent studies suggest an association with impaired synaptic 
response and a reduced spatial working memory (Gibson and Tomlinson, 1977; 
Hirano, 1994; Serrano-Pozo, Frosch, et al., 2011; Furgerson et al., 2014). 
Neuroinflammation is characterised by the activation of microglia and astrocytes in 
response to stress leading to an inflammatory response. In AD, activated microglia 
and reactive astrocytes have been observed around Aβ plaques and neurofibrillary 
tangles (Wake et al., 2009; Serrano-Pozo, Mielke, et al., 2011; Steele and Robinson, 
2012; Heneka et al., 2015). The loss of synapses precedes the loss of neurons and 
this synaptic loss appears to be the strongest correlate of a decline in cognition in 
AD (Terry et al., 1991; Overk and Masliah, 2014). The major contributor to synaptic 
loss has been associated with defects in axonal trafficking as studies suggest that 
hyperphosphorylated tau within dendritic spines in the pre-synaptic terminal disrupts 
synaptic function by inhibiting the trafficking of glutamate receptors or impairing 
synaptic anchoring resulting in impaired synaptic transmission (Hoover et al., 2010).  
1.1.3 Classical AD Pathology 
Aβ is formed from proteolytic cleavage of the amyloid precursor protein (APP). APP 
is a type 1 trans-membrane glycoprotein that is located on chromosome 21. The 
function of APP is not determined but a number of studies suggest that it could be 
involved in cell growth (Dawkins and Small, 2014). APP mRNA has been found to be 
expressed in many cells and is modified post-translationally by cleavage enzymes 
called secretases (α, β, γ). The site of cleavage on the c-terminal of APP and length 
of the final protein depends on which enzyme is used, α-secretase, β-secretase (β-
site APP-cleaving enzyme 1/ BACE) and γ-secretase (encoded by the presenilin 
genes PSEN1 & PSEN2) (Dawkins and Small, 2014).   
There are two main pathways in which APP undergoes proteolytic processing: the 
non-amyloidogenic pathway, which prevents Aβ formation; and the amyloidogenic 
pathway, which generates the Aβ fragment necessary for amyloid plaque formation 
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(Figure 1.1). To generate the Aβ fragment that aggregates in AD, firstly APP is 
cleaved by β-secretase on the extra-cellular portion, which produces ~100kDa 
fragment  called sAPPβ/APPsβ and has been shown to be involved in synaptic 
pruning during development (Nikolaev et al., 2009; Galvão et al., 2019). β-secretase 
cleavage is followed by cleavage in the hydrophobic transmembrane domain by γ-
secretase generating the Aβ peptide which can vary in length between 37-43 amino 
acids long depending on the exact location of cleavage by γ-secretase. Consecutive 
cleavage of APP results in the release of Aβ peptide into the lumen or the extra 
cellular domain (Haass et al., 2012). The action of γ-secretase enzymes generates 
an intracellular fragment known as amyloid precursor protein intracellular domain 
(AICD) which is considered to act as a transcription factor (Müller and Zheng, 2012). 
The Aβ42 fragment is thought to be the most amyloidogenic and is commonly found 
in plaques in AD brains (Herrup, 2015). The non-amyloidogenic pathway is 
characterised by cleavage of APP by α-secretase within the extra-cellular region 
forming the sAPPα/APPsα fragment. Subsequent cleavage by γ-secretase leads to 
the formation of AICD and p3 fragment, a truncated form of the Aβ peptide released 





















Figure 1.1: Cleavage sites of the secretase enzymes for APP. The amyloidogenic 
pathway involves a cleavage by β-secretase followed by cleavage by γ-secretase 
to produce the Aβ peptide (A).  Non-amyloidogenic pathway includes an initial 








1.1.4 Amyloid cascade hypothesis 
The amyloid cascade hypothesis (ACH) has been used to describe the pathogenesis 
of AD (Hardy and Higgins, 1992). This hypothesis is based on the finding that 
mutations in APP, in familial AD, lead to the formation of Aβ in neurons which 
significantly outweighs the clearance of Aβ and leads to accumulation of Aβ within 
the brain (Selkoe, 2000; A. Armstrong, 2014). In the original paper by Hardy & 
Higgins, they suggested that, due to the accumulation of Aβ there is an increase in 
Ca2+ which causes the hyperphosphorylation of tau proteins to create tangles; 
furthermore this increase in intracellular Ca2+ also signals for apoptosis (Hardy & 
Higgins 1992; Selkoe 2000). However, the hypothesis has been updated, missense 
mutations in APP and PSEN1/2 increase Aβ42 production throughout life leading to 
accumulation and oligomerisation within cortices. More recent evidence is 
suggesting that oligomeric forms of Aβ are the more toxic forms and start to 
accumulate before the formation of Aβ plaques (Gyure et al., 2001; Hayden and 
Teplow, 2013; Selkoe and Hardy, 2016; Roher et al., 2017). Oligomeric Aβ has been 
shown to have a neurotoxic effect as studies suggest that Aβ oligomers can directly 
insert into membranes, causing disruption by acting like a pore (Arispe, 2004; Cline 
et al., 2018). Aβ42 oligomers have subtle effects on synaptic efficacy and depostion 
of diffuse plaques occurs, which activate microglial and astrocytic inflammatory 
responses altering neuronal ionic homeostasis. This leads to oxidative damage, 
which changes the activity of kinases and phosphatases forming tau tangles. This 
results in neuronal and synaptic dysfunction resulting in neuronal loss and eventually 
dementia (Selkoe and Hardy, 2016).  
One study found that a mutation in the APP gene was found to be protective of AD 
and prevented a decline in cognition. A single nucleotide polymorphism resulting in a 
substitution of alanine to threonine at position 673, which is adjacent to β-secretase 
cleavage site, lead to a 40% reduction in amyloidogenc peptides in vitro, providing 
further supporting evidence to this hypothesis (Jonsson et al., 2012). Further 
evidence supporting this hypothesis is shown in patients with Down syndrome (DS) 
who have an extra copy of the APP gene as it is found on choromsome 21 (Head et 
al., 2018). In brains from DS patients, Aβ levels are significantly increased compared 
to control brains and further studies have shown that neuropathology accumulates 
between the ages of 30 and 40 years leading to an AD diagnosis by the age of 40 
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years (Wisniewski, Wisniewski and Wen, 1985; Teller et al., 1996). This early onset 
of AD has been attributed to an extra copy of the APP gene and increase levels of  
β-secretase homologue (BACE-2) which is also found on chromosome 21 (Hussain 
et al., 2000; Barbiero et al., 2003).  
1.1.4.1 Amyloid cascade hypothesis - Refutation  
In recent years ACH has undergone a great deal of scrutiny. The main weakness to 
ACH is the fact that there is a big overlap in Aβ plaque burdens between demented 
and non-demented individuals. The burden of plaques is a poor indicator for 
predicting dementia status, studies have shown that the burdens of tangles and 
plaques between demented and non-demented individuals converges at the oldest 
age so that the relationship of pathology to dementia status is attenuated; NFT are a 
better predictor of dementia compared to plaques however, they do not predict all of 
dementia (Matthews et al., 2009b; Savva et al., 2009; Wharton et al., 2011). 
Furthermore, the removal of Aβ plaques does not improve the symptoms of 
dementia (Holmes et al., 2008; Serrano-Pozo et al., 2010; Herrup, 2015). Clinical 
trials in which patients with AD were immunised for Aβ42 showed that amyloid 
plaques were cleared, however this clearance did not prevent the progression of 
cognitive impairment (Holmes et al., 2008). Furthermore, a recent phase 3 clinical 
trials for the Solanezumab (humanised analogue for m266), a monoclonal antibody 
which binds to Aβ, failed to improve cognition and functional ability in mild-to-
moderate AD patients as a result of reduced clearance of aggregated Aβ (Doody et 
al., 2014). Studies in mice showed that the m266 antibody was selective for the 
central domain of soluble Aβ and reduced Aβ burden by improving clearance of Aβ 
from the brain and plasma however, this was not the case in human trials (DeMattos 
et al., 2001; Doody et al., 2014).    
1.1.4.2 Amyloid cascade hypothesis – Anti-amyloid therapeutics 
Other anti-amyloid therapies also do not improve the clincial outcomes in AD 
patieints. For example in phase 3 clinical trials of Bapineuzumab, a monoclonal 
antibody, showed no significant difference between treated and placebo groups in 
cognitive tests scores, indicating that cognition had not improved (Salloway et al., 
2014). Studies using the murine homologue of Bapineuzumab (3D6) show that the 
antibody is targeted to the n-terminus of Aβ protein and can interact with both soluble 
and insoluble forms of Aβ (Zago et al., 2012).  Within the trial both carriers and non 
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carriers of the apolipoprotein E (APOE) ε4 allele were also investigated. They found 
that within APOE ε4 carriers, that were given the drug, there was a decrease in the 
rate of accummulation of amyloid within the brain. However, this was not significant 
compared to the non-carrier group (Salloway et al., 2014).  Aducanumab, another 
anti-amyloid antibody, which binds to both soluble oligomers and insoluble fibrils. 
During phase 1 clinicals trials, they found that aducanumab reduced overall Aβ 
within the brain and also showed improvements in cognitive tests (Sevigny et al., 
2016). However, as this drug approached phase 3 clinical trials, the trial had been 
stopped. The exact reason for terminiating this trial has not yet been published 
however, there is speculation that the drug does not slow down cognitive decline 
(Alzforum). This suggests that targetting Aβ cannot be the only form of treatment but 
rather a combination of treatments might be needed to slow down or halt cognitive 
decline (Selkoe, 2019).      
Other potential therapeutic targets could exploit the inhibition of γ-secretase. Small 
molecules such as semagacestat and avagacestat are used to inhibit the action of 
the enzyme. A phase 3 clinical trial for semagacestat had to be terminated before 
completion as this drug did not improve cognitive decline and caused the patients 
adverse side effects such as weight loss, skin cancers and infections (Doody et al., 
2013). Similarly a more recent phase 2 clinical trial for avagacestat showed that 
progression of dementia was not different compared to the placebo and brain 
atrophy rates were higher particullary in hippocampal regions (Coric et al., 2015).  
One study suggested that the failure of semagacestat in trials could be due to it 
being a non-competitive inhibitor. Tagami et al (2007) found that semagacestat 
caused an increase in intracellular γ-secretase cleavage by-products and Aβ, and 
that it decreased extracellular Aβ levels (Tagami et al., 2017). Other studies found 
that the inhibition of γ-secretase, via avagacestat, leads to the an increase in 
presenilin-1 (PS1) levels, the catalytic subunit of the γ-secretase enzyme (Sogorb-
Esteve et al., 2018). Rats treated with avagacestat for 21 days showed an increase 
in PS1 which increase the activity of γ-secretase and APP processing (Sogorb-
Esteve et al., 2018). 
Another possible avenue that could be explored to remove Aβ aggregates is the use 
of scyllo-inositol, a stereoisomer of inositol which, along with other stereoisomers, 
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prevents the formation of Aβ fibrils (McLaurin et al., 2000). This study also found that 
when primary human neuronal cell cultures were incubated with Aβ and scyllo-
inositol there was an increase in cell survival compared to incubation with Aβ alone. 
The authors suggested that this reduction in toxicity of Aβ could be a result of 
altering the distribution of the fibrils preventing aggregation (McLaurin et al., 2000). 
Phase 2 clinical trials involving the use of scyllo-inositol as a treatment for mild-
moderate AD showed no significant difference in the neuropsychological test scores 
between the placebo and scyllo-inositol groups (Salloway et al., 2011; Ahmed et al., 
2019). 
The lack of successful therapies for the removal of Aβ and having an improvement 
on cognitive function suggests that there may be more factors at work within the 
pathogenesis of AD or that the therapies need to be administered at pre-clinical 
stages of the disease to be effective (Selkoe, 2019).  
1.1.5 Tau pathology  
Tau is a major protein component of the neurofibrillary tangles within AD brains. Tau 
is a microtubule associated protein (MAP) expressed primarily in the axon of 
mammalian neurons (Binder, Frankfurter and Rebhun, 1985). The gene encoding for 
tau (MAPT) is found on chromosome 17 and due to alternative splicing of its mRNA, 
six molecular isoforms of tau exist within the human brain (Figure 1.2) (Iqbal et al., 
2009). Tau has many functions within these cells including: polymerisation and 
stabilisation of microtubules; fast transport of organelles along the microtubules; 
regulating microtubule dynamics at the distal portion of the axon; determining the 
polarity of the neuron during development, migration and morphology of neurons; 
and intracellular mitochondrial transport (Witman et al., 1976; Caceres and Kosik, 








Figure 1.2: Six isoforms of Tau. The N number refers to the number of exons 
expressed within the N-terminus of the isoform. The R number refers to the 
number of microtubule binding repeat domains found within the C-terminus. Not 






















In AD, tau is abnormally hyper-phosphorylated, causing a conformational change 
which then aggregates to form paired helical filaments (PHF) and neurofibrillary  
tangles (NFT) within neurons (Iqbal et al., 2009). The ACH suggests that Aβ and tau 
interact with each other to cause AD like pathology; with Aβ molecular pathology 
being upstream; however, this sequence has not yet been proven and is not fully 
explained within the hypothesis. According to the hypothesis, the formation of Aβ 
leads to the hyper-phosphorylation of tau proteins forming NFT (Boutajangout and 
Wisniewski, 2014).  The formation of NFT or pre-tangles can have a toxic effect upon 
the neurons. The toxicity of tau depends on the isoform that undergoes hyper-
phosphorylation; studies have found that the 4R-tau isoform (2N4R isoform) has a 
cytotoxic effect in rat primary hippocampal neurons. Co-culturing primary rat 
hippocampal neurons with a murine fibroblast cell line, modified to express human 
4R-tau isoform, saw an increase in cell death.  (Klenyaeva et al., 2014; Tatarnikova, 
Orlov and Bobkova, 2015). The biogenesis of NFTs involves tau oligomerisation, a 
toxic intermediate found within the cytosol, this mechanism has been observed to 
occur on the surface of microtubules when tau dissociates from microtubules leading 
to tau aggregation and the formation of NFTs (Makrides et al., 2003; Gendreau and 
Hall, 2013). One study has shown that soluble tau is associated with cognitive 
impairment within post mortem human AD brains and that oligomeric tau can be a 
good predictor of cognitive scores (Koss et al., 2016).  
1.1.5.1 Tauopathies 
Tau pathology and NFT are not just confined to AD, the deposition of tau has also 
been found in other neurodegenerative diseases and are known as tauopathies 
(Kovacs, 2015). Studies have demonstrated that two tau isoforms, 3R and 4R, have 
been commonly associated with tauopathies (Huefner et al., 2013; Medina, 
Hernández and Avila, 2016). One study investigated the isoform specific phenotype 
of the two human tau isoforms 3R and 4R in a Drosophila model (Sealey et al., 
2017). Sealey et al (2017) found that flies expressing the 3R isoform had impaired 
locomotion compared to the 4R isoform. However, the 4R isoform was associated 
with a decrease in learning and memory, increase in oxidative stress and stronger 
neurodegenerative phenotype and compared to 3R. This data suggests that the 
differences in isoform specific phenotype could be attributed to different interactions 
between the isoforms within the brain (Sealey et al., 2017).  
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In adult human brains the ratio of 3R:4R isoform is approximately 1, in tauopathies 
this ratio is altered as certain isoforms are predominantly found within aggregates 
(Andreadis, 2005; Sealey et al., 2017).  Picks Disease is characterised by the 
presence of Pick bodies within the neuronal cytoplasm. Pick bodies are tau filaments 
made from the 3R tau isoform and form straight tubules and twisted filaments 
approximately 15-18 nm and 22-24 nm in diameter, respectively. These Pick bodies 
are localised to granule cells of the dentate gyrus followed by the hippocampus and 
temporal and frontal cortical and subcortical structures (Zhukareva et al., 2002; 
Arima, 2006; Dickson, 2006). Progressive supranuclear palsy (PSP) is another 
tauopathy comprising of NFTs made up from the 4R tau isoform forming filaments 
and straight tubules in tufted astrocytes and oligodendroglial coiled bodies in the 
subthalamic nucleus, basal ganglia and brainstem (Arima, 2006; Dickson, 
Rademakers and Hutton, 2007). Corticobasal degeneration (CBD) is characterised 
by tau positive lesions formed from the 4R tau isoform. These tau lesions are 
localised to cortical and striatal neurons and glia, thread-like lesions are found in 
focal cortical regions and substantia nigra (Dickson et al., 2002). Argyrophilic grain 
disease (AGD) is characterised by the presence of argyrophilic and tau grains 
formed from the 4R tau isoform. These grains are localised pre-tangles and 
oligodendroglial coiled bodies in hippocampal and peri-amygdaloid white matter 
(Kovacs, 2015). Tau pathology has been observed in normal ageing brain and is 
made up from a combination of both 3R and 4R isoforms and has pathological 
overlap with the burdens seen in AD (Kovacs, 2015). A recent study assessed tau 
pathology in cognitively normal patients using positron emission tomography (PET) 
tau radiotracers and found greater retention of tau radiotracer in the entorhinal 
cortex, which was associated with a steeper decline in memory performance. This 
suggests that the early accumulation of pathological tau may influence changes in 
cognitive domains that are affected in AD and  in cognitively normal individuals 
(Ziontz et al., 2019).   
1.1.6 Neuropathological diagnosis of AD 
Neuropathological assessment of patient brains confirms AD diagnosis. Moderate 
atrophy in association cortex, limbic lobe structures and hippocampus followed by 
atrophy of the gyri within the frontal and temporal cortices has been observed in AD 
brains (Perl, 2010). This atrophy can lead to the enlargement of the lateral ventricles 
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and an overall decrease in brain weight (Piguet et al., 2009).  The Consortium to 
Establish a Registry for Alzheimer’s Disease (CERAD) was created to develop a 
standardised and validated measures to asses AD. The measures include clinical, 
behavioural, neuropsychological and neuropathological assessments (Fillenbaum et 
al., 2008). The neuropathological assessment consists of semi-quantitative 
histological analysis of microscopic sections from the neocortex (frontal, parietal, 
temporal and occipital cortices), hippocampus and amygdala. Semi-quantitative 
analysis assessed the frequency of senile plaques and neurofibrillary tangles in 
these brain regions and categorically scored into groups i.e. no pathology, 
mild/neuritic pathology, moderate-severe/diffuse pathology.  In conjunction with 
clinical history, neuropathological assessment using CERAD can help indicate the 
certainty of AD diagnosis (Fillenbaum et al., 2008). 
Thal phase reflects the severity of β-amyloidosis and follows Aβ deposition across 
the brain as AD progresses (Thal et al., 2002). Thal et al (2002) demonstrated the 
sequence of Aβ deposition within the brain and allocated five phases. Aβ depositions 
in phase 1 were localised to neocortical regions such as frontal, parietal, temporal 
and occipital lobes. Phase 2 sees Aβ depositions extend from the neo-cortex to the 
entorhinal and insular cortex. Phase 3 is characterised by Aβ deposits within the 
midbrain regions such the thalamus and hypothalamus. Phases 4 and 5 are 
characterised by Aβ deposits progressing to the brainstem and cerebellum 
respectively (Thal et al., 2002).   
Another method used to determine AD progression is by Braak and Braak staging 
(Braak and Braak, 1991). Braak and Braak staging reflects (relevant to the spectrum 
of ageing and AD) the hierarchy of tau deposition within the brain; this scheme is 
based on the localisation of NFTs within the allo- and isocortex to determine the 
stage of AD. The depositions of NFT have a closer correlation to dementia 
progression than Aβ deposition. Nevertheless, there is still an overlap with NFT 
deposition in demented and non-demented individuals which increases with age 
(Savva et al., 2009). There are six stages in total, progression through the stages 
indicate an increase in NFT deposition.  During stages I and II, NFT are localised to 
the transentorhinal and entorhinal regions; during stages III and IV, NFT spread into 
the limbic structures such as the hippocampus; stages V and VI, NFT spread 
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extends into neocortical regions such as association cortex (V) and primary cortex 
(VI) (Braak and Braak, 1991; Braak et al., 2006).    
1.2.1 Genetics 
AD can be categorised into early onset (EOAD) and late onset (LOAD). EOAD 
accounts for approximately 5-6% of all AD and one in ten patients with EOAD is 
associated with familial AD (FAD) and tends to have mutations in three key genes: 
presenilin 1 (PSEN1), presenilin 2 (PSEN2) and amyloid precursor protein (APP). 
FAD accounts for 0.5% of all AD cases and 50% of FAD cases have a mutation in 
one of the genes mentioned above (Cruts, Theuns and Van Broeckhoven, 2012; Zhu 
et al., 2015; Shea et al., 2016; Mendez, 2019). The average age of onset of familial 
AD is usually around 65 (Wu et al., 2012; Shea et al., 2016). Mutations in these 
genes (Table 1.1) lead to enhanced production of Aβ42 leading to EOAD, although 
they may have other effects. (Shea et al., 2016). 
1.2.2 Genes associated with early onset AD 
PSEN1 is a gene that is found on chromosome 14 and its protein product is involved 
in post translational modification of APP via γ-secretase. Approximately 215 
pathogenic mutations in PSEN1 have been found, the majority of which are 
missense mutations (Cruts, Theuns and Van Broeckhoven, 2012). These mutations 
cause an increase in the levels of Aβ42 compared to Aβ40 leading to the formation 
of Aβ plaques (Giri, Zhang and Lü, 2016). 
PSEN2 is a gene located on chromosome 1 and like PSEN1 it is involved in the post 
translational modification of APP. PSEN2 codes for the main complex of γ-secretase 
hence mutations in PSEN2 affect the activity of γ-secretase leading to an increase in 
the production of Aβ (Giri, Zhang and Lü, 2016). Only 19 pathogenic mutations in 
PSEN2 have so far been found to cause AD, as mutations in PSEN2 are rare (Cruts, 
Theuns and Van Broeckhoven, 2012). Studies have shown that mutations in PSEN2 
have an increased activity of β-secretase due to activation of protein kinases in the 
presence of reactive oxidative species (ROS) (Park et al., 2012). 
APP codes for a transmembrane glycoprotein whose specific function is yet to be 
determined. So far 49 mutations have been found in APP, if these mutations are 
located near the cleavage sites, they tend to have an impact on the size of the 
fragment that is cleaved by the secretase enzymes (Cruts, Theuns and Van 
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Broeckhoven, 2012; Giri, Zhang and Lü, 2016). A rare variant (A637T) has also been 
found to be protective against the development of AD. Here a substitution mutation 
in β-secretase region has been found, this mutation makes cleavage by β-secretase 
less favourable leading to a decrease in Aβ production (Jonsson et al., 2012; 
Maloney et al., 2014). APP is found on chromosome 21, studies in Down syndrome 
patients (trisomy 21) have shown to have an earlier onset of AD pathology compared 
to normal AD individuals (Prasher et al., 1998). This early onset of AD has been 
attributed to an extra copy of the APP gene and increase levels of  β-secretase 
homologue (BACE-2) which is also found on chromosome 21 (Hussain et al., 2000; 
Barbiero et al., 2003). 
1.2.3 Genes associated with late onset AD 
Most LOAD cases are sporadic. They can have a combination of genetic and 
environmental factors however, the genetic component is considered to be a 
stronger risk factor (Barber 2012). The gene apolipoprotein E (APOE) was one of the 
first genetic risk factors that was identified and has shown the strongest and most 
reproducible association with LOAD (Barber 2012; Rosenthal & Kamboh 2014). 
APOE is found on chromosome 19 and has 3 alleles- ε2, ε3 and ε4 - of which ε2 is 
said to be protective of LOAD and ε4 increases the risk of both EOAD and LOAD 
(Corder et al. 1993; Strittmatter et al. 1993; Rosenthal & Kamboh 2014; Karch & 
Goate 2015). APOE codes for a glycoprotein which is 299 amino acid long and is 
involved in cholesterol transport, neuroplasticity and inflammation within the CNS 
(Kim, Basak and Holtzman, 2009; Karch and Goate, 2015). Further studies have 
also shown that APOE interacts with Aβ and is involved in the clearance, 
aggregation and metabolism of Aβ (Kim, Basak and Holtzman, 2009; Karch and 
Goate, 2015).  APOE is mainly expressed in astrocytes and microglia however, 
neurons are also able to express this gene during AD, although at a lower level than 
astrocytes (Metzger et al., 1996; Xu et al., 2006; Kim, Basak and Holtzman, 2009).    
Recent genome sequencing studies discovered mutations in TREM2 can increase 
the risk of developing LOAD (Guerreiro et al., 2013; Jonsson et al., 2013). Trigger 
Receptor Expressed on Myeloid Cells 2 (TREM2) gene is found on chromosome 6 
and encodes a single pass immunoglobulin domain-containing transmembrane 
protein that is expressed in mononuclear phagocytes, such as osteoclasts and 
microglial cells, and is involved in regulation of phagocytosis, promotion of cell 
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survival and inhibition of inflammatory signalling (Colonna, 2003; Replogle et al., 
2015; Colonna and Wang, 2016). One variant of TREM2, R47H, has shown to 
increase the risk of developing AD by 2-3- fold, due to a SNP which substitutes 
arginine to histidine at amino acid 47 (Guerreiro et al., 2013; Jonsson et al., 2013). 
Within microglia, TREM2 is required to increase mechanistic target of rapamycin 
signalling and to boost microglial metabolism (Ulland and Colonna, 2018). Modelling 
TREM2 mutations in AD mice models have shown that microglia fail to accumulate 
around Aβ plaques and there is an increase in neuronal dystrophy in these regions 
compared to plaques covered with microglia. This may suggest that in AD mutations 
in TREM2 leads to the impairment, survival and migration of microglia (Condello et 
al., 2015; Yuan et al., 2016; Ulland et al., 2017; Ulrich et al., 2017).  
1.2.4 GWAS identifies genes involved with cholesterol metabolism in late onset 
AD 
GWAS studies have identified around 20 different genes or loci that are associated 
with LOAD and involved in cholesterol metabolism, these genes include: CLU, 
ABCA7 and SORL1 (Rosenthal and Kamboh, 2014; Giri, Zhang and Lü, 2016). The 
Clusterin gene (CLU) is found on chromosome 8 and codes for the protein clusterin, 
which like apoE is an apolipoprotein that plays an important role in lipid transport. 
The function of CLU has not yet been fully characterised; however, it has been 
hypothesised that clusterin could function as a chaperone protein or a heat-shock 
protein (Michel et al., 1997; Wilson and Easterbrook-Smith, 2000; Jones and 
Jomary, 2002; Giri, Zhang and Lü, 2016). CLU is expressed systemically as well as 
in the brain and that it may be a pro-apoptotic signal in a response to cellular stress 
(Jones and Jomary, 2002). In AD, clusterin levels are increased, and the levels of 
plasma clusterin are linked to the progression of AD (Deming et al., 2016; Giri, 
Zhang and Lü, 2016). Like apoE, clusterin is found in Aβ plaques and interacts with 
it, indicating that the CLU may play a role in classical AD pathology; clusterin 
suppresses the deposition of Aβ and prevents an inflammatory response and it also 
reduces apoptosis and oxidative stress within AD (Deming et al., 2016; Giri, Zhang 





Table 1.1: Genes associated with AD 
 
ABCA7 is located on chromosome 19, this gene is part of the ATP-binding-cassette 
gene family which are involved in the transport of lipids, such as cholesterol, across 
membranes against a concentration gradient (Holton et al., 2013; Giri, Zhang and 
Lü, 2016). ABCA7 mRNA is highly expressed in microglial cells within the 
hippocampus and plays a crucial role in cholesterol homeostasis. However, studies 
also show that ABCA7 regulates phagocytosis and is highly expressed in 
macrophages (Giri, Zhang and Lü, 2016). Within AD there seems to be a loss of 
function mutation in ABCA7 which is associated with AD pathogenesis, currently the 
mechanisms are not fully understood but recent data suggests that mutations in 
ABCA7 may lead to a reduction in clearance of Aβ as a consequence of perturbed 
phagocytosis within macrophages (Steinberg et al., 2015; Giri, Zhang and Lü, 2016).   
Gene 
Early onset (EO) or 
Late onset (LO) 
Chromosome Wild type function Role in AD 
ABCA7 LO 19 Lipid transport 
Perturbed 
phagocytosis leading 
to a reduction in 
clearance of Aβ 
APOE LO 19 Cholesterol transport 
Impaired cholesterol 
transport to neurons 
CLU LO 8 Lipid transport 
Loss of suppression 
of Aβ deposition 
SORL1 LO 11 
Processing and 
trafficking of APP 
Under-expression 
leads to over-
expression of Aβ 




Aβ plaques  
APP EO 21 Unknown 
Forms Aβ plaques 
which are neurotoxic 
PSEN1 EO 14 
Post-translational 
modification of APP 
Increase in the 
formation of Aβ 
plaques 
PSEN2 EO 1 
Post-translational 





SORL1 is located on chromosome 11 and is a member of the Vsp10p domain 
receptor family (Giri, Zhang and Lü, 2016). SORL1 has been shown to interact with 
APP and influence the proteolytic processing and trafficking of APP within the brain 
(Andersen et al., 2005). The mechanisms by which SORL1 participates in the 
pathogenesis of LOAD are yet to be established. Current data suggests that under-
expression of SORL1 leads to over-expression of Aβ and that SORL1 is also 
involved in the processing of APP via endocytic pathways which are crucial 
pathways in the formation of Aβ plaques (Offe et al., 2006; Giri, Zhang and Lü, 
2016).  
1.3.1 Cholesterol biology 
Cholesterol is an organic molecule (Figure 1.3) found within animal cell membranes. 
It is a type of sterol (lipid) molecule and forms the precursor for many steroid 
hormones. A key role of cholesterol is the assembly and function of lipid rafts within 
the cell surface membrane (Simons and Ilonen, 2000). Lipid rafts are areas within 
the phospholipid bilayer of the cell membrane that are primarily made from 
cholesterol and sphingolipids. They are involved in the sub-compartmentalisation of 
the plasma membrane and help determine the cellular polarity. Lipid rafts can also 
contain glycoproteins and glycolipids which aid in cellular signalling pathways 
(Simons and Ilonen, 2000; Simons and Sampaio, 2011). They play a role in post-
Golgi trafficking and endocytosis, as the lipid raft will form part of the vesicle during 
trafficking and endocytosis (Simons and Ikonen, 1997; Simons and Sampaio, 2011). 
Together cholesterol and lipid rafts play a role in the distribution of proteins across 
the cell and organelles, as well as signalling cascades and activating immune 






























Figure 1.3: Molecular cholesterol: This diagram shows the molecular structure of 
cholesterol. Dark wedges represent bonds out of the page and dashed wedges 
represent bonds into the page Not all Hydrogen molecules are shown. Not drawn 
to scale  
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1.3.2 Cholesterol in the brain 
The brain is a cholesterol rich organ; approximately 23% of the total cholesterol 
within the body is found within the brain (Dietschy, 2009; Vitali, Wellington and 
Calabresi, 2014). From this 23%, approximately 70-80% of the cholesterol is used in 
myelination of axons by oligodendrocytes (Dietschy, 2009; Hayashi, 2011; Vitali, 
Wellington and Calabresi, 2014). Myelin is made primarily from plasma membrane 
enriched with cholesterol and without myelination all major brain functions would be 
considerably slower causing a negative effect on survival (Snaidero and Simons, 
2014).  
Cholesterol is an essential component in dendrite and synapse formation,  as well as 
axonal guidance (Zhang and Liu, 2015). Cholesterol derived from glial cells plays a 
crucial role in synaptogenesis. A study in postnatal rat retinal ganglion cells (RGC) 
found that cholesterol is required for dendrite differentiation, which directly promotes 
presynaptic differentiation. When RGC were cultured in glial cultured media or with 
cholesterol there was an increase in MAP2 positive dendrites compared to controls, 
showing the importance of both cholesterol and the neuronal-glia interaction in 
synaptogenesis (Goritz, Mauch and Pfrieger, 2005; Zhang and Liu, 2015). Depletion 
of cholesterol within neurons leads to: impairment of exocytosis of synaptic vesicles; 
impairment of neuronal activity and neurotransmission; and the degeneration of 
dendritic spines (Zhang and Liu, 2015).  
Unlike other organs within the body, the brain cannot absorb cholesterol from the 
blood due to the blood brain barrier (BBB); so, the brain carries out de novo 
cholesterol biosynthesis to meet its cholesterol demand. Astrocytes and other glial 
cells undertake the bulk of cholesterol synthesis (Björkhem, Meaney and Fogelman, 
2004; Zhang and Liu, 2015). Cholesterol synthesis within the brain occurs via the 












Figure 1.4: Cholesterol Biosynthesis Pathway: This diagram shows a brief 
summary of the cholesterol synthesis pathway. Condensation of Acetyl Co A 
into Mevalonate is known as the mevalonate pathway. Post-squalene 
cholesterol production can occur via two pathways: Kandutsch-Russell and 
Bloch pathway.    
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1.3.3 Cholesterol biosynthesis 
Cholesterol biosynthesis is a complicated pathway and takes place within the 
peroxisome and the endoplasmic reticulum (ER) of a cell. The pathway begins with 
the condensation of acetyl Co A into mevalonate. During condensation, β hydroxy-β-
methyl glutaryl Co A (HMG-CoA) is produced, with the action of HMG CoA reductase 
(HMGCR) enzyme HMG-CoA is converted into mevalonate. This conversion is the 
rate-limiting step for the cholesterol biosynthesis pathway. Mevalonate is then 
converted into squalene in the ER via a series of condensation reactions. Squalene 
is subsequently converted into cholesterol; this can occur via two biochemical routes, 
the Bloch or Kandutsch-Russell pathways (Mazein et al., 2013). Both pathways have 
similar catalytic steps and products. They are distinguished by the penultimate 
reaction: in the Bloch pathway, cholesterol is produced by the reduction of 
desmosterol, whereas in the Kandutsch-Russell pathway cholesterol is preceded by 
7-dehydrocholesterol. Studies have shown that during cholesterol synthesis within 
the brain, a hybrid of both of the pathways are used, where cholesterol biosynthesis 
after lansosterol occurs according to the Bloch pathway and then after a certain 
number of steps switches to the Kandutsch-Russell pathway (Mitsche et al., 2015). 
Astrocytes have been shown to undertake the bulk of cholesterol biosynthesis for 
post-mitotic neurons.  (Pfrieger, 2003). The expression of APOE within astrocytes 
indicates that cholesterol transport to neurons is via apolipoproteins (Pfrieger and 
Ungerer, 2011). The literature suggests that cholesterol transport to the neurons 
could be a similar mechanism to the one found in hepatocytes i.e. assembly of a 
core particle in the ER which is then transported to the Golgi for further modification 
before secretion (Vance and Vance, 1990; Pfrieger and Ungerer, 2011). Neurons 
possess receptors for apoE (LRP1) suggesting that transport via cholesterol is by 
apoE and disruption to the apoE system could lead to an imbalance in cholesterol 
homeostasis within the neurons (Pfrieger and Ungerer, 2011; van den Kommer et 
al., 2012). A study by Clement et al (2009) found that exposure to oxidative stress 
causes an increase in the expression of HMGCR in neuronal cells; showing that 




1.3.4 Cholesterol homeostasis 
To maintain cholesterol homeostasis, cholesterol can be metabolised into the 
oxysterol 24-hydroxycholesterol (24-OHC). This conversion is catalysed by the 
enzyme cholesterol 24-hydroxylase which is encoded by CYP46A1 (Hughes et al., 
2013; Zhang and Liu, 2015). Compared to cholesterol, 24-OHC is more lipophilic and 
can easily pass through the BBB by simple diffusion making it an ideal molecule to 
measure cholesterol homeostasis within the brain via a simple blood test (Hughes et 
al., 2013). Studies have shown that high concentrations of 24-OHC (25-50μM) 
increases the production of free radicals within the brain, which leads to oxidative 
stress (Kölsch et al., 2001a; Gamba et al., 2015). 
Cholesterol homeostasis can also be achieved by regulating cholesterol biosynthesis 
in the ER by regulating SREBPs (sterol regulatory element-binding proteins). 
SREBPs are membrane bound proteins which cycle between the ER or Golgi body 
to the nucleus to regulate transcription of the genes involved in cholesterol 
biosynthesis (Simons and Ilonen, 2000; Goldstein, DeBose-Boyd and Brown, 2006). 
The cycling of SREBP is dependent on SCAP (SREBP cleavage-activating protein) 
which cleaves SREBPs twice allowing translocation from the Golgi to the nucleus.  
When cholesterol levels are normal, SREBP2 is found within the ER membrane and 
is bound to SCAP (Goldstein, DeBose-Boyd and Brown, 2006). SCAP is an ER 
membrane embedded protein which is involved in activating SREBP2 by proteolytic 
cleavage and chaperones SREBP2 from the ER to the Golgi (Sakai et al., 1997). 
SCAP consists of 8 membrane spanning domains which also contains a sterol 
sensing domain, the C-terminus contains a WD-repeat domain allowing binding of 
SCAP to SREBP2 (X. Hua et al., 1995; Brown and Goldstein, 1997). 
When cholesterol levels are low, translocation of the SREBP2/SCAP complex to the 
Golgi occurs. Within the Golgi, proteolytic cleavage activity of SREBP2 by SCAP 
releases the N-terminus of SREBP2 and translocate to the nucleus which increases 
the transcription of genes, such as HMGCR, which in turn leads to an increase in 
cholesterol synthesis (Sakai et al., 1996; Simons and Ilonen, 2000; Goldstein, 
DeBose-Boyd and Brown, 2006). When an increase in cellular cholesterol levels is 
detected by SCAP, translocation of the SREBP2/SCAP to the Golgi is inhibited 
preventing cleavage of SREBP2 (Sun et al., 2005). In addition, at high cellular 
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cholesterol levels the binding of HMGCR to INSIG-1 (Insulin-Induced Gene 1) and 
INSIG-2  (Insulin-Induced Gene 2) marks HMGCR for ubiquitination and degradation 
leading to the rapid suppression of cholesterol synthesis within the brain (Goldstein, 
DeBose-Boyd and Brown, 2006; DeBose-Boyd, 2008; Dietschy, 2009).  
Maintaining cholesterol homeostasis within the brain is crucial as studies in animals 
and cells suggest a link between excess brain cholesterol and an increase in amyloid 
production (Hughes et al., 2013). Hypercholesterolemia increases the chances of 
cleavage by γ-secretase of the C99 terminal of APP to release the Aβ polypeptide; 
however, the exact mechanisms by which Aβ production is affected by cholesterol 
still remains unknown (Fassbender et al., 2002). Other studies have shown that APP 
may regulate cholesterol turnover within neurons (Pierrot et al., 2013a). APP down-
regulates neuronal cholesterol levels via SREBP pathway in rat cortical neurons; 
however, in astrocytes APP does not influence cholesterol biosynthesis.  
Altered cholesterol metabolism has also been found in Huntington’s disease (HD). 
Studies have found that the levels of 24-OHC decrease in HD post mortem brain 
tissue with a reduction in the levels of cholesterol 24-hydroxylase (Kreilaus et al., 
2015). The production of 24-OHC in neurons has been hypothesized to initiate 
cholesterol transport from astrocytes to the neurons as a method of maintaining 
homeostasis (Pfrieger, 2003).  Disruption within cholesterol synthesis or transport 
within astrocytes could contribute to neuronal dysfunction. In a study by Valenza et 
al (2014), they found that astrocytes are responsible for cholesterol dysfunction 
within HD as the supply of cholesterol to the neurons has decreased (Valenza et al., 
2014).  
1.4.1 The Blood Brain Barrier  
The blood brain barrier (BBB) is a physical barrier between the central nervous 
system and the periphery and is crucial in maintaining homeostasis within the brain. 
The BBB consists of capillary endothelial cells and a basement membrane which is 
surrounded by pericytes and astrocytic endfeet (Sweeney, Sagare and Zlokovic, 
2018). The presence of tight junctions within brain endothelial cells restricts the 
paracellular exchange of molecules and allows small lipid-soluble molecules or 




1.4.2 The Blood Brain Barrier in AD 
BBB dysfunction is a feature of neurodegeneration and can contribute to the 
pathogenesis of AD (Cai et al., 2018; Ajikumar et al., 2019). BBB dysfunction is 
characterised by an increase in permeability which could be caused by degeneration 
of cells that form the BBB. A study in transgenic mice carrying the APOE E4 allele 
demonstrated accelerated BBB breakdown and pericyte degeneration (Halliday et 
al., 2016). Another study observed BBB breakdown within the hippocampus in 
patients with MCI compared to age matched controls. CSF analysis found a 
correlation between BBB breakdown and increased levels of soluble platelet-derived 
growth factor receptor-β, a marker of pericyte injury (Montagne et al., 2015). These 
studies show that pericyte injury contributes to the breakdown of BBB within the 
hippocampus. Furthermore, hippocampal BBB breakdown was observed before 
hippocampal atrophy suggesting that BBB breakdown occurs before the onset of 
neurodegeneration (Montagne et al., 2015; Sweeney, Sagare and Zlokovic, 2018). 
The degeneration of endothelial cells can also contribute to BBB dysfunction, 
particularly a decrease in expression of tight junction proteins. Tight junctions are an 
integral part of the BBB, they form a diffusion barrier between capillary endothelial 
cells preventing substances from peripheral circulation entering the brain (Ballabh, 
Braun and Nedergaard, 2004). Nishitsuji et al (2011) used a triple co-culture system 
including primary murine brain endothelial cells, pericytes and astrocytes to model 
the BBB and to investigate the effects of astrocytic APOE knockout and expressing 
different APOE alleles on tight junction integrity. This study found that 
transendothelial electric resistance, a marker of tight junction integrity, was reduced 
in apoE4 mice compared to apoE3, indicating an increase BBB permeability 
(Nishitsuji et al., 2011). This suggests that astrocytic apoE expression can regulate 
the permeability of the BBB through tight junction integrity.  
The accumulation and toxicity of Aβ can contribute to BBB disruption by causing 
direct damage to pericytes, astrocytes and endothelial cells (Cai et al., 2018; 
Sweeney, Sagare and Zlokovic, 2018). One study assessed the effects of Aβ on the 
interaction between astrocytes and endothelial cells in mono and co-culture 
(Spampinato et al., 2017). Spampinato et al (2017) found that in a co-culture system, 
incubation with Aβ leads to endothelial barrier dysfunction, characterised by reduced 
claudin-5 expression and increased permeability to FITC-conjugated dextran. The 
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dysfunction of endothelial cells has been attributed to an increase in matrix 
metalloprotease 9 activity, caused by increased astrocytic expression of vascular 
endothelial growth factor, which leads to the disruption of claudin-5 and therefore 
BBB dysfunction (Spampinato et al., 2017).  
1.4.3 The Blood Brain Barrier and cholesterol transport in AD 
Due to the large size of cholesterol molecule, it cannot easily diffuse through the 
BBB, thus the use of cholesterol transporters, such as ATP-binding cassette 1 
(ABCA1), contribute to cholesterol efflux at the BBB (Do et al., 2015). A study by Do 
et al (2015) used a triple transgenic mouse model of AD to investigate the 
expression of ABCA1 at the BBB. An increase in ABCA1 expression was observed 
at all timepoints in transgenic mice compared to age matched wildtype controls. In 
addition, Do et al (2015) observed a significant increase in cholesterol efflux in 
transgenic mice aged 3 and 6 months compared to the controls (Do et al., 2015).  
This suggests that in AD, BBB dysfunction can lead to an increase in cholesterol 
efflux from the CNS.   
1.5.1 Changes in the brain during ageing  
Ageing, one of the greatest risk factor for developing AD, is characterised by the 
accumulation of cellular damage over time; leading to the loss of physiological 
integrity, impairing function and increasing the vulnerability to death  (López-Otín et 
al., 2013). The process of ageing affects many cellular processes, some of which are 
involved in development of AD; however, many suggestions have been put forward 
to describe the process of ageing that occurs within the brain (Martin, Dotti and 
Dolores, 2010; López-Otín et al., 2013). Myelin breakdown is a common 
phenomenon that occurs during the progression of ageing and has been observed in 
mild cognitive impairment (MCI) and dementia. Myelin breakdown releases 
cholesterol and other nutrients into the CSF and extracellular space causing an 
increase in cholesterol levels which leads to neuronal death (Bartzokis, 2011; 
Hughes et al., 2013).  
Changes in mitochondria have also been associated with advancing age. Studies 
suggest that, during normal ageing, mitochondrial mass increases and there is a 
decline in the activity of complex I and complex IV and an increase in manifestation 
of oxidative stress markers (Barrientos et al., 1997; Navarro and Boveris, 2007; 
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Boveris and Navarro, 2008; Bartzokis, 2011). In AD brains the activity of complex I 
and complex IV decreases, leading to a depletion in ATP stores which prevents APP 
cleavage by α-secretase and promotes cleavage with β-secretase to produce Aβ 
(Gabuzda et al., 1994; Tamagno et al., 2002; Swerdlow, 2011).    
During natural ageing there is loss of brain cholesterol, however the amount of 
cholesterol that is lost does not correlate with age; and the rate of change in 
cholesterol levels varies depending on the brain region (Martin, Dotti and Dolores, 
2010). The distribution of apoE during ageing is yet to be fully elucidated; studies in 
rats have shown that there is a decrease in apoE protein expression in the 
hypothalamus and cortex but an increase within the hippocampus (Jiang et al., 2001; 
Terao et al., 2002). During ageing there is an increase in the amount of cholesterol 
24-hydroxylase enzyme leading to an increase in production of oxysterols, this 
down-regulates cholesterol synthesis within astrocytes and reverse cholesterol 
transport (E G Lund, Guileyardo and Russell, 1999; Clement et al., 2009; Martin, 
Dotti and Dolores, 2010).  
1.5.2 Cholesterol changes in the brain during AD  
During AD, it has been suggested that there is an imbalance in cholesterol 
homeostasis, but the exact mechanisms by which this occurs are still unknown. 
Some studies suggest that there is a decrease in brain cholesterol due to a reduction 
in cholesterol synthesis. This reduction in synthesis is due to a decrease in 
expression of the gene for 3β-hydroxysterol Delta 24-reductase (Selective AD 
indicator 1- seladin1) – the enzyme involved in converting desmosterol to cholesterol 
(Greeve et al., 2000; Waterham et al., 2001; Martin, Dotti and Dolores, 2010). 
Cholesterol transport from glial cells to neurons is also altered in AD. The apoE ε4 
allele is a genetic risk factor for AD, this allele has a lower ability to release 
cholesterol from glial cells resulting in a decrease in cholesterol level within the 
neurons (J.-S. Gong et al., 2002; Martin, Dotti and Dolores, 2010). Studies in mice 
have shown that apoE is involved in BBB integrity; expression of human apoE4 in 
mice, showed BBB breakdown by activation of proinflammatory signalling in 
pericytes, leading to neurotoxic proteins from the blood entering neurons (Bell et al., 
2012).   The ε4 allele also has a decreased activity in clearance leading to Aβ 
accumulation (Lomnitski et al., 1999; DeMattos, 2004; Martin, Dotti and Dolores, 
2010). The 24-hydroxylase enzyme is present in neuritic plaques in AD and is 
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deficient in neurons making them more susceptible to stress and its expression is 
increased in the presence of oxidative stress (Brown, Theisler, Silberman, 
Magnuson, Gottardi-Littell, John M Lee, et al., 2004; Ohyama et al., 2006; Martin, 
Dotti and Dolores, 2010). The levels of 24-OHC are also decreased in AD brains, 
studies show that 24-OHC favour the non-amyloidogenic processing of APP 
however, the mechanisms by which this is achieved are still unknown (Sparks et al., 
1994; Heverin et al., 2004; Martin, Dotti and Dolores, 2010).  
1.5.3 Oxidative stress in the brain during ageing 
Oxidative stress is a feature of brain ageing and may contribute to the pathogenesis 
of AD. It is defined as the imbalance between biochemical processes leading to ROS 
being produced and those processes responsible for the removal of ROS (Harman, 
1981; Recuero et al., 2009). Accumulation of ROS within neurons causes DNA 
damage and induces a DNA damage response, which leads to cellular senescence 
and may contribute to neuronal dysfunction. Previous work in our lab has 
demonstrated that oxidative DNA damage is associated with lower cognitive 
measures at early stages of AD pathology (Simpson et al., 2015). Further work 
investigated the changes in gene expression in neurons in high vs low DNA damage 
responses using gene microarray analysis. This study identified that an 
overexpression in six out of the ten genes probes involved in cholesterol 
biosynthesis was associated with a high DNA damage response (Simpson et al., 
2016). Studies also indicate that neuronal loss in AD may be due to an increase in 
oxidative stress (Moreira et al., 2005; Recuero et al., 2009). In the presence of 
oxidative stress cholesterol biosynthesis is induced. This was shown in a study by 
Recuero et al (2009) they induced oxidative stress by treating neuroblastoma cells 
with xanthine oxidase and found that HMGCR expression within neurons was 








1.6 Overall aims of this thesis 
Currently, we are aware of the importance of maintaining cholesterol homeostasis 
within the brain for normal brain function and evidence is further suggesting that 
cholesterol may have a role in the processing of APP to produces Aβ plaques; 
however, the exact mechanisms remain unknown. This thesis aims to characterise 
how cholesterol production and cholesterol metabolism change during the 
progression of AD. The overall hypothesis is that cholesterol dysregulation in the 
brain contributes to dementia and to progression of Alzheimer’s disease (Figure 1.5). 
We further hypothesise that dysregulation of cholesterol biosynthesis occurs at the 
earliest stages of AD, with an initial compensatory stage that fails. We also will 
investigate the hypothesis that dysregulation of cholesterol biosynthesis in the 
neuron-astrocyte unit contributes to dementia by impairing neuronal function due to 
impaired cholesterol metabolism and through generation of pro-oxidative stress 
metabolites.  
Objectives: 
• Define changes in the expression of genes that encode cholesterol 
biosynthesis pathway enzymes in neurons and astrocytes in an ageing 
population-representative neuropathology cohort in relation to AD progression 
and oxidative DNA damage. This was carried out by isolating neurons and 
astrocytes using laser capture micro-dissection to produce an enriched 
sample from frozen temporal cortex sections. The cell extractions were used 
for quantitative real time PCR to measure the expression of genes involved in 
cholesterol biosynthesis.  
• Examine the effects of acute and chronic stress on cholesterol metabolism in 
the neuron-astrocyte unit using astrocyte and neuron monocultures. This was 
carried out by culturing Lund human mesencephalic cells (LUHMES), a 
neuronal cell line, and primary human foetal astrocytes separately in 
monoculture examining the effect of a single and double exposure to 

























































Figure 1.5: Diagram illustrating the hypothesis of the project: Dysregulation of 
cholesterol biosynthesis in the neuron-astrocyte unit contributes to dementia 
by impairing neuronal function due to impaired cholesterol metabolism and 
through generation of pro-oxidative stress metabolites.  
50 
 
2.0 Histological characterisation of key regulators of cholesterol biosynthesis 
in the ageing brain 
2.1 Introduction 
Due to the significance of cholesterol in maintaining optimum neuronal function, the 
control of cholesterol production within the brain is of paramount importance. De 
novo cholesterol production in the brain occurs via the cholesterol biosynthesis 
pathway mainly in astrocytes (Pfrieger, 2003; Maria Giudetti et al., 2015), and the 
rate of cholesterol production is regulated by the action of the HMG-CoA reductase 
(HMGCR) enzyme (Sharpe and Brown, 2013a). HMGCR is a trans-membrane 
glycoprotein which is found within the endoplasmic reticulum (ER) membrane and 
catalyses the conversion of HMG-CoA into mevalonate (Figure 1.4 and Figure 2.1) 
(Hwang et al., 2016). It is encoded by the HMGCR gene, which is found on 
chromosome 5 and generates a monomer consisting of  888 amino acids (Kumar et 
al., 2019). The HMGCR monomer contains three domains: The N-domain (N-
terminal); S-domain and L-domain (C-terminal). The catalytic portion of the enzyme 
consists of four monomers to form a tetramer and substrate binding occurs within the 
S and L domains at the junction between monomers (Istvan and Deisenhofer, 2000).  
Sterol Regulatory Element-Binding Proteins (SREBP) regulate the expression of 
HMGCR. SREBP’s are transcription factors that are localised to the ER membrane 
which regulate cholesterol production within cells (Sakai et al., 1997). Three isoforms 
of SREBP are expressed in mammals, SREBP-1a, SREBP-1c and SREBP2 
(Goldstein, DeBose-Boyd and Brown, 2006). All three isoforms are incorporated into 
the ER in the same orientation, with both N-terminus and COOH-terminus facing the 
cytosol which is also where SREBP Cleavage-Activating Protein (SCAP) binds to 
SREBP after synthesis (Sakai et al., 1997). SREBP-1a and SREBP-1c are encoded 
by a gene located on chromosome 17 and is involved in the activation of 
transcription of genes involved in cholesterol, fatty acid and triglyceride synthesis 
(Xianxin Hua et al., 1995; Horton, Goldstein and Brown, 2002). The gene encoding 
SREBP2 is found on chromosome 22 and is specifically involved in the activation of 
transcription of genes involved in cholesterol biosynthesis (Xianxin Hua et al., 1995; 
Horton, Goldstein and Brown, 2002). All SREBP isoforms have a similar structure, 
the N-terminus is a transcription factor belonging to the basic-helix-loop-helix-leucine 
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(bHLH) zipper family, followed by a transmembrane domain and the C-terminus 
contains a regulatory domain (Sakai et al., 1997).    
Regulation of the cholesterol biosynthesis pathway occurs via cleavage and 
trafficking of SREBP2. When cholesterol levels are low, SCAP cleaves SREBP2 
which migrates to the nucleus to promote the transcription of genes involved in 
cholesterol biosynthesis, such as HMGCR, upregulating cholesterol synthesis 
(Simons and Ilonen, 2000; Goldstein, DeBose-Boyd and Brown, 2006). When 
cholesterol levels increase, HMGCR binds to INSIG-1 (insulin-induced gene 1) and 
INSIG-2 (insulin-induced gene 2) which mark HMGCR for ubiquitination and 
degradation which leads to the rapid suppression of cholesterol synthesis within the 
brain (Goldstein, DeBose-Boyd and Brown, 2006; DeBose-Boyd, 2008; Dietschy, 
2009).  
The processing of APP within membranes is also influenced by cholesterol levels 
found within the membranes (Grimm, Rothhaar and Hartmann, 2012). One study 
found that in SHSY-5Y cells, cleavage with β-secretase was favoured within 
cholesterol enriched lipid rafts suggesting that α-secretase cleavage is favoured 
within cholesterol-depleted regions of the membrane (Cordy et al., 2003; Grimm, 
Rothhaar and Hartmann, 2012). A study by Pierrot et al., (2013) demonstrated the 
role APP plays in cholesterol biosynthesis regulation. In primary rat cortical neurons, 
moderate expression of APP was found to decrease cholesterol biosynthesis as well 
as a decrease in SREBP mRNA expression (Pierrot et al., 2013b). APP was found to 
inhibit the site-2 mediated release of SREBP preventing the nuclear localisation of 
the SREBP transcription factor domain. However, in primary rat cortical astrocytes  
APP did not interact with SREBP suggesting that within astrocytes APP does not 
play a role in the regulation of cholesterol biosynthesis (Pierrot et al., 2013b). These 
results were further confirmed in vivo, where transgenic mice expressing different 
APP mutants, showed a downregulation in SREBP expression (Pierrot et al., 2013b). 
Furthermore, an SNP found within the promoter region of the HMGCR gene was 
found to increase the risk of AD and accelerate progression of AD (Porcellini et al., 
























1) HMG-CoA + NADPH  Mevaldyl-CoA + NADP+ 
2) Mevaldyl-CoA + H+  Mevaldehyde + CoASH 
3) Mevaldehyde + NADPH +H+  Mevalonate 
Figure 2.1 Cholesterol biosynthesis rate determining step: The three steps 




For this study, post-mortem human tissue was obtained from the Cognitive Function 
and Ageing Study (CFAS). CFAS is a prospective multicentre epidemiological study 
of the ageing population (>65 years of age) in the UK which represents the spectrum 
of age-related neurodegenerative pathologies and range of cognitive impairment, 
enabling neuropathological correlates of dementia to be determined 
(http://www.cfas.ac.uk). The study was based around six centers across the UK 
(Cambridgeshire, Oxford, Nottingham, Newcastle, Liverpool and  Gwynedd) with an 
initial screening process including a mini-mental state examination and an 
automated geriatric examination for computer-assisted taxonomy to assess cognitive 
impairment in candidates, this was followed up after 6 years with a total of 3145 
patients that had been screened and interviewed as part of the study (Ince, 2001; 
Brayne, McCracken and Matthews, 2006; Matthews et al., 2009; Wharton et al., 
2011). The neuropathology cohort consists of 525 brain donations from all six 
centers, from which the Cambridge cohort consists of 100 brains with both frozen 
and fomalin fixed samples available (Wharton et al., 2011).  
CFAS is a longitudinal ageing population representative study which means that 
there is a wide range of cases with and without dementia, making it a valuable 
resource for studying the progression of dementia in a population. This approach 
reveals the variability within a population and provides an idea of the spectrum that is 
encompased within this disorder. Furthermore, due to the nature of this study it 
facilitates an unbiased assessment of relationships between pathology and dementia, 
as cases are not pre-selected based on clinical groups and are free from sampling 
biases. This provides complementary information to classical case-control studies. 
Studies on the CFAS neuropathology cohort have shown that AD pathology is the 
commonest association with dementia and multiple pathologies also associate and 
coexist with dementia with age being the biggest risk factor, especially over 90 years 
of age. Additionaly, a smaller brain weight, small vessel disease and hippocampal 
atrophy, increase the risk of dementia.  The study also found that both demented 
and non-demented individuals had classical AD pathology and the overlap in Aβ 
plaque burden increases at the oldest ages however, a severe tangle score was only 
observed in 20% of demented patients and was a better discriminator in both 
demented and non-demented individuals (Matthews et al., 2009; Savva et al., 2009; 
Wharton et al., 2011).   
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Previous population-based studies involving CFAS have demonstrated that oxidative 
DNA damage is associated with lower cognitive measures at early stages of AD 
pathology (Simpson et al., 2015). Further work investigated the changes in gene 
expression in neurons in high vs low DNA damage responses using gene microarray 
analysis. This study identified that an overexpression in six out of the ten genes 
probes involved in cholesterol biosynthesis was associated with a high DNA damage 
response (Simpson et al., 2016). A fold change of 4.5 (p=0.0008) for HMGCR and a 
down-regulation in SREBF2 with a fold change of -1.1 (p=0.001) was observed. This 
study also found an association with neuronal DNA damage response and the levels 
of the cholesterol metabolite 24(S)-hydroxycholesterol (24(S)-OHC) in the 
cerebrospinal fluid (CSF) (r=0.30. p=0.033) and 24(S)-OHC negatively correlated 
with increasing Braak and Braak stage (r=-0.29, p=0.040). This data suggests that at 
early Braak and Braak stages, oxidative DNA damage is associated with increased 
cholesterol biosynthesis. This may be a compensatory mechanism that fails as AD 
progresses. 
Cholesterol has a vital role in maintaining normal neuronal function during 
development and throughout adult life and given that oxidative stress is a feature of 
brain ageing, it is important to characterise changes in cholesterol biosynthesis that 
occur as the brain ages. To determine if a decline in HMGCR expression occurs at 
older ages, suggesting a reduction in cholesterol biosynthetic capacity at older ages, 
post-mortem human brain tissue was obtained from Edinburgh Medical Research 
Council Sudden Death Brain Bank. Donors to this cohort had no history of 
neurological disorders and spanned a large age range (16-75 years of age), making 
the cohort ideal to assess the changes in cholesterol synthesis during ageing. This 
cohort will help determine if there are changes in HMGCR expression during ageing 
regardless of dementia or AD and will determine if changes in cholesterol synthesis 
occur as the brain ages, potentially contributing to impaired brain function. The 
CFAS neuropathology cohort is an aging population representative cohort and 
recruited patients who were 65 years old and above and so contains a wide 
spectrum of pathology and dementia status allowing the assessment of cholesterol 
biosynthesis over disease progression. The use of Edinburgh cohort, an ageing 
series, allow characterisation of cholesterol biosynthesis in relation to the effects of 
old age.  
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2.2 Aims and Objectives 
The aim of this study was to investigate how the expression of HMGCR and 
SREBP2, key regulators of cholesterol biosynthesis, vary in the ageing brain and 
how the expression of these regulators are affected by dementia status, Alzheimer’s 
neuropathology, DNA damage and neuroinflammation.  
We hypothesise that changes in the expression of the key regulators of cholesterol 
biosynthesis are associated with increased Alzheimer’s neuropathological change, 
oxidative DNA damage and neuroinflammation leading to dysfunction of cholesterol 
synthesis within the ageing brain. 
The objectives for this chapter are:  
• Characterise cellular localisation of HMGCR using immunohistochemistry 
• Validate HMGCR antibody expression. 
• Provide a quantitative analysis of the immunoreactivity of HMGCR expression 
within temporal cortex tissue from the CFAS Cambridge Cohort. 
• Carry out non-parametric analysis to determine if variation in HMGCR 
immunoreactivity is associated with dementia status and Alzheimer’s 
neuropathological change. 
• Carry out further statistical analysis to determine if variation in HMGCR 
immunoreactivity correlates to markers of oxidative stress and 
neuroinflammation. 
• Characterise and quantify expression of HMGCR in an aging cohort. 
• Determine if variation in HMGCR immunoreactivity is associated with the 
effects of ageing. 
• Characterise the expression of SREBP2 using immunohistochemistry within 














List of materials can be found in Appendix 6.1.1 
 
2.3.1 Human Brain Tissue 
Post-mortem human brain tissue was obtained from the Cambridge centre of CFAS 
(n=99). One hemisphere was sampled and fixed using formalin and stored at RT. 
The other hemisphere was sliced in the coronal plane and snap frozen, and stored at 
-80°C. For both frozen and fixed sections the temporal cortex (Brodmann area 20/21) 
was investigated and the ethical approval (15/SW/0246) can be found in the 
appendix (appendix 6.3) alongside the cohort demographics (appendix table 6.3.1).  
Post-mortem formalin fixed human prefrontal association cortex (Brodmann area 8/9) 
was obtained from the Edinburgh Medical Research Council Sudden Death Brain 
Bank. Neuropathology was specifically assessed in Brodmann area 8/9 using the 
immunoreactivity of Aβ and tau to determine if any neurodegenerative features were 
present. The cohort represented various age groups such as 16-30yrs (n=3), 31-45 
yrs (n=3), 46-60 yrs (n=5), 61-75 yrs (n=4) and 75+ yrs (n=1). Ethical approval can 
be found (TR75/19) in the appendix (appendix 6.4) alongside the cohort 
demographics (appendix 6.4.1).   
2.3.2 Immunohistochemistry  
Immunohistochemistry (IHC) was carried out using the standard horseradish 
peroxidase-conjugated avidin-biotin complex (ABC-HRP) IHC technique (Vectastain 
Elite kit, Vector Laboratories UK) with 3,3’-diaminobenzidine (DAB) (Vector 
laboratories, UK) as substrate. Formalin fixed paraffin embedded (FFPE) sections 
(5μM) were de-waxed in two changes of xylene (Fisher Scientific, UK) and 
rehydrated  through a graded series of ethanol (absolute, 95%, 70%) (VWR 
Chemicals, France) and placed in a pressure cooker in the corresponding buffer 
(Table 2.1) (Menarini Diagnostics, UK). Antigen retrieval was carried out (125°C at 
20psi for 30 seconds), before sections were cooled to RT in running tap water and 
blocked for endogenous peroxidase in 3% (v/v) H2O2/Methanol (Fisher Scientific UK) 
for 20 minutes at RT. The sections were blocked, followed by primary antibody 
incubation (Table 2.1). Following incubation, sections were washed with TBS for 5 
minutes at RT and incubated with 0.5% (v/v) biotinylated (50 µl in 10ml of 1.5% (v/v) 
goat serum) secondary antibody for 30 minutes, followed by another wash with TBS 
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for 5 minutes at RT. The sections were then incubated with 2% (v/v) ABC-HRP (100 
µl of both reagent A and B in 10 ml of TBS, prepared 30 minutes prior to use) for 30 
minutes followed by a wash with TBS for 5 minutes at RT. The antibody binding was 
visualised by incubating the sections with DAB for 5 minutes at RT and the reaction 
was stopped with d.H2O. The sections were washed in tap water, counterstained in 
Harris’s haematoxylin for 30 seconds and blued in Scotts Tap water for 10 seconds. 
The sections were dehydrated in a graded series of ethanol (70%, 95%, absolute) 
and cleared in xylene before mounting with DPX and glass coverslips. Once 
mounted the sections were placed in an oven overnight at 37°C to dry. Rabbit 
isotype controls and omission of primary antibody (negative controls) were included 
to confirm antibody specificity. HMGCR antibody optimisation can be found in the 
appendix (appendix 6.1). 
Antibody (Catalogue number) 
Species, optimised dilution and 
incubation conditions 
Antigen retrieval 
HMGCR (Abcam, UK) 
(ab174830) 
Rabbit monoclonal, 1/100, 
overnight at 4°C 
pH 9.5 buffer, 
pressure cooker, 1hr 
HMGCR (Atlas Antibodies, 
Sweden) (AMAb90619) 
Mouse Monoclonal, 1/100, 
overnight at 4°C 
pH 9.5 buffer, 
pressure cooker, 1hr 
SREBF2 (Abcam, UK) (ab28482) 
Rabbit IgG polyclonal, 1/100, 1hr 
at RT 
pH 6 buffer, 
microwave 10 minutes 
GFAP (Dako, Denmark) 
(Z033401-2) 
Rabbit IgG polyclonal, 1/500, 
overnight at 4°C 
n/a 
Table 2.1: Antibodies used for Immunohistochemistry 
 
2.3.3 Frozen Immunohistochemistry 
Frozen cryosections (7μm) were warmed to RT within the lamina hood for 5 minutes. 
The sections were fixed and permeabilised in ice cold acetone (VWR chemicals, 
France) for 3 minutes and air-dried briefly at RT. The sections were blocked in 1.5% 
(v/v) goat normal serum for 30 minutes at RT, followed by an overnight incubation at 
4°C with HMGCR (Table 2.3) (Abcam, UK). The sections were washed with TBS for 
5 minutes at RT and incubated with 0.5% biotinylated secondary antibody for 30 
minutes, followed by a wash with TBS for 5 minutes at RT. The sections were 
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incubated with 2% (v/v) ABC-HRP for 30 minutes followed by a wash with TBS for 5 
minutes at RT. The antibody binding was visualised by incubating the sections with 
3,3’-diaminobenzidine for 5 minutes at RT and the reaction was quenched with 
d.H2O. The sections were washed in tap water, counterstained in Harris’s 
haematoxylin for 30 seconds and blued in Scotts Tap water for 10 seconds. The 
sections were dehydrated in a graded series of ethanol (70%, 95%, absolute) and 
cleared in xylene before mounting with DPX and glass coverslips. Once mounted the 
sections were placed in an oven overnight at 37°C to dry. Rabbit isotype controls 
and omission of primary antibody (negative controls) were included to confirm 
antibody specificity.  
2.3.4 Quantification and statistical analysis of variation of HMGCR expression   
For quantification, two parallel ribbons were imaged throughout all layers of the 
cortex of each stained section. These images were quantified using the Analysis^D 
software (Figure 2.2A). This programme counted the number of pixels that had been 
stained and compared them to the total number of pixels in the image producing a 
percentage immunoreactivity value for each case. The programme was set so that 
specific immunolabelling of HMGCR was detected above a threshold value and non-
specific background staining was excluded from the final percentage (Figure 2.2B 
and C). For each case, the average percentage of immunoreactivity was recorded 
and used for statistical analysis.  
Statistical analysis was carried out using SPSS Statistics v25 (IBM, UK). A 
Kolmogorov Smirnov test was carried out to determine if the data was normally 
distributed. To investigate the associations between AD neuropathology and 
HMGCR immunoreactivity a Kruskal-Wallis (KW) test was carried out. The 
Jonckheere-Terpstra (JT) test was carried out to identify any trends between groups. 
Spearman rank correlation test was used to investigate correlations between 
percentage HMGCR immunoreactivity and DNA damage response, AD 
neuropathology progression, brain pH, inflammation and post-mortem delay. Data 
from previous publications and studies were used for statistical analysis (Savva et al., 
2009; Simpson et al., 2015). AD neuropathology progression was measured using 
Braak and Braak group staging and Thal β-Amyloid phase. For statistical analysis, 
Braak and Braak stages were combined to allow comparisons between Braak and 
Braak groups, Thal phases were also grouped to allow for comparison between and 
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Thal phases. Groups were defined as follows: for Braak and Braak, group 1 
contained stages 0-II (entorhinal), group 2 contained stages III-IV (limbic) and group 
3 contained stages V-VI (isocortical); for Thal, group 1 contained phases 1-2, group 
2 contained phases 3-4 and group 3 contained phases 5-6. To determine if the 
variation in neuronal expression of HMGCR associated with dementia status a 
Mann-Whitney U test was carried out. The effect of HMGCR immunoreactivity on risk 
of dementia was analysed using logistic regression. Statistical analysis in relation to 
dementia status was carried out by Connor Richardson, University of Newcastle. All 















Figure 2.2. Quantification of HMGCR expression: A set of images was taken 
across the all layers of the cortex ranging from just below the pia-surface (LHS) 
all the way to the white matter regions (RHS) for each section (A). Using 
Analysis^D software to set colour thresholds and calculate percentage 
immunoreactivity, original image (B) and the image highlighting the areas with 
positive immunoreactivity (C).   
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2.3.5 Dual Labelling IHC of co-localisation of HMGCR with astrocytes 
To confirm co-localisation of HMGCR with astrocytes dual labelling was performed. 
IHC for HMGCR was carried out as outlined above (2.3.2) using the ABC-HRP 
technique and Vectastain Elite Kit (Vector Laboratories, UK) with DAB (Vector 
Laboratories, UK) as substrate. After DAB incubation, the sections were blocked in 
1.5% (v/v) goat normal serum for 30 minutes at RT, followed by 15 minutes 
incubation with avidin at RT (first component of avidin/biotin blocking kit, Vector 
Laboratories, UK). After blocking, the sections were washed with TBS once and then 
incubated with biotin (second component of the avidin/biotin blocking kit, Vector 
Laboratories, UK) for 15 minutes at RT. The excess biotin was removed and the 
sections where incubated with GFAP antibody (1:500 dilution) overnight at 4°C. The 
sections were washed in TBS for 10 minutes, prior to the addition of biotinylated anti-
rabbit secondary antibody (50μl in 1.5% (v/v) goat serum) for 1hr at RT. The sections 
were washed in TBS for 10 minutes, prior to the addition of the alkaline 
phosphatase-conjugated avidin-biotin complex (ABC-AP, Vector Laboratories, UK) 
(100μl of reagent ‘A’, 100μl of reagent ‘B’ in 5 ml TBS, prepared at least 30 minutes 
prior to use) for 1hr at RT and washed with TBS for 10 minutes, ensuring all TBS 
was removed after the wash. The sections were incubated in the alkaline 
phosphatase substrate (Vector Red, Vector Laboratories, UK) (100 μl reagent 1, 2, 
and 3 in 5 ml Tris-HCL, 100mM) for 10-20 minutes, allowing enough time for the 
reaction to develop. The reaction was stopped by washing the slides with d.H2O. The 
sections were washed in tap water, counterstained in Harris’s haematoxylin for 30 
seconds and washed in tap water. The sections were dehydrated in a graded series 
of ethanol (70%, 95%, absolute) and cleared in xylene before mounting with DPX 
and glass coverslips. Once mounted, the sections were placed in an oven overnight 
at 37°C to dry. Rabbit and mouse isotype controls and omission of primary antibody 
(negative controls) were included to confirm antibody specificity.  
2.3.6 Bicinchoninic acid assay (BCA) 
LUHMES and astrocyte cell pellets were obtained as outlined in chapter 4.3.1 and 
4.3.3 HeLa cell pellet was obtained from Dr Emma Smith and was used as a positive 
control. The cell pellets were lysed in ice-cold extra-strong lysis buffer followed by 
centrifugation at 16,000 g at 4°C for 5 minutes. Tissue protein extracts were obtained 
from previous studies carried out within the lab (Viggars et al., 2011). To determine 
the protein concentration of the cell and tissue protein extract, a BCA protein assay 
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was performed according to the manufacturer’s instructions (ThermoFisher Scientific, 
USA). BSA protein standards were freshly prepared at concentrations ranging from 
0-2 mg/ml using extra strong lysis buffer. Absorbance of samples was measured at 
550 nm wavelength using PHERAStar spectrophotometer and protein concentration 
values were interpolated from the protein standard curve. Samples were diluted 
using extra strong lysis buffer to ensure equal proteins concentrations were used.  
2.3.7 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Samples were mixed with (4x) Laemmli sample buffer and heated at 100°C for 5 
minutes and centrifuged at 10,000g for 1 minute. The samples were loaded 12% (v/v) 
polyacrylamide gel with 4% (v/v) stacking gel (Table 2.2). Molecular weight standard, 
Precision Plus Dual Colour Protein Standard (Bio-Rad Laboratories Ltd, UK) was 
also loaded with the protein samples. Gels were electrophoresed at 120V for 
approximately 1.5 hrs or until the dye front had reached the bottom of the gel.  
 5% Stacking gel 12% Resolving gel 
Acrylamide 1.7ml 4ml 
Resolving buffer - 2.5ml 
Stacking buffer 2.5ml - 
10% (w/v) APS 50µl 50µl 
TEMED 20µl 20µl 
dH2O 5.8ml 3.5ml 
Table 2.2: Composition of stacking and resolving gel 
 
2.3.8 Western Blotting 
Following electrophoresis, gels were placed onto nitrocellulose membranes (GE 
Healthcare, UK), which was sandwiched between sponges and filter paper 
(Whatman Laboratories) in an X-Cell transfer module (Life Technologies) and 
submerged in transfer buffer. Protein transfer was carried out at 300 mA for 2 hrs 
and the success of the transfer was checked using Ponceau Red. The membrane 
was blocked for non-specific binding in 5% (v/v) milk in PBS-T for 1 hr at RT, 
followed by a primary antibody (Table 2.3) incubation at 4°C overnight. Following 
primary antibody incubation, the membranes were washed 3 times in 1x PBS-T for 
10 minutes followed by an incubation with species-specific HRP conjugated 
secondary antibody (Table 2.3) for 1 hr at RT. Following secondary antibody 
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incubation, the membranes were washed 3 times in 1x PBS-T for 10 minutes prior to 
incubating with enhanced chemiluminescent substrate (EZ-ECL Biological Industries, 
Israel) and visualising the membranes using the G-box Chemi-XT CCD Gel imaging 
system (Syngen, UK).  
Antibody (Catalogue number) Species, optimised dilution and incubation 
conditions 
HMGCR (Abcam, UK) (ab174830) Rabbit monoclonal, 1/1000, overnight at 4°C 
α-tubulin (clone DM1A), (Sigma Aldrich, 
UK) (T6199) 
Mouse monoclonal, 1/10,000, overnight at 
4°C 
Anti-rabbit HRP (Promega, UK) (W4011) Goat polyclonal, 1/5000, 1hr at RT 
Anti-mouse HRP (Promega, UK) (W4021) Goat polyclonal, 1/5000, 1hr at RT 

































2.4.1 HMGCR is expressed in pyramidal neurons in the temporal cortex  
Immunohistochemistry showed that the HMGCR enzyme was expressed in 
pyramidal neurons of the temporal cortex. Positive immunostaining in neurons was 
observed in all cases throughout the cohort, with some variation in intensity of 
immunolabelling between cases. The expression was punctate and localised to the 
cytoplasm of neuronal cell bodies and proximal processes (Figure 2.3 A and B). The 
variation in HMGCR expression was not normally distributed (Kolmogorov-Smirnov 
p=0.092) with a mean percentage immunoreactivity across the cohort of 3.90, 
standard deviation of 2.86, median of 3.87 and an interquartile range of 3.56 (Figure 
2.3 C). To ensure that the variation in immunostaining was not an artefact of brain 
donation, correlations between brain pH (r=0.094, p=0.405) and post-mortem delay 
(r=-0.026, p=0.813) were determined. 
To determine if the variation in neuronal expression of HMGCR changed with AD 
neuropathology we examined variation across Braak and Braak groups as a 
measure of NFT progression (KW p=0.559) (JT p=0.578) (Figure 2.3 D) (Table 2.4). 
We found that HMGCR expression did not vary with Braak and Braak stage. 
Variation between HMGCR immunoreactivity did not vary with Thal Aβ staging for 
the cohort. Thal Aβ staging was examined as a measure of Aβ progression (KW 
p=0.311) (JT p=0.171) (Table 2.5). To further assess the relationship to AD 
neuropathology, variation in HMGCR immunoreactivity was also assessed according 
to local measures of AD neuropathology in temporal cortex. There were no 
significant differences in HMGCR immunoreactivity between different neuritic plaque 
density groups (KW p=0.791) (JT p=0.551), or neurofibrillary tangle score groups 
(KW p=0.430) (JT p=0.741). No significant correlations were found between 
neuronal HMGCR immunoreactivity and Aβ percentage immunoreactivity (r=-0.027, 
p=0.800), and phosphorylated tau (AT8) percentage immunoreactivity (r=-0.083, 
p=0.434).   
Data from previous studies in our lab was used to study correlations with HMGCR 
immunoreactivity and markers of oxidative stress, DNA damage and 
neuroinflammation (Simpson et al., 2015).  To determine if HMGCR 
immunoreactivity correlated with markers of DNA damage response we examined 
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γH2AX immunoreactivity in both neurons (r=-0.039, p=0.706) and astrocytes 
(r=0.060, p=0.563). Furthermore, protein expression of malondialdehyde, was 
assessed by western blotting, was also examined as a measure of oxidative stress 
(r=-0.008, p=0.966). This shows that neuronal HMGCR percentage immunoreactivity 
does not vary with markers of DNA damage response and oxidative stress. To 
investigate correlations between neuroinflammation and HMGCR immunoreactivity, 
we examined CD68 immunoreactivity (r=-0.034, p=0.752) and MHCII 
immunoreactivity (r=-0.055, p=0.617) as a measure of microglial activation. This data 
shows that the variation in neuronal HMGCR percentage immunoreactivity does not 
correlate with markers of neuroinflammation.  
Braak and Braak Groups N Mean SD SEM Median Range 
1 (0-II) 30 3.64 3.02 0.553 3.41 14.60 
2 (III-IV) 51 4.14 2.84 0.398 3.98 14.35 
3 (V-VI) 18 3.66 2.73 0.287 4.01 10.31 
Table 2.4: Case summaries of average percentage immunoreactivity of HMGCR 
in temporal cortex according to Braak and Braak groups 
 
Thal Aβ Phase N Mean SD SEM Median Range 
0 13 3.20 2.14 0.593 3.26 6.64 
1 9 3.92 4.21 1.403 2.73 14.09 
2 17 4.24 3.64 0.882 2.67 13.53 
3 24 3.37 2.81 0.574 3.18 10.75 
4 19 4.70 1.92 0.441 4.93 7.35 
5 17 3.93 2.71 0.657 4.02 10.31 
Table 2.5: Case summaries of average percentage immunoreactivity of HMGCR 
































































Figure 2.3. HMGCR is expressed in pyramidal neurons in the temporal cortex. 
Representative images from the cohort show that HMGCR expression was 
associated with pyramidal neurons throughout all layers of the temporal cortex (A, 
black arrow). HMGCR immunoreactivity was predominantly detected in the 
cytoplasm of neuronal cell bodies and proximal processes (B, black arrows). 
Histogram of the average immunoreactivity of HMGCR shows that the distribution of 
HMGCR expression does not follow a normal distribution throughout the cohort (C). 
Boxplot of the percentage area of immunoreactivity indicated that expression of 
HMGCR does not show an association with Alzheimer-type neuropathology in the 
ageing brain (D). Scale bar represents 50μm. 
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2.4.2 Validating HMGCR expression  
Positive immunolabelling for HMGCR was found in pyramidal neurons. The 
expression was punctate and localised to the cytoplasm of neuronal cell bodies and 
proximal processes The literature suggests that astrocytes are responsible for 
cholesterol biosynthesis within the brain thus expression would be preferentially 
expected in astrocytes (Pfrieger, 2003; Maria Giudetti et al., 2015). Hence, to 
validate this novel finding and confirm HMGCR expression observed in the CFAS 
tissue, the optimised HMGCR staining protocol was repeated in frozen tissue 
sections to confirm that the fixation process of the tissue did not affect the binding of 
the HMGCR antibody. Frozen temporal cortex sections from the Cambridge CFAS 
cohort were used and the HMGCR antibody was incubated overnight at 4°C. This 
also demonstrated HMGCR immunopositive pyramidal neurons in the temporal 
cortex, with immunoreactivity localised to the cytoplasm of neuronal cell bodies and 
proximal processes, an identical pattern to that observed in the FFPE tissue (Figure 
2.4 A). Further validation was carried out by repeating the optimised IHC protocol on 
FFPE tissue from the CFAS cohort, using an alternative anti-HMGCR monoclonal 
antibody purchased from another company (Atlas Antibodies). This antibody targeted 
an epitope from 484-497 amino acids compared to the Abcam antibody, which 
targeted an epitope from 400-500 amino acids. IHC staining using this antibody 
confirmed the punctate immunolabelling pattern localised to the cytoplasm and 
proximal processes of pyramidal neurons (Figure 2.4 B).  
To further confirm the Abcam antibody specificity a western blot was carried out 
(Figure 2.4 C). Cell lysates from Hela cells, cultured neurons (LUHMES) and 
astrocytes (primary human foetal astrocytes) and human post-mortem temporal 
cortex protein extract (TCx) were used. Neuronal and astrocytic cell lines were used 
to confirm neuronal and astrocytic HMGCR expression in vitro and validate staining 
pattern observed in temporal cortex tissue. Temporal cortex protein extract was used 
to confirm antibody specificity and expression of HMGCR in temporal cortex and 
validates that the immunoreactivity observed in temporal cortex sections. HeLa cell 
lysates were used as a positive control. A band was present around 97kDa for all 
samples, at the expected size for HMGCR, confirming the specificity of the HMGCR 
















































Figure 2.4. Validation of HMGCR expression. HMGCR expression was validated by 
carrying out the optimised staining protocol in frozen tissue (A) and using another 
antibody that had been purchased from another company (Atlas Antibodies) (B). In 
both images, HMGCR expression was associated with pyramidal neurons of the 
temporal cortex in frozen tissue sections (black arrows). HMGCR 
immunoreactivity was punctate and found within the cytoplasm of the cell soma 
and proximal processes (black arrows) HMGCR immunoreactivity was detected in 
the cytoplasm of the neuronal cell bodies and proximal processes. (C) Shows a 
western blot for the HMGCR antibody (Abcam, UK) for HeLa cells, post-mortem 
human temporal cortex protein extract, LUHMES astrocyte lysates. (A) Scale bar 
represents 50μm. (B) Scale bar represents 100µm.  
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2.4.3 Glial expression of HMGCR 
The pattern of HMGCR immunoreactivity within the temporal cortex of the 
Cambridge cohort varied between cases. Within the cortex and white matter border 
regions of some cases, HMGCR expression was associated with cells 
morphologically resembling glial cells (Figure 2.5 A). In approximately 35% of the 
cohort, positive glial expression was observed in what appeared morphologically to 
be astrocytes and oligodendrocytes within the white matter regions of the temporal 
cortex sections. To confirm that these positive cells were glial, double–staining IHC 
was carried out for HMGCR and GFAP (astrocytic marker). HMGCR did not co-
localise with GFAP expressing astrocytes in the temporal cortex and white matter 
regions (Figure 2.5 B and C).  
2.4.4 HMGCR expression does not vary with ageing 
To investigate if pyramidal neuronal HMGCR declines with ageing, which may imply 
a decline in cholesterol biosynthesis, further IHC was carried out on young, middle 
aged and old subjects. Formalin fixed prefrontal association cortex (Brodmann area 
8/9) tissue samples from the Edinburgh medical Research Council Sudden Death 
Brain Bank were used. The optimised HMGCR staining protocol was performed on 
each case (n=16). The cases showed positive immunolabelling in pyramidal neurons 
of the prefrontal association cortex, with immunoreactivity localised to the cytoplasm 
of neuronal cell bodies and proximal processes (Figure 2.6 A). Quantification was 
carried out as previously described in 2.3.4. HMGCR neuronal expression did not 
vary significantly between age groups (KW p=0.206), and there was no trend to 
increased or decreased expression with increasing age (JT p=0.641). To ensure that 
the immunostaining was not an artefact of brain donation, correlations between brain 


























































Figure 2.5. HMGCR does not correlate with GFAP expressing astrocytes:  
Immunopositive glial cells in the cortex were detected in approximately 35% of the 
cohort and was associated with cells morphologically resembling astrocytes (A, 
black arrows) and glia (A, red arrows).Using dual labelling, HMGCR 
immunoreactivity (B, red arrow) does not co-localise with GFAP positive 
astrocytes in temporal cortex (A, black arrow). In white matter regions of temporal 
cortex, GFAP positive astrocytes did not co-localise with HMGCR, however 
astrocyte like morphology was observed in HMGCR positive cells (B, black 



























Figure 2.6. HMGCR expression does not change with age: HMGCR immunoreactivity is 
associated with pyramidal neurons in the prefrontal cortex (Brodmann area 8/9) (A). 
HMGCR immunoreactivity was predominantly detected in the cytoplasm of neuronal cell 
bodies and proximal processes. Scale bar represents 100 µm. HMGCR expression is 
not associated with ageing (n=16) (B). Ages were grouped accordingly 0= 16-30yrs 
(n=3), 1= 31-45 yrs (n=3), 2= 46-60 yrs (n=5), 3= 61-75 yrs (n=4) and 4= 75+ yrs (n=1). 
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2.4.5 HMGCR immunoreactivity does not change with dementia status 
To determine if the variation in neuronal expression of HMGCR was associated with 
dementia status a Mann-Whitney U test was carried out. From the cohort 58 cases 
had a dementia diagnosis before death (median=3.70, IQR= 1.69-4.96) and 38 
cases had no dementia (median=3.70, IQR= 1.64-6.10) (Figure 2.7 A).  There was 
no significant difference between HMGCR immunoreactivity between demented and 
non-demented individuals (MW, p=0.59). The distribution of HMGCR 
immunoreactivity by dementia status across specific Braak and Braak stages and 
Thal phases was determined (Figure 2.9 B and C). A pairwise comparison of means 
using Tukey’s adjustment found no significant difference between HMGCR 
immunoreactivity and dementia status at specific Braak and Braak stages and Thal 
phases. The effect of HMGCR immunoreactivity on risk of dementia was analysed 
using logistic regression (Figure 2.7 D). A univariate model adjusted for only age at 
death and sex as covariates, as well as a multivariate model adjusted for Braak and 
Braak, Thal and CAA pathology was produced. HMGCR immunoreactivity was 
analysed as continuous scales and categorically divided into tertiles. None of 
HMGCR models showed any effect on risk of dementia. Statistical analysis in 
relation to dementia status was carried out by Connor Richardson, University of 
Newcastle.  
2.4.6 SREBP2 is expressed in both astrocytes and neurons 
SREBP2 immunoreactivity was present in both neurons and astrocytes. SREBP2 
immunoreactivity within the temporal cortex was associated with neurons and 
localised to the cytoplasm and proximal process within cortical regions (Figure 2.8 A). 
At the cortical and white matter border SREBP2 immunoreactivity was associated 
with astrocytes and localised to the cytoplasm and astrocytic processes (Figure 2.8 
B). As no significant correlations between HMGCR and AD and other pathologies 
were observed, the sole aim of this study was to confirm expression and localisation 
of the key regulator within the brain, hence quantification of SREBP2 



























































Figure 2.7. HMGCR expression does not change with dementia status: HMGCR 
percentage immunoreactivity was compared to dementia status. Box and violin plots 
displaying the distribution and probability density of HMGCR immunoreactivity by 
dementia status (A). Box plots show median, IQR and range, area around the box 
displays the probability density. Wider sections of the violin plots represent a higher 
probability that members of the population will take on the given value; narrower 
sections represent a lower probability. Violin plots showing the distribution of 
HMGCR immunoreactivity by dementia status at specific Braak and Braak stage (C) 
and Thal phase (D). No significant difference between HMGCR immunoreactivity and 
dementia status was found. Table D shows the output from logistic regression 
modelling (D). A univariate model adjusted for age at death and sex, multivariate 
models adjusted for Braak and Braak, Thal and CAA pathology. HMGCR 
immunoreactivity was modeled on a continuous scale and categorically by tertiles. 
Results are presented as odd ratios (OR) with 95% confidence intervals (CI) and p 
values. Statistical analysis and violin plots courtesy of Connor Richardson, University 





















































Figure 2.8. SREBP2 is expressed in both neurons and astrocytes: SREBP2 
immunoreactivity was associated with pyramidal neurons within the temporal cortex 
(A) and (C). SREBP2 immunoreactivity was also present in astrocytes within the 
white matter and grey matter border regions of the temporal cortex (B) and (D). 




The cholesterol biosynthesis pathway has a vital role in maintaining normal neuronal 
function. In this chapter the expression of key regulatory proteins in cholesterol 
biosynthesis were characterised using IHC. HMGCR was localised to pyramidal 
neurons in both temporal and prefrontal association cortex. SREBP2 was localised 
to both astrocytes and neurons in the temporal cortex. This study found that the 
variation in the expression of HMGCR, determined by IHC, did not alter with 
dementia status, increasing AD neuropathology, neuronal DNA damage, 
neuroinflammation or ageing.   
2.5.1 Neuronal expression of HMGCR in the temporal cortex    
Immunohistochemical characterisation of HMGCR in human post-mortem temporal 
cortex tissue showed positive immunolabelling in pyramidal neurons in all cases and 
positive immunoreactivity in oligodendrocytes and astrocytes was observed in 
approximately 35% of the cohort. The presence of this key rate-limiting enzyme and 
its regulator SREBP2 suggests that the pyramidal neurons of the temporal cortex 
may synthesise cholesterol. This is a significant finding as many studies have shown 
glial cells to undertake the bulk of the cholesterol production within the brain 
(Pfrieger, 2003; Nieweg, Schaller and Pfrieger, 2009; Pfrieger and Ungerer, 2011; 
Zhang and Liu, 2015). There is experimental data to suggest that neurons can 
synthesis cholesterol as well as glial cells. In murine hippocampal cells, resistant to 
oxidative stress from H2O2, a decrease in the mRNA levels of HMGCR was observed 
however, these cells also showed an increase in total cholesterol levels. This shows 
that neurons express HMGCR and are able to synthesise cholesterol (Clement et al., 
2009). Rat pyramidal neurons have also been shown to express enzymes involved in 
neurosteroidogenesis, which suggests that neurons synthesise cholesterol as a 
precursor molecule for other steroid hormones (Tsutsui et al., 2000). Further studies 
using primary rat neurons have shown that neurons are able to uptake radioactively 
labelled acetate (a precursor molecule for cholesterol synthesis) and synthesise 
cholesterol. However, the efficiency of cholesterol synthesis is lower in neurons 
compared to glial cells (Nieweg, Schaller and Pfrieger, 2009) 
The cholesterol biosynthesis pathway comprises of the mevalonate, Bloch and 
Kandutsch-Russell pathway. In neurons a hybrid between the Bloch and Kandutsch-
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Russell pathways have been shown to be involved in cholesterol production (Mitsche 
et al., 2015). New evidence suggests that murine cortical neurons retain an active 
mevalonate pathway and redirect its resources to maintaining activity within this 
pathway rather than producing cholesterol (Moutinho, Nunes and Rodrigues, 2017). 
By studying the RNA-Seq transcriptome in murine cortical neurons, the expression of 
genes involved in both pre and post squalene pathways were down regulated in 
comparison to astrocytes. However, genes involved in the non-sterol pathway were 
upregulated. This suggests that within murine cortical neurons, the mevalonate 
pathway is maintained and used in the production of isoprenoids rather than 
cholesterol (Cahoy et al., 2008b; Zhang et al., 2014; Moutinho, Nunes and 
Rodrigues, 2017). This data would suggest that one possible reason for HMGCR 
expression within neurons is to allow the production isoprenoids such as farnesyl 
pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) rather than 
cholesterol (Eckert et al., 2009).  
FPP and GGPP are isoprenoids which are involved in the prenylation of proteins, a 
post-translational modification, allowing insertion into membranes and determining 
their function and localisation. FPP is formed from the mevalonate arm of the 
cholesterol biosynthesis pathway and is a precursor for both cholesterol and GGPP 
(Eckert et al., 2009). The literature suggests that prenylated proteins such as FPP 
and GGPP may have a role in AD pathogenesis. One study reported the involvement 
of GGPP in γ-secretase activity in SH-SY5Y neuroblastoma cells; and FPP and 
GGPP increase the Aβ levels in H4 neuroglioma cells by increasing γ-secretase 
activity (Kukar et al., 2005; Urano et al., 2005).   
Further studies have shown that levels of FPP and GGPP are altered in AD. Using 
post-mortem human frontal cortex tissue, Eckert et al (2009), found that FPP and 
GGPP levels were increased in male AD patients compared to controls, whereas 
cholesterol levels and HMGCR gene expression did not differ between the two 
groups (Eckert et al., 2009). Inhibition of HMGCR, using statins, in mice showed a 
reduction in FPP, GGPP and cholesterol levels (Eckert et al., 2009). This suggests 
that within neurons the mevalonate arm of the cholesterol biosynthesis pathway is 
diverted to isoprenoid synthesis rather than cholesterol, providing a possible 
explanation as to why HMGCR expression is observed in pyramidal neurons.  
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2.5.2.1 HMGCR expression in relation to AD pathologies    
The neuronal expression of HMGCR did not correlate with Braak and Braak stages 
or Thal phase in this study.  Furthermore, the expression of HMGCR did not 
correlate with markers of DNA damage or neuroinflammation. A study found that 
both APP and β-amyloid interact with cholesterol and catalyse the metabolism of it 
into 7β-hydroxycholesterol, which is neurotoxic (Nelson and Alkon, 2005). However, 
our data suggests that there is no correlation between HMGCR expression and 
amyloid plaque expression. Aβ can exist in multiple forms: monomeric, oligomeric, 
fibrils and aggregates, hence it’s crucial that when measuring Aβ it’s important that 
the relevant form is investigated (Ladanza et al., 2018). In the study by Simpson et al 
(2010) from which the β-amyloid immunoreactivity data was obtained, an antibody 
which labelled residues 8-17 of the N-terminal of the Aβ peptide was used and this 
labelled β-amyloid plaques (J. E. Simpson et al., 2010). This antibody labels both 
diffuse and compact forms of tissue deposits but does not provide a measure of 
oligomeric Aβ. 
Oxidative stress is a feature of brain ageing and may contribute to the pathogenesis 
of AD. It is defined as the imbalance between biochemical processes leading to ROS 
being produced and those processes responsible for the removal of ROS (Harman, 
1981; Recuero et al., 2009). Accumulation of ROS within neurons causes DNA 
damage and induces a DNA damage response which leads to cellular senescence 
and may contribute to neuronal dysfunction (Simpson et al., 2015). 
Neuroinflammation is the activation of microglia as a response to brain injury, 
pathogens, neurotoxins and abnormal stimulation within the CNS (Bradl and Hohlfeld, 
2003; Carson et al., 2006; Park et al., 2011). Prolonged activation of microglia leads 
to secretion of cytokines and neurotoxins leading to chronic neuroinflammation and 
contributing to neurodegeneration (Lyman et al., 2014). Neuroinflammation has been 
shown to be involved in the pathogenesis of AD (Shabab et al., 2017). Studies 
suggest that mitochondrial dysfunction in microglia results in excess ROS production 
and stimulates pro-inflammatory cytokine release, which induces neuroinflammation 
and promotes neuronal damage (Vyas et al., 2016; Wu et al., 2016). 
To assess variation with DNA damage, HMGCR immunoreactivity was compared to 
γH2AX immunoreactivity in the temporal cortex (J. E. Simpson et al., 2010). H2AX is 
a core histone molecule, which forms part of the nucleosome complex, and is 
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recruited at sites of double stranded breaks (DSBs) where it is phosphorylated on 
the 139th serine residue to form γH2AX foci. The presence of foci aids in the 
recruitment of DNA repair machinery and acts as an indicator of DSBs in a 1:1 
manner allowing assessment of DNA damage (Kuo and Yang, 2008). Our data 
suggests that there is no correlation between HMGCR expression and neuronal 
γH2AX expression suggesting that the variation in expression in HMGCR does not 
correlate to DNA damage.  
Previous studies from our lab have shown that at low Braak and Braak stages there 
is an increase in oxidative stress markers compared to high Braak and Braak stages. 
Furthermore, high levels of oxidative stress was associated with a DNA damage 
response (DDR) (J. E. Simpson et al., 2010). Further work based on gene 
expression showed that there was an overexpression of HMGCR in cases with high 
neuronal DDR suggesting that there is a link with oxidative DNA damage (Simpson 
et al., 2016). The results from the study by Simpson et al (2016) do not contradict the 
findings from this current study however; there are differences between the two 
studies, which could account for the differing results.  The work carried out in this 
study was on temporal cortex regions of brain compared to the frontal cortex tissue 
that was used for the study by Simpson et al, (2016). Another key difference is that 
in the study by Simpson et al, (2016) measured RNA quantitatively whereas in this 
current study HMGCR was measured using immunohistochemistry. Quantifying 
using immunohistochemistry has limitations as this method only takes into account 
the number of pixels that contain the chromogen and not the density of chromogen 
present, it is difficult to quantify the protein amount, as the number of pixels is not 
directly proportional to the amount of antigen (Matkowskyj et al., 2003).    
The deposition of Aβ plaques is a source of oxidative stress leading to DNA damage 
within neurons. The base excision repair (BER) system is a mechanism responsible 
for repairing DNA damage caused by oxidative stress (Kwiatkowski et al., 2016). 
One study found that patients with AD showed an increase in the level of DNA 
damage compared to control patients. They also observed polymorphisms in genes 
involved in the BER response which may contribute to the increase in DNA damage 
(Kwiatkowski et al., 2016).     
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HMGCR immunoreactivity was compared to CD68 immunoreactivity in the temporal 
cortex to assess whether it was affected by neuroinflammation. CD68 is a 
glycosylated type 1 transmembrane glycoprotein localised to endosomal/lysosomal 
compartments and is expressed on the surface of macrophages (Chistiakov et al., 
2017). Within the brain, the microglia play the role of macrophages and act as a first 
line of defence against pathogens and changes to homeostasis (Hendrickx et al., 
2017). CD68 is located in the lysosmal compartments near the nucleus in ramified 
and amoeboid microglia and its expression increases during phagocytosis, 
suggesting that it is a marker of microglial activation, and for neuroinflammation 
(Hendrickx et al., 2017). Our study found that the immunoreactivity of HMGCR did 
not correlate with immunoreactivity of CD68.   One study looked at the effect of a 
high cholesterol diet in young and old mice and found that in aged mice on a normal 
diet microglial activation was observed and in mice fed with a high cholesterol diet 
showed a further increase in microglial activation and secretion of inflammatory 
cytokines such a IL-1β, IL-6 and TNF-α (Chen et al., 2018). This suggests that a high 
cholesterol diet could cause neuroinflammation via microglial activation, however the 
data from this study does not demonstrate this relationship.  
2.5.2.2 HMGCR as a potential therapeutic target for AD    
Statins are a class of drugs that inhibit the action of HMGCR and are prescribed to 
patients with hypercholesterolemia. Considering the fact that the prescription of 
statins is increasing, especially amongst the ageing population, it is important to 
assess the effect they have on AD progression (Trusler, 2011). Statins are 
competitive inhibitors which target the active site of the HMGCR enzyme. When 
bound, statins result in a conformational change of the active site preventing the 
binding of its endogenous substrate and disabling functional structure (Stancu and 
Sima, 2001). Studies have shown that cholesterol-lowering drugs reduce the levels 
of Aβ. However, the use of statins as a therapy for AD needs further research 
(Refolo et al., 2001; McGuinness et al., 2014). BBB permeability of statins depends 
on the type of statin, lipophilic statins can easily cross the BBB compared to 
hydrophilic statins (Daneschvar, Aronson and Smetana, 2015). A trial showed that 
atorvastatin had a positive effect on cognition in patients with mild-to-moderate AD 
compared to a placebo (Sparks et al., 2006). After 6 months there was an 
improvement in the Alzheimer Disease Assessment Scale-Cognitive (ADAS-cog) 
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score and this therapy was more effective in patients that carried the apoE ε4 allele. 
However, this study only had 63 participants all of which had been diagnosed with 
AD (Sparks et al., 2006). Another trial found that simvastatin did not have an effect 
on ADAS-cog and had no effect on the progression of AD symptoms (Sano et al., 
2011). Within the CFAS cohort a few cases had been recorded to take stains, 
however due to the lack of data and few n numbers any relationships between 
HMGCR immunoreactivity and statin use was not assessed.  
One study using a transgenic mouse model has shown that cholesterol lowering 
drugs can reduce the levels of β-amyloid (Refolo et al., 2001). This study used a 
compound called BM15.766 which inhibits the activity of 7-dehydrocholesterol-Δ7-
reductase which is involved in the conversion of 7-dehyrocholesterol to cholesterol 
(Mazein et al., 2013). They found that treatment with this drug reduced the levels of 
Aβ42 and Aβ40 as well as a reduction is plasma cholesterol levels and induced 
hypocholesterolaemia. Unfortunately the drug compound used caused a toxic build-
up of sterols making it an unviable option for human clinical trials however, it is a 
good proof of principle that by using pharmacological intervention to lower 
cholesterol levels can cause a reduction in Aβ levels (Refolo et al., 2001). Currently 
there is no convincing evidence that statins provide an effective treatment for AD and 
so further research into this avenue needs to be carried out. 
2.5.3 Glial expression of HMGCR in the temporal cortex 
In cortical and white matter boundary areas, positive immunolabelling for HMGCR 
was found in glial cells such as astrocytes and oligodendrocytes in approximately 35% 
of the cohort.  One study showed that both rat retinal ganglion cells and rat 
astrocytes cells synthesise cholesterol. However, cholesterol synthesis in neurons 
was inefficient compared to cholesterol synthesis within glial cells, possibly due to 
the lack of enzymes involved further downstream (Nieweg, Schaller and Pfrieger, 
2009; Moutinho, Nunes and Rodrigues, 2017). Astrocytes use the Bloch pathway to 
carry out cholesterol synthesis following the synthesis of Lansosterol via the 
mevalonate pathway; and the synthesised cholesterol is transported to neurons 
using apolipoproteins (Nieweg, Schaller and Pfrieger, 2009; Pfrieger and Ungerer, 
2011). As a result, expression of HMGCR in glial cells within the cortex might be 
expected but this was not demonstrated in our study. 
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Approximately 80% of total brain cholesterol is incorporated into myelin membranes. 
Myelin is an extension of the oligodendrocyte plasma membrane which 
encompasses axons allowing fast transduction of neuronal signals across a large 
distance, critical for essential brain functions (Saher and Stumpf, 2015). Cholesterol 
which contributes to the formation of myelin is synthesised by oligodendrocytes, in a 
study which conditionally knocked out fdft1, a gene involved in the condensation of 
squalene synthase (part of the mevalonate arm of the cholesterol biosynthesis 
pathway), in mice oligodendrocytes. They found that in the conditional knockout, the 
mice exhibited motor deficits such as ataxia and impaired control of hind limbs 
(Saher et al., 2005). Histological characterisation showed severe demyelination in 
white matter tracts in brain and spinal cord, providing evidence of the importance of 
cholesterol synthesis in oligodendrocytes for myelin synthesis (Saher et al., 2005). 
This suggests that HMGCR is expressed in oligodendrocytes and could be 
responsible for the positive immunoreactivity observed in our study. 
Our study found that HMGCR did not co-localise with GFAP expression in the 
temporal cortex. GFAP is a protein, which makes up the intermediate filaments of the 
astrocytic cytoskeletal, in reactive astrocytes this protein is overexpressed (Carter et 
al., 2019). However, studies have found that GFAP only accounts for 15% of the 
astrocyte volume and 40% of astrocytes within the adult rat hippocampus do not 
express GFAP (Walz and Lang, 1998; Bushong et al., 2002). This suggests that 
carrying out staining with a different marker may be more appropriate, such as 
NDRG2 or ALDH1L1. Aldehyde dehydrogenase L 1 (ALDH1L1) is an astrocytic 
marker which is present in astrocytic cell bodies and extensive processes, 
immunohistochemical staining in rat tissue has shown an increased number of 
ALDH1L1 positive astrocytes compared to GFAP positive astrocytes (Neymeyer, 
Tephly and Miller, 1997; Cahoy et al., 2008a).  NDGR2 is a gene associated with cell 
differentiation and proliferation, which is specifically expressed in mature, 
nonreactive and non-proliferating astrocytes (Shen et al., 2008; Flügge et al., 2014). 
One study found that NDRG2 is a more appropriate marker for cortical astrocytes in 
mouse cerebral regions compared to GFAP however, GFAP is better at labelling 
astrocytic processes and branches in the white matter regions such as the corpus 
callosum and cerebral peduncles (Z. Zhang et al., 2019).  Recent work carried out in 
our lab has also demonstrated that NDGR2 positively correlates with tau pathology 
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within the aging brain (Fadul et al., 2020). This study shows that not all astrocytes 
are NDGR2 positive, so no matter which markers are selected, not all astrocytes will 
be labelled. Use of multiple astrocytic markers would allow more astrocytes to be 
labelled and further determine co-localisation with HMGCR.   
2.5.4 HMGCR expression during ageing 
Since cholesterol plays such a vital role in maintaining neuronal function, therefore 
cholesterol synthesis becomes crucial during development. A study in mice 
demonstrated that during the first three weeks of life the rate of cholesterol synthesis 
is 250 µg/day, however after three weeks, the rate drops to 25-35 µg/day (Quan et 
al., 2003). Conversely, most of the cholesterol produced during development, 
contributed to myelin formation and therefore, the cholesterol is synthesised by 
oligodendrocytes (Dietschy, 2009).  
Neurons are capable of synthesising cholesterol during development. A study in 
mice where cholesterol biosynthesis in forebrain projection neurons was ablated 
showed that cholesterol demand is maintained by microglial cholesterol production 
and delivery, however they found that after birth neuronal degeneration occurred 
(Fünfschilling et al., 2012). In vitro studies showed that the ablation of cholesterol 
synthesis in forebrain projection neurons lead to neuronal death in 2-4 days in vitro 
(Fünfschilling et al., 2012). Further evidence demonstrating neuronal de novo 
cholesterol synthesis in vitro where primary murine cortical neurons were cultured in 
cholesterol free medium, cholesterol accumulation within the neurons was observed 
(Genaro-Mattos et al., 2019a).  
During ageing, there is an overall decrease in cholesterol levels however; the degree 
of change depends on the specific region. In a study that looked at human post-
mortem brains they found that in grey and white matter regions there was a 
significant decreases in cholesterol content compared to younger brains whereas, in 
the pons there was very little change in cholesterol content over ageing (Söderberg 
et al., 1990). These changes in cholesterol have been suggested to be caused by 
synapse loss and a reduction in neuron size (de Chaves and Narayanaswami, 2008).   
Over the course of life cholesterol synthesis within the brain decreases. One study 
examined the concentrations of various intermediate sterols from the cholesterol 
biosynthesis pathway in the hippocampus from post-mortem human tissue. In both 
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young and elderly group, the cholesterol concentrations remained constant. However, 
the concentration of lathosterol and lanosterol (cholesterol precursors) was 
significantly higher in the younger group compared to the elderly group (Thelen et al., 
2006). This suggests that cholesterol synthesis is reduced during ageing. Further 
evidence supporting this was found by Raihan et al., where microRNA miR-335-3p 
was elevated in murine hippocampal brain as well as aged murine primary 
astrocytes. MiR-335-3p was found to supress the action of HMGCS1 and HMGCR 
by binding to the 3’ untranslated region (3’UTR) of mRNA preventing protein 
synthesis in astrocytes, thus reducing cholesterol production (Raihan et al., 2018).        
In our study, we found that HMGCR was expressed in the pyramidal neurons in 
prefrontal association cortex (Brodmann area 8/9). This suggests that the expression 
of HMGCR is uniform within the cerebral cortices as identical punctate staining within 
the cytoplasm and proximal processes in both temporal and prefrontal cortices was 
observed. The post-mortem tissue was obtained from the Edinburgh Medical 
Research Council Sudden Death brain bank; the cases that were used had no 
history of neurological disease and covered a large age range (16-75+ years of age). 
The expression of HMGCR did not show any correlation to an increase in age. 
However, this expression could be due to the neurons using the mevalonate arm of 
the pathway to synthesis isoprenoids. The isoprenoids FPP and GGPP have been 
shown to be significantly increased in 23-month old mice compared to 3-month-old 
mice at a protein level however; at gene expression level no difference was 
observed. Interestingly the levels on HMGCR gene expression was increased in 
older mice however, cholesterol levels remained unaffected (Hooff et al., 2012). This 
suggests that HMGCR expression is used for isoprenoid production rather than 
cholesterol synthesis, as murine adult neurons in vivo have been shown to survive 
without endogenous cholesterol synthesis (Fünfschilling et al., 2007).  
2.5.5 HMGCR expression and dementia 
Data from this current study showed that there was no significant association 
between HMGCR immunoreactivity within the temporal cortex and dementia status. 
A population-based prospective study called the Conselice study of brain ageing 
patients were recruited based on age. Biological and clinical data was collected from 
the patients over two interviews five years apart. Licastro et al (2010) applied a novel 
data mining process to identify consistent patterns and systematic relationships 
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between variables using a minimum spanning tree (MST) algorithm to determine any 
links. This study found that both variants of HMGCR genotype were relevant factors 
for developing dementia (Licastro et al., 2010). Another epidemiological study found 
that the splice variant rs3846662 of HMGCR was a potent modifier of AD risk (Leduc 
et al., 2015). HMGCR gene has two possible alleles G and A, alternative splicing 
leads to full length and a variant containing a single nucleotide polymorphism (SNP) 
at locus rs3846662 which results in alternative splicing of exon 13. The skipping of 
exon 13 (Δ13) is more common in A allele rather than the G allele. The exact effect 
of the SNP remains unknown but it is suggested that it may result in a reduced or 
lack of enzymatic activity (Johnson et al., 2003; Burkhardt et al., 2008; Medina and 
Krauss, 2009; Yu et al., 2014). In the study by Leduc et al (2015) the HMGCR splice 
variant was studied in three case control cohorts and found that the G allele was a 
protective variant for sporadic AD and delayed the onset of sporadic AD in women 
(Leduc et al., 2015). These studies suggest a clear link between HMGCR and 
dementia whereas this current study found no significant difference. It is important to 
note that, the studies by Licastro et al (2010) and Leduc et al (2015) measure 
HMGCR at a genetic level in a mixture of blood plasma and brain tissue. Whereas, in 
this study we have measured HMGCR at a protein level in a specific region of the 
brain this could account for the differences in results between the studies. 
2.5.6 SREBP2 expression  
In our study, we found SREBP2 to be localised in both astrocytes and neurons within 
the temporal cortex. SREBP2 is a membrane bound transcription factor, which is 
involved in the regulation of transcription of genes involved in cholesterol 
biosynthesis (Zhang and Liu, 2015). Within neurons, SREBP2 was localised to the 
cytoplasm and the proximal processes, within astrocytes positive immunolabelling 
was found in the cytoplasm and astrocytic processes. Astrocytic immunoreactivity 
was absent within the cortical layers however, it was present within the cortical and 
white matter boundary. The presence of SREBP2 suggests that cholesterol levels 
have depleted within the cells and cholesterol biosynthesis is trying to be 
upregulated (Horton et al., 2003).    
When the level of cellular cholesterol is low, SREBP2 forms a complex with SCAP 
(SREBP cleaving-activating protein) and is translocated from the endoplasmic 
reticulum (ER) membrane to the Golgi apparatus membrane, where it undergoes 
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proteolytic cleavage by proteases. This cleavage produces two fragments, one of 
which can translocate to the nucleus and switches on genes for cholesterol 
biosynthesis (HMGCR) and cholesterol uptake through low-density lipoprotein (LDL) 
receptors (Goldstein, DeBose-Boyd and Brown, 2006).  
When an increase in sterols is detected within the ER, cholesterol binds to SCAP, 
which leads to a conformational change and causing it to bind with INSIG. INSIG is 
an ER protein which binds to the SCAP/SREBP2 complex preventing translocation 
from the ER to the Golgi (Yang et al., 2002). This prevents the proteolytic processing 
and cholesterol biosynthetic gene expression decreases (Goldstein, Rawson and 
Brown, 2002). Furthermore, during high cholesterol levels, HMGCR is degraded as a 
result of INSIG-1 binding to the sterol sensing domain of HMGCR, leading to 
accelerated ubiquitination (Sever et al., 2003). 
The data sheet provided by the antibody supplier (Abcam, UK) states that the 
antibody is specific to amino acids 876-890 of SREBP2 peptide. This falls within the 
COOH-terminal of the protein forming part of the regulatory domain within the 
cytosolic portion of the protein (Horton, Goldstein and Brown, 2002). When 
cholesterol levels are normal SCAP binds to the COOH-terminal keeping it within the 
ER (Sakai et al., 1997). This suggests that the cytosolic expression of SREBP2 in 
both astrocytes and neurons suggest that there are no changes in cellular 
cholesterol, as expression is not localised to Golgi body or nucleus.  
The expression of SREBP2 has been demonstrated in neurons and astrocytes in 
previous studies. One study found that insulin activates the cholesterol biosynthesis 
pathway in mouse primary cortical neurons, where a significant increase in SREBP2 
gene expression was observed at 100 nM of insulin. In type-1 insulin deficient mice a 
decrease in SREBP2 expression was observed at both protein and mRNA levels 
suggesting that the absence of insulin was down regulating cholesterol biosynthesis 
(Suzuki et al., 2010). Knockdown of SREBP2 in mouse hypothalamic cultured 
neurons showed a decrease in synaptic markers in vivo this hypothalamic 
knockdown translated to an increase in nocturnal food intake and affects the 
circulation of norepinephrine and glucagon (Suzuki et al., 2010). Additionally, 
SREBP2 knockdown in cultured murine astrocytes shows a reduction in neurite 
outgrowth in co-culture, in vivo astrocytic knockdown leads to impaired brain 
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development and motor and behavioural defects (Ferris et al., 2017). This 
demonstrates the crucial role SREBP2 plays in maintaining overall brain function and 
specifically maintaining normal neuronal function.  
Studies have demonstrated that Aβ may have a role to play in cholesterol 
biosynthesis. One study found that oligomeric Aβ inhibited SREBP2 maturation in 
neurons in vitro (Mohamed et al., 2018a). Incubating rat sympathetic, rat striatal 
(St14A) and cortical neurons with 20 µM of oligomeric Aβ a significant reduction in 
protein expression was observed in all cell types. Furthermore, in TgCRND8 mice 
(mouse model for AD) lower levels of SREBP2 were observed in frontal cortices, 
suggesting that Aβ may negatively regulate cholesterol biosynthesis (Mohamed et al., 
2018a). Further evidence demonstrating the regulatory role of Aβ was shown by 
Wang et al (2014) where, different ways of processing of Aβ had a different effect of 
cholesterol metabolism (Wang et al., 2014). In a human astocytoma cell line and AD 
patient derived fibroblasts, cleavage of APP by α-secretase had a positive effect on 
SREBP2 leading to an increase in expression on cholesterol biosynthetic genes, 
whereas cleavage with β-secretase had the opposing effect (Wang et al., 2014). In 
primary rat cortical neurons, oligomeric Aβ reduced cellular cholesterol by reducing 
cholesterol synthesis however, a change in SREBP2 expression was not observed, 
suggesting that cholesterol synthesis is inhibitied at a post-transcitional level (J. S. 
Gong et al., 2002). Together, these studies demonstrate the role APP processing 
and Aβ has on cholesterol metabolism.    
NFT may also play a role in SREBP2 mediated cholesterol synthesis. One study 
found that the N-terminal of SREBP2 was localised in the cytoplasm of pyramidal 
neurons from the hippocampus in AD brains, compared to age-matched control 
brains where the N-terminal of SREBP2 was localised to the nucleus (Wang et al., 
2019). The study also found that a negative assocaitation with AT8-positive NFTs 
and the nuclear localisation of SREBP2, suggesting that NFTs may be involved in 
the regulation of cholesterol synthesis (Wang et al., 2019).  
2.5.7 Limitations 
The use of IHC has certain limitations; for example, the quantification method that is 
used, types of antibody used and the tissue type. Furthermore, the IHC method does 
not provide a linear assessment of protein concentration and cannot provide a 
measure of enzyme activity. This makes it difficult to assess if HMGCR is 
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enzymatically active to result in an increase in cholesterol biosynthesis - therefore a 
measure of brain cholesterol was carried out to see if HMGCR expression 
associated with brain tissue cholesterol levels (3.4.20). There are two main ways in 
which tissue for IHC can be prepared: firstly, and the most common is formalin-fixed 
paraffin embedded (FFPE) tissue; the second is by snap freezing the tissue using 
liquid nitrogen and fixing using acetone (S. R. Shi et al., 2008). The use of FFPE 
tissue requires antigen retrieval, this reverses crosslinks between proteins leading to 
unmasking of the epitope however, sometimes this may alter the way in which the 
antigen is recognised by the antibody, making comparisons between studies difficult 
(Engel and Moore, 2011).  
Other points to consider when comparing IHC studies include the type of antibody 
that is used. In this study a monoclonal antibody was used, these types of antibodies 
are more specific compared to polyclonal antibodies however; this may also become 
a limiting factor, as small changes in the epitope sequence, such as ones that may 
occur during antigen retrieval, would prevent binding (Lipman et al., 2005). 
Polyclonal antibodies on the other hand can still recognise a host of antigenic 
epitope sequences, meaning that changes that may occur during antigen retrieval 
can still cause antibody/antigen complexes. However, this decrease in specificity can 
lead to cross reactivity and increase non-specific background staining (Lipman et al., 
2005).   
The method of quantification will have a role to play when comparing studies. The 
method employed within this study was based on the percentage total 
immunoreactivity per image. However, as this method only takes into account the 
number of pixels that contain the chromogen and not the density of chromogen 
present, it is difficult to quantify the protein amount, as the number of pixels is not 
directly proportional to the amount of antigen (Matkowskyj et al., 2003). In addition, 
the detection system used by the programme is not linear, which means that once a 
pixel exceeds the threshold value and is marked as positive the amount of protein 
that is present becomes irrelevant and is not considered in the final percentage value. 
Furthermore, the use of ABC/DAB to amplify and visualise the binding of the 
antibody plateaus at a certain maximum, this in turn prevents the further binding of 
antibody to antigen from being detected and therefore having an impact on 
quantification as the immunoreactivity is not a true representation of antigen 
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expression. One way in which this could be avoided is by using primary antibodies 
which are conjugated with a fluorophore or horseradish peroxidase, allowing for a 
more accurate representation, however it may be difficult to visualise if there is a low 
concentration of antigen expression (Matkowskyj et al., 2003).  
Other limitations that need to be considered for this study are the markers of 
oxidative stress and neuroinflammation that have been used. This study used 
markers that had been characterised using IHC so therefore the limitations of these 
needs to be considered. Furthermore, in this study correlation analysis was carried 
out on γH2AX as a marker for DNA damage from oxidative stress, other markers 
such as Malondialdehyde (marker of lipid peroxidation), 8-hydroxydeoxyguanosine 
(marker of oxidative DNA damage), thioredoxin-2 (marker of ROS induced oxidative 
stress) and peroxiredoxin-3 (marker of ROS induced oxidative stress). The use of 
multiple oxidative stress markers would further validate any associations with 
HMGCR immunoreactivity and oxidative stress. Similar limitations also apply to 
markers of neuroinflammation, correlation analysis was carried out on CD68 
immunoreactivity as a marker of microglial activation, other markers such as major 
histocompatibility complex class 2 (marker of microglial activation) and GFAP 
(marker of gliosis) could be used to provide a more robust analysis of association of 
HMGCR immunoreactivity and neuroinflammation.  
2.6 Conclusion 
This study has found that HMGCR expression was associated with pyramidal 
neurons throughout all layers of the temporal cortex. This is a novel finding as 
currently the literature suggests that glial cells are responsible for cholesterol 
biosynthesis within the brain however, we have found that the key regulatory enzyme 
of the pathway is expressed in neurons. Neuronal expression of HMGCR is not 
altered by Alzheimer-type neuropathology, markers of oxidative stress and markers 
of neuroinflammation. No significant association between HMGCR immunoreactivity 
within the temporal cortex and dementia status were found. Positive immunolabelling 
was also observed in prefrontal association cortex and quantification showed that 
HMGCR expression did not change with age. HMGCR expression was localised to 
the cytoplasm and proximal process of pyramidal neurons and expression was also 
observed in cells morphologically resembling astrocytes and oligodendrocytes within 
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white matter regions of temporal cortex sections. Dual-IHC confirmed that HMGCR 
and GFAP positive astrocytes did not co-localise in the temporal white matter and 
cortical regions. One possible explanation for the neuronal expression of HMGCR, 
could be that neurons are using the mevalonate arm of the cholesterol biosynthesis 
pathway to synthesis isoprenoids and other molecules, rather than cholesterol. 
Furthermore, this study has also shown that SREBP2, a master gene regulator for 
the cholesterol biosynthesis pathway is expressed in both neurons and astrocytes in 
temporal cortex and white matter regions, respectively. SREBP2 is localised to the 
neuronal cytoplasm and proximal process and within astrocytic cytoplasm and 





































3.0 Determining expression of key regulators of cholesterol homeostasis and 
measuring cholesterol concentration in the ageing brain 
3.1 Introduction  
Cholesterol homeostasis within the brain is achieved by balancing de novo 
cholesterol biosynthesis, cholesterol metabolism and cholesterol efflux. Maintaining 
cholesterol homeostasis within the brain is crucial as cholesterol is fundamental for 
development and during adult life (Zhang and Liu, 2015).  Cholesterol biosynthesis is 
regulated by the action of two key enzymes, HMG CoA reductase (HMGCR) and 
Sterol Regulatory Element-Binding Protein 2 (SREBP2). HMGCR encodes for an 
enzyme which catalyses the conversion of HMG-CoA into mevalonate and is the rate 
determining step of the cholesterol biosynthesis pathway (Sharpe and Brown, 
2013b). HMGCR is localised to the endoplasmic reticulum (ER) membrane and 
immunohistochemical analysis for this study has shown that HMGCR protein is 
expressed in the pyramidal neurons within the temporal cortex (2.4.1). SREBP2 
gene encodes for a transcription factor which is responsible for controlling the 
expression of genes involved with cholesterol biosynthesis such as HMGCR (Sakai 
et al., 1996; Simons and Ilonen, 2000; Goldstein, DeBose-Boyd and Brown, 2006). 
Immunohistochemical analysis from this study has demonstrated that the SREBP2 
protein was expressed in both the cytoplasm of neurons and astrocytes in the 
temporal cortex and cortical and white matter boundary respectively (2.4.6).  
Within the brain, neurons and glia do not have the capability of breaking down 
cholesterol and so rely on the liver for degradation. However, the blood brain barrier 
(BBB) prevents cholesterol from entering the peripheral circulation and reaching the 
liver (Sun, Yu and Tan, 2015). One major excretion route of cholesterol within the 
brain is via conversion to oxysterols such as 24S-hydroxycholesterol (24S-OHC) and 
27-hydroxycholesterol (27-OHC) which can easily pass through the BBB into the 
peripheral circulation and be further metabolised into bile acids within the liver (Sun, 
Yu and Tan, 2015; Zhang and Liu, 2015; Chang et al., 2017). The conversion of 
cholesterol into 24S-OHC is catalysed by the enzyme cholesterol 24-hydroxylase 
which is encoded by the gene CYP46A1, which is a member of cytochrome P450 
protein family (Erik G. Lund, Guileyardo and Russell, 1999). The conversion of 
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cholesterol into 27-OHC is catalysed by sterol 27-hydroxylase and is encoded by the 
gene CYP27A (Heverin et al., 2005).  
CYP46A1 gene is located on chromosome 14q32.1 and contains 15 exons, which 
result in a protein that contains approximately 500 amino acids. The enzyme is 
localised to the ER membrane and is preferentially expressed within neurons (Erik G. 
Lund, Guileyardo and Russell, 1999). Genetic association studies have found that a 
single nucleotide polymorphism (SNP) within an intron between exon 3 and 4 of the 
CYP46A1 gene is significantly associated with AD compared to healthy controls and 
is also associated with an increase in 24S-OHC/cholesterol ratios in CSF (Kölsch et 
al., 2002). Another study found that one allele of CYP46 (TT allele) caused by a SNP 
in which a T is substituted for C 151 bases 5’ to exon 3 (rs754203) was associated 
with increased Aβ peptide levels in both the brain and CSF of AD patients; and 
increased levels of phosphorylated tau within CSF of AD patients (Papassotiropoulos 
et al., 2003). However, the same SNP did not show any significant associations with 
AD, brain Aβ or NFT levels in a different cohort (Ingelsson et al., 2004). Further 
studies have shown that the TT-homozygote genotype in young healthy patients had 
the smallest parahippocampal and hippocampal volumes compared to heterozygotes 
and CC-homozygotes (Hänggi et al., 2011). These studies suggest that SNPs in 
CYP46A1 may be a risk factor for AD.  
Studies in vitro have shown that 24S-OHC has a neurotoxic effect by producing free 
radicals leading to oxidative stress and eventual cell death via apoptosis (Kölsch et 
al., 1999, 2001b).  Human neuroblastoma cells exposed to exogenous 24S-OHC, 
showed a significant increase in α-secretase activity and a significant decrease in β-
secretase activity (Famer et al., 2007). This study suggests that the presence of 
24S-OHC promotes the non-amyloidogenic pathway due to the activation of α-
secretase. Another study found that treating human neuroblastoma cells expressing 
human APP with physiological concentrations of 24S-OHC resulted in a decrease in 
Aβ production, suggesting that the reduction in Aβ production could be due to 24S-
OHC inhibiting the tracking of APP within the ER (Urano, Ochiai and Noguchi, 2013). 
This study further reinforced the protective effect 24S-OHC and hence CYP46A1 
expression on preventing the formation of Aβ peptides.     
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The CYP27A1 gene is part of the cytochrome p450 family and encodes for a 
mitochondrial enzyme 27-hydroxylase. Within the liver, 27-hydroxylase is involved in 
catalysis of the first step of bile acid biosynthetic pathway and in other tissues 27-
hydroxylase is involved in converting cholesterol into 27-OHC and 3β-hydroxy-5-
cholestenoic acid (Dubrac et al., 2005). 27-OHC is the most abundant oxysterols 
found within the peripheral circulation and flows into the brain as it can easily cross 
the BBB, but 27-OHC can also be synthesised within the brain as CYP27A1 
expression has been observed in neurons, astrocytes and oligodendrocytes 
(Lütjohann et al., 1996a; Brown, Theisler, Silberman, Magnuson, Gottardi-Littell, 
John M. Lee, et al., 2004; Pataj et al., 2016).  
Studies have found that 27-OHC may induce or exacerbate AD like pathology. 
Human neuroblastoma cells co-cultured with rat glioma cells showed a cytotoxic 
effect by inducing a significant reduction in cell viability and proliferation. 
Furthermore, a significant decrease in mRNA and protein expression of cholesterol 
biosynthetic genes such as HMGCR and SREBP2 was observed and a significant 
increase in cholesterol transport genes expression such as ATP binding cassette A1 
(ABCA1)  and liver X receptor-α (LXR-α) (Wang et al., 2016). This study suggests 
that an increase in 27-OHC may disrupt cholesterol homeostasis and could 
contribute to pathogenesis of neurodegenerative diseases. Further studies in 
APP/PS1 transgenic mice showed that treating the mice with 27-OHC produced a 
decline in learning and memory as well as increased Aβ plaque deposition in the 
hippocampus (X. Zhang et al., 2019). Studies carried out in patients with mild 
cognitive impairment found significantly increased levels of plasma 27-OHC and 
plasma levels of 27-OHC correlated with plasma levels of Aβ1-40 (X. Zhang et al., 
2019). These studies suggest that 27-OHC levels and hence the action of 27-
hydroxylase enzyme may contribute to AD pathology.   
Oxysterols have the potential to be a diagnostic biomarker for neurodegenerative 
disease. 24S-OHC mainly originates from the brain and has a half-life of 
approximately 12 hours within the plasma, the plasma levels of 24S-OHC are 
dependent upon the rate of metabolism within the liver and rate of brain secretion 
(Bretillon et al., 2000). One study found that plasma 24S-OHC levels were negatively 
correlated with Mini Mental Score, other studies have found that high levels of 
plasma oxysterols is correlated with larger hippocampal volumes in healthy middle-
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aged individuals (Papassotiropoulos et al., 2000; Koschack et al., 2009). 
Furthermore, similar studies have found an increased plasma 24S-OHC was present 
in AD and vascular dementia patients; these contrasting findings could be explained 
by differences in the severity of disease (Lütjohann et al., 2000; Leoni and Caccia, 
2011). Considering the fact that the use of cholesterol lowering drugs, liver disease 
and body mass index and overall cholesterol levels can affect 24S-OHC levels within 
the plasma, plasma levels should be carefully interpreted before making correlations 
and diagnosis (Bretillon et al., 2000; Brown and Jessup, 2009; Leoni and Caccia, 
2011).  
Targeting cholesterol metabolism could be a potential treatment for AD. A drug 
screening study in neuronal induced pluripotent stem cells (iPSCs) derived from AD 
patients found that allosteric activation of CYP46A1 enzyme using the small 
molecule efavirenz reduces the levels of phosphorylated tau within the neurons 
without altering astrocyte viability (van der Kant et al., 2019). However, some studies 
suggest that inhibition of cholesterol 24-hydroxylase enzyme using small molecules 
such a imidazo(1,2-a)pyridines could be another potential therapeutic strategy (Uto, 
2015). Repurposing of statins has been found to decrease the levels of plasma 24S-
OHC in AD patients by approximately 20%, which suggests that statins may have a 
direct effect on brain cholesterol metabolism (Vega et al., 2003). Further studies 
have demonstrated that statins (that can easily pass across the BBB), such as 
lovastatin have neuro-protective effects (He et al., 2006). He et al (2006) induced 
brain injury in rats using kainic acid and found an increase in cholesterol and 24S-
OHC levels in the hippocampus following exposure. In rats injected with both kainic 
acid and lovastatin, reduced cholesterol and 24S-OHC levels were observed; this 
reduction in oxysterols levels decreases the chance of free radical damage to 
neurons (Kölsch et al., 1999; He et al., 2006). These studies suggest that regulating 
oxysterols such as 24S-OHC could be a potential therapeutic target for 
neurodegenerative disease such as AD. 
Regulating cholesterol efflux is important in maintaining cholesterol homeostasis. 
One enzyme involved in cholesterol transport is the ATP-binding cassette transporter 
A1 (ABCA1) and is encoded by ABCA1 gene. ABCA1 is located on chromosome 
9q31.1 and contains approximately 50 exons and is ubiquitously expressed and 
localised to the plasma membrane (Dean, Hamon and Chimini, 2001).  ABCA1 
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encodes a protein 2,261 amino acids long that contains two transmembrane 
domains and two nucleotide binding domains, and is involved in the ATP-dependent 
transport of lipids across membranes (Phillips, 2018).  
For efficient ABCA1 dependent cholesterol efflux, lipid free apolipoproteins such as 
apoA1, apoAII and apoE are required. Within the CNS apoE is the major 
apolipoprotein, ABCA1 activity is critical to apoE protein lipidation, as ABCA1 
chaperones intracellular cholesterol from endosomes into apoE to form the apoE 
HDL (Vance and Hayashi, 2010). The lack of lipidation of apoE4 makes it more 
prone to forming aggregates and developing AD pathology (Hatters et al., 2006; 
Raulin et al., 2019). A study using mouse astrocytes found that apoE4 expression 
lead to ABCA1 being retained in the late endosome, thus reducing ABCA1 activity 
and decreasing the lipidation of apoE4 (Rawat et al., 2019). These studies suggest 
that ABCA1 has a critical role in transporting cholesterol from astrocytes to neurons 
via apoE proteins. The lack of ABCA1 activity can reduce apoE4 lipidation which 
prevents cholesterol transport as well as inhibiting Aβ degradation (Rawat et al., 
2019).  
Further studies in ABCA1 knockout mice found a decrease in cortical and CSF apoE 
levels; however, no changes in free and esterified cholesterol were observed in the 
mice (Wahrle et al., 2004). This suggests that in vivo ABCA1 activity is not crucial for 
regulating brain tissue cellular lipid levels. Additionally, in primary mice astrocyte 
cultures, a marked reduction in secretion of cholesterol into the media was observed 
in ABCA1 knockout cells and smaller apoE particles with reduced cholesterol content 
were also observed (Wahrle et al., 2004). This suggests that there are ABCA1 
independent pathways to apoE lipidation and release; however, ABCA1 is more 
efficient and effective.  
Studies have indicated that ABCA1 may play a role in AD pathogenesis. Microarray 
analysis of the hippocampus from AD patients showed an increase in expression of 
ABCA1 (Blalock et al., 2004; Carter, 2007). This was further consolidated by other 
studies that found a significant increase in both mRNA and protein levels of ABCA1 
in the hippocampus of AD brains. Up-regulation of ABCA1 was not observed in other 
brain areas such as the cerebellum, suggesting that this increase in ABCA1 
expression is associated with AD pathology (Kim et al., 2010). 
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ABCA1 activity could be a potential novel drug target to treat AD. A study by Boehm-
Cagan et al (2016) used transgenic mice expressing human analogues of apoE3 and 
apoE4 and treated the mice with a peptide (CS-6253) which stimulates ABCA1 
activity. This study found that in apoE4 mice treatment with CS-6253 led to a 
significant reduction of Aβ and phosphorylated tau immunoreactivity in the 
hippocampus compared to control apoE4 mice (Boehm-Cagan et al., 2016). 
Furthermore, mice treated with the peptide showed a significant improvement in 
performance of cognitive tests such as the Morris water maze. This data suggests 
that activation of ABCA1 may reverse the pathological effects of the apoE4 and 
reduce AD pathology, suggesting that AD pathology may arise due to lack of ABCA1 
activity and reduced lipidation of apoE. 
For this study, the assessment of changes in cholesterol biosynthetic and 
metabolism gene expression was conducted using frozen temporal cortex tissue 
from the CFAS Cambridge neuropathology cohort from which sub-populations of 
neurons and astrocytes were isolated using laser capture microdissection (LCM). 
LCM is a method that is used to isolate specific cell types or region of interest from a 
section of tissue. It combines immunohistological and histological methods to identify 
a sub-population of cells or regions of interest, with microscopy techniques allowing 
isolation of a specific sub-population of cells or a region of interest and producing an 
enriched sample. The LCM microscope has an infrared laser attached to it and in 
conjunction with an LCM cap, which has a thermoplastic film attached to the bottom 
of the cap. When the cap is placed on top of a tissue section and the laser is fired, 
this causes the thermoplastic film to melt and adhere to the tissue below. Therefore, 
when the cap is removed it also removes the region or cells of interest directly below, 
RNA/DNA can be extracted and used for gene expression studies (Simpson, 
Wharton and Heath, 2018). The LCM method was used to determine cholesterol 
biosynthetic gene expression in sub-populations of astrocytes and neurons isolated 
from the temporal cortex and investigating the specific changes that occur within the 
cells, rather than the entire tissue. This allows for a more detailed look at changes in 
cholesterol biosynthesis and metabolism at a cellular level and how AD pathology 
may alter this. 
For this study four key genes involved in cholesterol homeostasis were investigated 
to assess changes in relation to AD progression. The genes selected were HMGCR, 
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SREBP2, CYP46A1 and ABCA1. Previous work from our lab carried out microarray 
analysis on neurons isolated from frontal cortex sections from CFAS Cambridge 
neuropathology cohort with low and high DNA damage response (DDR) (Simpson et 
al., 2016). Importantly this study had included all low Braak and Braak stage (I-II) 
cases (n=39) within the cohort and so the variation was not accounted for by AD 
pathology and was not examined by the paper. That study found a fold change of 4.5 
(p=0.0008) for HMGCR and a down-regulation in SREBF2 with a fold change of -1.1 
(p=0.001) was associated with a high DDR. It was further extended to investigate the 
levels of 24S-OHC in CSF samples from the CFAS neuropathology cohort and found 
that 24S-OHC negatively correlated with increasing Braak and Braak stage (r=-0.29, 
p=0.040) and a significant correlation between 24S-OHC levels in CSF and astrocyte 
DDR (r=-0.43, p=0.001) and neuronal DDR (r=-0.30, p=0.033) across all Braak and 
Braak stages. This study prompted the selection of the four key genes to further 
investigate individual changes in cholesterol homeostasis in astrocytes and neuronal 
sub-populations in relation to AD progression.   
This current study also measured the levels of brain cholesterol within the temporal 
cortex to investigate if changes in cholesterol biosynthetic and metabolism genes 
lead to an over-all change in brain cholesterol levels and whether these changes are 
associated with AD progression and pathology. To determine brain tissue cholesterol 
levels the Amplex Red cholesterol assay was used. Amplex Red cholesterol assay is 
based on an enzyme-coupled reaction, which detects both cholesteryl esters and 
free cholesterol. Cholesterol esterase (CE) hydrolyses cholesteryl esters into 
cholesterol which is then oxidised by cholesterol oxidase (CO) to produce H2O2 and 
cholest-4-ene-3-one (Amundson and Zhou, 1999). H2O2 is detected using the 
Amplex Red reagent (10-acetyl,3,7-dihydroxyphenoxazine), in the presence of 
horseradish peroxidase (HRP) Amplex Red reagent has a 1:1 stoichiometry to H2O2 
and produces resorufin. Resorufin has absorption and fluorescence emission 
maxima at approximately 571 nm and 585 nm respectively, this wavelength 
minimises the effect of auto-fluorescence from biological samples (Amundson and 







3.2 Aims and Objectives 
The aim of this study was to define the changes in expression of genes involved in 
cholesterol biosynthesis, metabolism and efflux in neurons and astrocytes isolated 
from human temporal cortex tissue in relation to AD neuropathology progression, 
oxidative DNA damage and neuroinflammation. This study also aimed to measure 
the levels of brain cholesterol within temporal cortex tissue to see if changes in 
cholesterol biosynthetic gene expression impact overall brain cholesterol levels.  
We hypothesise that changes in cholesterol biosynthetic gene expression in neurons 
and astrocytes are associated with AD neuropathology, oxidative DNA damage and 
neuroinflammation leading to a decrease in overall cholesterol levels in the temporal 
cortex.  
The objectives of this chapter are: 
• Optimise and validate LCM for isolating neurons and astrocytes from temporal 
cortex regions. 
• Determine the expression of HMGCR, SREBP2, CYP46A1 and ABCA1 in 
astrocyte and neuronal populations isolated from the temporal cortex from a 
pan-Braak and Braak sub-cohort using qualitative real-time PCR.  
• Determine if changes in cholesterol biosynthetic and metabolism gene 
expression is associated with AD neuropathology progression and pathology 
and other AD pathological markers such as oxidative stress and 
neuroinflammation. 
• Measure levels of brain cholesterol using Amplex Red Cholesterol assay in 
frozen temporal cortex tissue.  
• Determine if changes in tissue cholesterol levels associated with AD 
progression and neuropathology and other AD pathological markers such as 
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3.3.1 Human brain tissue 
Post-mortem human brain tissue was obtained from the Cambridge centre of CFAS 
and a sub cohort was used for this study (n=32). Cases were stratified according to 
Braak and Braak groups and selected based on pH and post-mortem delay (PMD). 
Braak and Braak groups were defined as follows: Braak and Braak, group 1 
contained stages 0-II (entorhinal) (n=12), group 2 contained stages III-IV (limbic) 
(n=10) and group 3 contained stages V-VI (isocortical) (n=10). Freshly prepared 
frozen cryosections (7 µm) were used for Laser capture microdissection (LCM). 
Frozen sections of the temporal cortex (Brodmann area 20/21) were investigated for 
this study and the ethical approval can be found in the appendix (15/SW/0246) 
(appendix 6.2).  
3.3.2 RNA extraction from post-mortem tissue 
Total RNA extraction was carried out before LCM to assess the initial RNA quality of 
each tissue sample. A cryosection (10 µm) was collected into a sterile tube. The 
section was homogenised in 100 µl of TRIzol (Fisher Scientific, UK) using a 
handheld homogeniser. After homogenisation, an additional 900 µl of TRIzol and 200 
µl of chloroform (Sigma-Aldrich, UK) was added and the samples vortexed for 15 
seconds. The samples were incubated at RT for 3 minutes, before being centrifuged 
(Sigma-Aldrich, UK) at 12,000g at 4°C for 15 minutes. The upper aqueous layer of 
the supernatant was removed and transferred into a sterile tube. 500 µl of 
isopropanol (Fisher Scientific, UK) was added and samples left to stand at RT for 10 
minutes. The samples were centrifuged at 12,000g at 4°C for 10 minutes and the 
supernatant was discarded. The RNA pellet was washed with 1 ml of ice-cold 75% 
ethanol (VWR Chemicals, France), vortexed and centrifuged at 7500g at 4°C for 5 
minutes. The supernatant was carefully discarded and the pellet air dried for 5-10 
minutes before re-suspending the pellet in 20 μl of RNAase free water (Zymo 
research, US). The samples were incubated at 65°C for 10 minutes and RNA stored 
at -80°C until required. The RNA concentration of each sample was determined 
using the NanoDrop Spectrophotometer (ThermoFisher Scientific, USA) and RNA 
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integrity was determined using the bioanalyzer and Agilent RNA 6000 Nano Chip 
(Agilent Technologies, USA).    
3.3.3 Rapid immunohistochemistry for laser capture microdissection of 
astrocytes 
Freshly prepared frozen cryosections (7μm) were collected onto uncharged glass 
slides. The sections were fixed and permeabilised in ice cold acetone (VWR 
Chemicals, France) for 3 minutes and air-dried briefly at RT. The sections were 
blocked in 1.5% goat normal serum for 3 minutes, followed by 3 minutes incubation 
at RT with primary rabbit anti-glial fibrillary acidic protein (anti-GFAP) antibody (Dako, 
Denmark [Z033401-2]) at a 1/50 dilution. The sections were washed with sterile TBS 
and incubated with 0.5% (v/v) biotinylated anti-rabbit secondary antibody for 3 
minutes, followed by a brief wash with sterile TBS. The sections were incubated with 
2% (v/v) ABC-HRP for 3 minutes followed by a wash with sterile TBS. The antibody 
binding was visualised with DAB for 5 minutes at RT and the reaction was stopped 
with sterile d.H2O. The sections were dehydrated in increasing ethanol 
concentrations (70%, 95% and absolute) and cleared in xylene for 5 minutes and 
placed in a lamina flow hood to dry for a minimum of an hour. 
3.3.4 Toluidine Blue staining for laser capture microdissection of neurons 
Freshly prepared frozen cryosections (7μm) were collected onto uncharged glass 
slides. The sections were fixed and permeabilised in ice cold acetone (VWR 
Chemicals, France) for 3 minutes and air-dried briefly at RT. The slides were 
immersed in toluidine blue for 1 minute and then washed in Diethylpyrocarbonate 
(DEPC)-treated d.H2O for 1 minute. The sections were dehydrated in graded series 
of ethanol (70%, 95% and absolute) and cleared in xylene for 5 minutes and then 
placed in a lamina flow hood to dry for a minimum of an hour.  
3.3.5 Laser Capture Microdissection (LCM) 
LCM was performed using Pixcell laser capture microdissection system (Arcturus, 
Thermofisher scientific, UK) at x20 magnification. An LCM cap was placed over the 
tissue section and an infrared laser fired to micro-dissect approximately 1000 GFAP+ 
astrocytes and 1000 neurons per cap (laser power: 55 mW, laser pulse: 15 ms and 
laser spot size: 7.5 µm). The thermoplastic film was carefully removed from the cap 
using sterile forceps and placed in a 0.5 ml sterile tube for RNA extraction. 
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3.3.6 RNA extraction following LCM 
Using the Picopure RNA isolation kit (Thermo fisher scientific, UK), 50 μl of 
extraction buffer was added to the 0.5 ml sterile tube containing thermoplastic film 
and the sample was incubated at 42°C for 30 minutes. 250 μl of conditioning buffer 
was added to the RNA extraction column and allowed to precondition at RT for 5 
minutes before centrifugation (Thermofisher scientific, UK) at 13,000 g for 1 minute 
prior to use. Following the 42 °C incubation, 50 μl of 70% ethanol was added to each 
LCM extracted sample and samples transferred to the RNA extraction column; 
centrifugation was carried out at 100 g for 2 minutes to allow the RNA to enter the 
column followed by a faster spin at 13,000 g for 1 minute, all flow-through was 
discarded. The columns were washed with 100 μl wash buffer 1 and centrifuged at 
8,000 g for 1 minute followed by 100 μl of wash buffer 2 at 8,000 g for 1 minute 
before a final wash step in 100 μl of wash buffer 2 centrifuged at 13,000 g for 2 
minutes. The column was placed into a 1.5 ml sterile tube and 11 μl of elution buffer 
was added to the column; this was allowed to incubate for 1 minute at RT before 
centrifugation at 1000 g for 1 minute followed by a faster spin at 13,000 g for 1 
minute. The eluted RNA was stored at -80°C. The RNA concentration of each 
sample was determined using the NanoDrop Spectrophotometer (ThermoFisher 
Scientific, USA) and RNA integrity was determined using the Agilent RNA 6000 Pico 
Chip (Agilent Technologies, USA).     
3.3.7 Cell enrichment validation 
To confirm cell enrichment of each extracted RNA sample RT-PCR was performed. 
Firstly, each RNA sample was synthesised into cDNA qScript cDNA mix (Quanta 
biosciences, US). Following the manufacturer’s protocol 50 ng of RNA was placed 
into a labelled 0.2 ml sterile tube, followed by 2 μl of Q-script (Quanta biosciences, 
US) and samples were made up to 10 µl with RNAase free water. The samples were 
placed into the thermocycler (Peltier Thermal cycler, MJ Research, USA) and 
incubated at: 25°C for 5 minutes, 42°C for 30 minutes, 85°C for 5 minutes, before 
being held at 4°C.  
To confirm cell enrichment relevant primers were prepared and aliquoted to create 5 
pM/μl primer stocks (Solis Biodyne, Estonia) (Table 3.1). To 1 μl of each cDNA 
sample, 4 μl 5X Green Firepol PCR mix (Eurofins Genomics, Germany), 1 μl forward 
and 1 μl reverse primer and 13 μl RNAase free water was added and the samples 
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were briefly centrifuged and placed into the thermocycler. The PCR programme 
consisted of denaturation at 95°C for 10 minutes and products were amplified in 40 
cycles (95°C 15 seconds, and 60°C for 1 minute) followed by a final incubation at 
22°C for 10 minutes, before being held at 10°C. Non-template control (NTC) samples, 
in which cDNA was replaced with 1 μl of RNAase free water, was used to determine 
the specificity of primers. 
Gene Name Primer Sequence Product size (bp) 
GFAP F 5’-GCA GAA GCT CCA GGA TGA AAC 
R 5’-TCC ACA TGG ACC TGC TGT C 
213 
NeuN F 5’-ACG ATG GTA GAG GGA CGG AA 
R 5’-AAT TCA GGC CCG TAG ACT GC 
127 
β-Actin F 5’-TCC CCC AAC TTG AGA TGT ATG AAG 
R 5’-AAC TGG TCT CAA GTC AGT GTA CAG G 
100 
Table 3.1: Primers used for cell enrichment validation   
3.3.8 3% Agarose gel electrophoresis of PCR products 
All PCR products were run on a 3% (w/v) agarose gel to check they were the 
expected size. A 3% (v/v) agarose gel was prepared by adding 3 g of agarose to 100 
ml of x1 Tris-acetate-EDTA (TAE) buffer. The mixture was heated in the microwave 
on full power until all the agarose had completely dissolved. The solution was cooled 
to RT under a running tap and 1 μl of ethidium bromide was added. The gel mix was 
poured into the gel cast and a gel comb added, the gel was allowed to set for 
approximately 20 minutes at RT. The comb was removed, and the gel placed in the 
electrophoresis tank containing x1 TAE buffer. 10 μl of each cell specific cDNA 
samples and NTC samples were loaded into the wells and 7 μl of hyperladder V 
(Bioline, UK) was also loaded as a DNA base pair marker. The gel was run at 
constant (100 V) for 1 hr, after which the PCR products were visualised using a G-
box Gel imaging system (Syngen, UK).  
3.3.9 Quantitative real time PCR (q RT-PCR) 
To measure changes in cholesterol biosynthetic gene expression q RT-PCR was 
carried out. Extracted RNA from post-mortem tissue cell isolations was synthesised 
into cDNA as outline above (refer to 3.4.7). cDNA was diluted to a concentration of 
2.5 ng/µl. The PrimeTime qPCR assays (Integrated DNA Technologies) (Table 3.2) 
were used. PCR was performed using 50 ng cDNA, 500nM of forward and reverse 
primer, 250 nM probe and 1x LUNA universal probe qPCR master mix (New England 
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Biolabs, UK) in a total volume of 10 μl per sample. Each sample was assessed in 
triplicate and analysed in a 384 well PCR plate (BioRad) sealed with PCR film lid 
(BioRad) on a BioRad CFX384 Real time system.  The PCR programme consisted of 
denaturation at 95°C for 5 minutes, products were amplified in 39 cycles of (95°C for 
10 seconds and 60°C for 30 seconds), followed by a final cycle at 95°C for 1 minute, 
55°C for 30 seconds, and 95°C for 30 seconds.  Cycle threshold (Ct) values were 
determined by the number of cycles it takes for the fluorescence from gene probes to 
reach the threshold value, which is determined by 10 standard deviations above 
background florescence. Thus, increased expression of a gene has lower Ct values 
compared to a higher Ct value which indicates reduced gene expression. β-actin was 
also amplified on each plate to normalise the gene expression levels using the 
comparative Ct, (ΔΔCt) method of quantification. The relative concentration values 
for each gene were calculated relative to the mean ΔCt expression for Braak and 
Braak group 1 or Thal group 1 for each cell type. 
3.3.10 Quantification and statistical analysis of cholesterol biosynthetic genes in 
LCM isolated neuron and astrocytes 
Statistical analysis was carried out using SPSS Statistics v26 program (IBM, UK) 
(Figure 3.1). Gene expression data was normalised to β-actin expression and the 
relative concentration was calculated relative to Braak and Braak group 1 and Thal 
group1 for each cell type and gene. Gene expression was tested for normality using 
the Kolmogorov-Smirnov (KS) test and by visualisation of histograms, and the mean, 
median and interquartile range calculated. Non-parametric Kruskal-Wallis (KW) and 
Jonckheere-Terpstra (JT) tests were performed to determine whether any significant 
differences and trends between neuronal and astrocytic cholesterol biosynthetic 
gene expression and AD neuropathology progression (Braak and Braak group 
staging and Thal β-Amyloid phase).  
Non-parametric analyses (KW and JT tests) were also used to determine any 
significant differences and trends in cholesterol biosynthetic gene expression in 
astrocytes and neurons with AD neuropathology within the temporal cortex (CERAD 
Aβ plaque and tangle scores). Spearman rank correlation was used to determine any 
relationships between neuronal and astrocytic cholesterol biosynthetic gene 
expression with total percentage HMGCR immunoreactivity, 24(S)-OHC levels in 
CSF, oxidative stress (ɣH2AX, 8-hydroxydeoxyguanosine [8-OHdG] and 
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Malondialdehyde [MDA] expression), β-amyloid, phosphorylated tau expression 
(AT8), brain pH, neuroinflammation (CD68, GFAP and MHCII), and post-mortem 
delay (PMD) in the cases. Data on Aβ, AT8, pH, PMD, oxidative and 
neuroinflammatory markers was obtained from previous studies on the same cohort 
in the temporal cortex (CFAS Cambridge Neuropathology cohort)  (J E Simpson et 
al., 2010; Simpson et al., 2015). All tests were two tailed and the p<0.05 was set as 
the level for significance. Outliers were identified based on distribution displayed on 
a histogram and box plots and extreme data points with a relative concentration 
greater than 3 and one SD away from the upper quartile. Outliers must meet both 























































































Figure 3.1. Quantification and statistical analysis of qPCR data: A flow chart outlining 
















Prime Time® Assay 
ID 
Reference Exon Primer Sequence Probe Sequence 














ATP Binding Cassette 







transcription factor 2 
(SREBF2) 
Hs.PT.58.39417166 NM_004599 16-17 1) 5’-TTCCTTCTGCCATTGCGA-3’ 2) 5’-ACAGTAGCAGGTCACAGGT-3’ 
5’-56-FAM/CTATGGAGC/ZEN/AGCCTCAACGTCAGT/3IABkFQ/-
3’ 
Beta-Actin (ACTB) Hs.PT.39a.22214847 NM_001101 1-2 1) 5’-ACAGAGCCTCGCCTTTG-3’ 
2) 5’-CCTTGCACATGCCGGAG-3’ 5’-56-FAM/TCATCCATG/ZEN/GTGAGCTGGCGG/3IABkFQ/-3’ 
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3.3.11 Amplex Red cholesterol Assay 
Post-mortem human brain tissue was obtained from the Cambridge centre of CFAS 
cohort and all available frozen temporal cortex tissue was used for this study (n=63). 
To extract cholesterol from post-mortem human brain tissue, freshly prepared frozen 
cryosections (10 μm) were collected into sterile tubes and mass of tissue was 
measured and noted. The section was homogenised in 200 µl of 1x reaction buffer 
(provided with the kit) (Thermo fisher scientific, UK) using a handheld homogeniser. 
After homogenisation, an additional 800 µl of 1x reaction buffer (Thermo fisher 
scientific, UK) was added and the samples vortexed for 15 seconds and stored at     
-80°C.  
Amplex Red cholesterol assay was purchased from Thermo fisher scientific, UK and 
was carried out according to manufacturer’s protocol. Briefly, brain tissue cholesterol 
samples were diluted 500-fold and 50 μl was pipetted into separate wells of a 96-well 
microplate (Merck, Germany). Cholesterol standards were also prepared by diluting 
cholesterol reference standard (provided with the kit) into 1x reaction buffer to 
produce cholesterol concentrations of 0-7.5 μM, alongside a positive control of 10 
μM of H2O2 (provided with the kit). 50 μl of positive control and cholesterol standards 
were pipetted into separate wells of a 96-well microplate. Amplex red working 
solution was prepared using HRP, cholesterol oxidase, cholesterol esterase and 
Amplex red reagent in 1x reaction buffer according to manufacturer’s protocol. 50 μl 
of Amplex red working solution was added to each well containing samples and 
controls. Each sample was ran in triplicate. The plate was incubated at 37 °C for 30 
minutes and protected from light. The excitation fluorescence was measured at 540 
nm and the emission was measured at 590 nm using the PHERAStar 
spectrophotometer. For each well, background fluorescence was corrected for by 
subtracting the no-cholesterol control. Cholesterol concentration was calculated by 
plotting a standard curve using the known cholesterol values and the cholesterol 
concentration for samples were interpolated from the curve. Cholesterol 
concentrations were divided by the mass of tissue that was used to extract 
cholesterol from to give cholesterol concentration per mg of tissue.  
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3.3.12 Statistical analysis of cholesterol concentration in whole tissue 
cholesterol extracts 
Statistical analysis was carried out using SPSS Statistics v26 program (IBM, UK). 
Cholesterol concentration per mg of tissue was tested for normality using the 
Kolmogorov-Smirnov (KS) test and by visualisation of histograms, and the mean, 
median and interquartile range calculated. Non-parametric Kruskal-Wallis (KW) and 
Jonckheere-Terpstra (JT) tests were performed to determine whether any significant 
differences and trends between cholesterol concentration and AD progression 
(Braak and Braak group staging and Thal β-Amyloid phase). Non-parametric 
analysis (KW and JT tests) were also used to determine any significant differences 
and trends in cholesterol concentration with cortical microinfarcts. A Mann-Whitney 
(MW) test was carried out to determine any significant differences in cholesterol 
concentration and the presence of cerebral amyloid angiopathy (CAA). Spearman 
rank correlation was used to determine any relationships between cholesterol 
concentration with neuronal and astrocytic cholesterol biosynthetic gene expression, 
total percentage HMGCR immunoreactivity, 24(S)-OHC levels in CSF, oxidative 
stress (ɣH2AX and Malondialdehyde [MDA] expression), β-amyloid, phosphorylated 
tau expression (AT8), brain pH, neuroinflammation (CD68, GFAP and MHCII), and 
post-mortem delay (PMD) in the cases. Data on Aβ, AT8, pH, PMD, vascular 
pathology, oxidative and neuroinflammatory markers was obtained from previous 
studies on the same cohort in the temporal cortex (CFAS Cambridge 
Neuropathology cohort)  (Ince, 2001; Matthews et al., 2009b; J E Simpson et al., 
2010; Simpson et al., 2015). Further non-parametric tests were carried out to 
determine differences and trends with further markers of oxidative stress (Trx2 and 
Prx3 immunoreactivity) (unpublished data). To determine if the variation in brain 
tissue cholesterol concentration associated with dementia status a Mann-Whitney U 
test was carried out. The effect of tissue cholesterol concentration on risk of 
dementia was analysed using logistic regression. All tests were two tailed and the 
p<0.05 was set as the level for significance. Statistical analysis in relation to 
dementia status and corresponding violin plots was carried out by Connor 








3.4.1 Case selection 
The CFAS Cambridge cohort contains a total of 100 frozen samples. From this a 
sub-cohort (n=32) were selected based on pH and post-mortem delay (PMD), to 
ensure better quality RNA before LCM as degradation occurs during the LCM 
process (Table 3.3). To characterise the changes in gene expression in relation to 
AD progression cases from all three Braak and Braak groups were also selected: 
Braak and Braak group 1 (n=12), group 2 (n=10) and group 3 (n=10).  
3.4.2 LCM isolated enriched populations of astrocytes and neurons from frozen 
post-mortem human tissue 
Large pyramidal neurons were clearly visible under a microscope using (toluidine 
blue) histological stain (Figure 3.2 A). Using immuno-LCM, GFAP+ astrocytes were 
easily distinguishable under the microscope through their stellate morphology 
(Figure 3.2 B). Approximately 1000 astrocytes and 1000 neurons were captured to 
obtain approximately 50 ng extracted RNA (2.4-20 ng/μl).   
Cell enrichment was assessed for each sample following LCM by RT-PCR analysis 
of glial and neuronal transcripts. All astrocyte samples showed a strong band for 
GFAP at 213 bp while neuronal samples showed a strong band for NeuN at 127 bp. 
β-actin (100 bp) was used as a positive control for both samples. A non-template 
control (NTC) containing no cDNA was used as a negative control (Figure 3.3).  
3.4.3 RNA quality decreases following LCM  
The RNA integrity number (RIN) of each frozen tissue block (n=32) was analysed 
pre-LCM and post-LCM using the Agilent RNA 6000 Pico Chip (Agilent Technologies, 
USA) (Figure 3.4). The mean RIN of the tissue blocks pre-LCM was 3.0 (range 1-
6.9). Following LCM, a decrease in RIN was observed. For astrocyte RNA samples 
the mean RIN was 2.4 (range 1-2.9) and for neuron RNA samples the mean RIN 





























































Table 3.3. Sub-cohort case details used in the LCM study: RNA integrity was assessed in 
32 cases of the CFAS Cambridge neuropathology cohort selected based on brain pH 
measured at the time of death and post-mortem delay (PMD). RNA quality was also 

























Figure 3.2. Isolation of neurons and astrocytes: Neurons identified by toluidine blue 
and GFAP+ astrocytes were isolated from temporal cortex sections of the CFAS 
Cambridge cohort. Isolation of neurons (A) (black arrows), isolation of astrocytes (B) 






























Figure 3.3. RT-PCR analysis of neurons and astrocytes isolated from post-mortem tissue 
using LCM: Astrocyte enriched samples are associated with high transcript levels of 
GFAP and low expression of NeuN (A, red ring). Neuronal enriched samples are 
associated with high transcript levels of NeuN and low expression of GFAP (B, red 
ring). Hyperladder V (Bioline, UK) was used to determine base pairs length and β-actin 
was used as a positive control. 
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3.4.4 Successful amplification of cholesterol biosynthetic genes using qPCR 
qPCR was successfully carried out to determine the gene expression HMGCR, 
CYP46A1, ABCA1 and SREBP2 in astrocytes and neurons isolated from post-
mortem human temporal cortex sections (Figure 3.5).  
3.4.5 Relative concentration of cholesterol biosynthetic genes is not normally 
distributed in astrocytes and neurons 
Distributions of relative concentration values for each gene were tested for normality 
using the Kolmogorov-Smirnov (KS) test. Histograms were also plotted to visualise 
the distribution of relative concentration values of the genes in astrocytes (Figure 3.6 
B-E) and neurons (Figure 3.7 B-E). A non-parametric approach was used because 
although the KS values were not significant indicating a normal distribution however, 
inspection of histograms suggests that the data is not normally distributed. As a 
quality control measure the effect of pH and post-mortem delay (PMD) on the 
relative concentration values for the four genes was assessed using a Spearmen’s 
rank correlation test for each cell type. No significant correlations between relative 
concentration in both astrocytes and neurons with pH and PMD (Table 3.4).  
3.4.6 SREBP2 relative concentration in astrocytes shows a trend to decrease 
with Braak and Braak stage 
To determine how the relative concentration of cholesterol biosynthetic genes in 
astrocytes related to NFT progression, we examined the relationship to Braak and 
Braak groups. No significant differences or trends were observed for HMGCR, 
CYP46A1 and ABCA1 between Braak and Braak groups in astrocytes (Figure 3.8). 
However, a significant trend to decrease between SREBP2 relative concentration 
and Braak and Braak groups was observed (JT; p= 0.031), but a significant 





























Figure 3.4. RNA quality human post-mortem CNS samples cases before and after LCM: The 
RNA quality of the frozen tissue samples was assessed on the Agilent 2100 bioanalyser, 
(A) represents a suitable sample for LCM with a RIN value of 4.7. LCM reduces the 
quality of RNA (B) astrocytic post-LCM RNA, RIN 2.4 and (C) neuronal post-LCM RNA, 





















































Figure 3.5. Successful gene amplification using qPCR: The qPCR 
amplification curves for astrocytes and neurons to determine 
gene expression for HMGCR, CYP46A1, ABCA1 and 
SREBP2 respectively and corresponding NTC curve (A-D). 























































Figure 3.6. Distribution of the expression of key genes involved in cholesterol 
biosynthesis in isolated astrocytes: Relative concentration (RC) values for each gene 
were calculated relative to Braak and Braak Group 1, using the ΔΔCT calculations 
following normalisation to β-actin expression. The table shows the descriptive 
statistical values for each gene in astrocytes (A). Data was tested for normality using 
Kolmogorov-Smirnov (KS). The distribution of the RC values for HMGCR, CYP46A1, 


























































Figure 3.7. Distribution of the expression of key genes involved in cholesterol 
biosynthesis in isolated neurons: Relative concentration (RC) values for each gene 
were calculated relative to Braak and Braak Group 1, using the ΔΔCT calculations 
following normalisation to β-actin expression. The table shows the descriptive 
statistical values for each gene in neurons (A). Data was tested for normality using 
Kolmogorov-Smirnov (KS). The distribution of the RC values for HMGCR, 
























































Table 3.4. Correlation matrix between cholesterol 
biosynthetic gene expression in astrocytes and neurons 
with pH and PMD: Spearmen’s rank correlation test 
was carried out to determine any correlations between 
relative concentration values for cholesterol 
biosynthetic genes from astrocytes (A) and neurons 
(B) with pH and post-mortem delay (PMD). Where r is 
the correlation coefficient and p is the significance 
value. Relative concentration values for each gene 




Figure 3.8. SREBP2 gene expression in astrocytes decreases with Braak and Braak groups: The table shows the descriptive 
statistical values for each gene in astrocytes in each Braak and Braak group. The table also shows the p values for KW 
and JT tests to assess differences between the RC values in astrocytes for cholesterol biosynthetic genes and Braak and 
Braak groups (A). Box plots show the distribution of astrocytic relative concentration for (y-axis) HMGCR, CYP46A1, 
ABCA1 and SREBP2 respectively across Braak and Braak groups (x-axis) (B-E). SREBP2 expression in astrocytes 
suggests a significant trend to decrease as Braak and Braak group increases. No significant differences between 
HMGCR, CYP46A1 and ABCA1 astrocytic gene expression and Braak and Braak groups were identified. Relative 








































Figure 3.9. SREBP2 gene expression in neurons increases with Braak and Braak groups: The table shows the descriptive 
statistical values for each gene in neurons in each Braak and Braak group. The table also shows the p values for KW and 
JT tests to assess differences between the relative concentration values in neurons for cholesterol biosynthetic genes 
and Braak and Braak groups (A). Box plots show the distribution of neuronal relative concentration for (y-axis) HMGCR, 
CYP46A1, ABCA1 and SREBP2 respectively across Braak and Braak groups (x-axis) (B-E). SREBP2 expression in 
neurons suggests a significant difference and trend to increase as Braak and Braak group increases. No significant 
differences between HMGCR, CYP46A1 and ABCA1 neuronal gene expression and Braak and Braak groups were 






3.4.7 SREBP2 relative concentration in neurons increase with Braak and Braak 
stage 
To determine how the relative concentration of cholesterol biosynthetic genes in 
neurons related to NFT progression, we examined the relationship to Braak and 
Braak groups. No significant differences or trends were observed between HMGCR, 
CYP46A1 and ABCA1 with Braak and Braak groups in neurons (Figure 3.9). 
However, a significant difference (KW; p=0.046) and a trend to increase (JT; 
p=0.011) was observed between SREBP2 relative concentration and Braak and 
Braak groups was observed. Post hoc analysis following Bonferroni correction, 
showed a significant difference between Braak and Braak group 1 and Braak and 
Braak group 3 (KW; p=0.045).  
3.4.8 HMGCR and SREBP2 relative concentration in neurons decreases and 
increases with neurofibrillary tangle pathology respectively 
To determine how the relative concentration of cholesterol biosynthetic genes in 
astrocytes and neurons related to tangle pathology, we examined the relationship to 
local CERAD neurofibrillary tangle score in the cortex (Savva et al., 2009; Wharton 
et al., 2011). No significant differences or trends were observed between any of the 
four genes with tangle score in astrocytes (Figure 3.10). No significant differences or 
trends were observed between CYP46A1 and ABCA1 neuronal relative 
concentration with tangle score (Figure 3.11). HMGCR expression in neurons also 
showed a trend to decrease (JT; p=0.022) as tangle score increases. Post hoc 
analysis following Bonferroni correction, showed no significant difference between 
tangle scores. A significant difference (KW; p=0.022) and a trend to increase (JT; 
p=0.005) was observed between SREBP2 relative concentration and tangle score. 
Post hoc analysis following Bonferroni correction, showed a significant difference 










Figure 3.10. Cholesterol biosynthetic gene relative concentration changes in astrocytes 
do not change with tangle pathology: No significant differences between astrocytic 
gene expression and tangle scores were identified (A). Box plots showing the 
distribution of astrocytic relative concentration (y-axis) for HMGCR, CYP46A1, ABCA1 
and SREBP2 respectively across tangle scores (x-axis) (B-E). 0= no tangles, 1= mild 
tangles 3=moderate-severe tangles. Relative concentration values for each gene were 





















































Figure 3.11. HMGCR and SREBP2 relative concentration in neurons decreases and 
increases with tangle pathology respectively: No significant differences between 
neuronal CYP46A1 and ABCA1 relative concentration and tangle scores were 
identified (A). SREBP2 expression in neurons suggests a significant difference and 
trend to increase as tangle score increases. HMGCR expression in neurons suggests 
a significant trend to decrease as tangle score increases.  Box plots showing the 
distribution of astrocytic relative concentration (y-axis) for HMGCR, CYP46A1, ABCA1 
and SREBP2 respectively across tangle scores (x-axis) (B-E). 0= no tangles, 1= mild 
tangles 3=moderate-severe tangles. Relative concentration values for each gene were 






3.4.9 Cholesterol biosynthesis gene expression in astrocytes and neurons does 
not change with Thal Aβ phases. 
To determine whether the cholesterol biosynthesis gene expression in astrocytes 
and neurons relates to Aβ progression, we examined the relationship to Thal Aβ 
phases. Relative concentration values for each gene were calculated relative to Thal 
Group 1. No significant differences or trends were observed between any of the four 
cholesterol biosynthetic gene relative concentration with Thal Aβ groups in both 
astrocytes (Figure 3.12) and neurons (Figure 3.13). 
3.4.10 HMGCR gene relative concentration in neurons decreases with plaque 
pathology  
To determine how the relative concentration of cholesterol biosynthetic genes in 
astrocytes and neurons related to plaque pathology, we examined the relationship to 
local CERAD plaque score in the cortex (Savva et al., 2009; Wharton et al., 2011). 
No significant differences or trends were observed between any of the four genes 
with plaque score in astrocytes (Figure 3.14). No significant difference or trends were 
observed between CYP46A1, ABCA1 and SREBP2 gene relative concentration with 
plaque score in neurons (Figure 3.15). However, a significant difference (KW; 
p=0.022) and a trend to increase (JT; p=0.020) was observed between HMGCR 
relative concentration and plaque score. Post hoc analysis following Bonferroni 
correction, showed a significant difference between plaque score of 1 and plaque 
score of 0 (KW; p=0.042) and trend (JT; p=0.031). Relative concentration values for 








































Figure 3.12. Cholesterol biosynthetic gene relative concentration in astrocytes does not change with Thal groups: The table 
shows the descriptive statistical values for each gene in astrocytes in each Thal group. The table also shows the p values 
for KW and JT tests to assess differences between the relative concentration values in astrocytes for cholesterol 
biosynthetic genes and Thal groups (A). Box plots show the distribution of astrocytic relative concentration for (y-axis) 
HMGCR, CYP46A1, ABCA1 and SREBP2 respectively across Thal groups (x-axis) (B-E). No significant differences 
between cholesterol biosynthetic gene relative concentration in astrocytes and Thal groups were identified. Relative 
concentration values for each gene were calculated relative to Thal Group 1. 




































Figure 3.13. Cholesterol biosynthetic gene relative concentration in neurons does not change with Thal groups: The table 
shows the descriptive statistical values for each gene in neurons in each Thal group. The table also shows the p values 
for KW and JT tests to assess differences between the relative concentration values in neurons for cholesterol 
biosynthetic genes and Thal groups (A). Box plots show the distribution of astrocytic relative concentration for (y-axis) 
HMGCR, CYP46A1, ABCA1 and SREBP2 respectively across Thal groups (x-axis) (B-E). No significant differences 
between cholesterol biosynthetic gene relative concentration in neurons and Thal groups were identified. Relative 
concentration values for each gene were calculated relative to Thal Group 1. 

























































Figure 3.14. Cholesterol biosynthetic gene relative concentration changes in astrocytes 
do not change with plaque pathology: No significant differences between astrocytic 
gene expression and plaque scores were identified (A). Box plots showing the 
distribution of astrocytic relative concentration (y-axis) for HMGCR, CYP46A1, ABCA1 
and SREBP2 respectively across plaque scores (x-axis) (B-E). 0= no plaques, 1= mild 
plaques 3= moderate-severe plaques. Relative concentration values for each gene 





















































Figure 3.15. HMGCR gene relative concentration changes in neurons decreases with 
plaque pathology: No significant differences between CYP46A1, ABCA1 and SREBP2 
neuronal gene expression and plaque scores were identified (A). HMGCR expression 
in neurons suggests a significant difference and trend to decrease as plaque score 
increases. Box plots showing the distribution of astrocytic relative concentration (y-
axis) for HMGCR, CYP46A1, ABCA1 and SREBP2 respectively across plaque scores 
(x-axis) (B-E). 0= no plaques, 1= mild plaques 3= moderate-severe plaques. Relative 





3.4.11 HMGCR, ABCA1 and SREBP2 gene relative concentration in neurons 
correlate with AT8 immunoreactivity  
To assess whether the cholesterol biosynthetic gene relative concentration in 
astrocytes and neurons were related to local AD pathology we examined the 
relationship of two classical markers of AD pathology; namely the extent of Aβ and 
AT8 pathology determined by percentage area immunoreactivity in the temporal 
cortex, previously determined in our lab group (J E Simpson et al., 2010). No 
significant correlations between cholesterol biosynthetic gene relative concentration 
in astrocytes and markers of classical AD pathology were observed (Figure 3.16 A).  
No significant correlations between CYP46A1 gene relative concentration in neurons 
and markers of classical AD pathology were observed (Figure 3.16 B). The relative 
concentration of HMGCR in neurons showed a moderate negative correlation with 
AT8 immunoreactivity (r=-0.458, p=0.032) (Figure 3.16 C). The relative 
concentrations of ABCA1 and SREBP2 in neurons showed moderate positive 
correlations with AT8 immunoreactivity (r=0.541, p=0.046; r=0.574, p=0.016 
respectively) (Figure 3.16 D and E respectively).   
3.4.12 HMGCR gene relative concentration in neurons correlates with markers 
of DNA damage in neurons 
To assess whether the cholesterol biosynthetic gene relative concentration in 
astrocytes and neurons were related to markers of oxidative stress and DNA 
damage, we examined the relationship of oxidative stress markers (Malondialdehyde 
[MDA] and 8-hydroxydeoxyguanosine [8-OHdG]) and DNA damage markers 
(γH2AX), previously determined in our lab group (J. E. Simpson et al., 2010). This 
study found that no significant correlations between cholesterol biosynthetic gene 
relative concentration in astrocytes and MDA protein expression and 8-OHdG 
immunoreactivity. Furthermore, we found no significant correlations cholesterol 
biosynthetic gene relative concentration in astrocytes and γH2AX immunoreactivity 
in astrocytes and neurons (Figure 3.17 A). This study also found that no significant 
correlations between cholesterol biosynthetic gene relative concentration in neurons 
and MDA protein expression and 8-OHdG immunoreactivity. We also found no 
significant correlations in CYP46A1, ABCA1 and SREBP2 gene relative 
concentration in neurons and γH2AX immunoreactivity in astrocytes and neurons 
(Figure 3.17 B). However, the relative concentration of HMGCR in neurons showed a 
moderate positive correlation with γH2AX immunoreactivity in neurons (r=0.419, 
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p=0.046) but no significant correlation was observed with γH2AX immunoreactivity in 
astrocytes (Figure 3.17 C).  
3.4.13 HMGCR gene relative concentration in neurons correlates with markers 
of neuroinflammation  
To assess whether the cholesterol biosynthetic gene relative concentration in 
astrocytes and neurons were related to markers of neuroinflammation and gliosis, 
we examined the relationship of neuroinflammation markers (MHC class 2 and CD68) 
and gliosis markers (GFAP), previously determined in our lab group (J. E. Simpson 
et al., 2010). This study found that no significant correlations between cholesterol 
biosynthetic gene relative concentration in astrocytes and MHCII and CD68 
immunoreactivity. Furthermore, we found no significant correlations cholesterol 
biosynthetic gene relative concentration in astrocytes and GFAP immunoreactivity 
(Figure 3.18 A). This study also found that no significant correlations between 
CYP46A1, ABCA1 and SREBP2 gene relative concentration in neurons and MHCII, 
CD68 and GFAP immunoreactivity (Figure 3.18 B). The relative concentration of 
HMGCR in neurons showed a moderate positive correlation with MHCII 
immunoreactivity (r=0.490, p=0.039) but no significant correlation was observed with 
CD68 and GFAP immunoreactivity (Figure 3.18 C).  
3.4.14 Cholesterol biosynthetic gene relative concentration in astrocytes and 
neurons does not correlate with markers of cholesterol biosynthesis and 
metabolism 
To assess whether the cholesterol biosynthetic gene relative concentration in 
astrocytes and neurons was related to markers of cholesterol biosynthesis and 
metabolism, we examined the relationship of HMGCR immunoreactivity and 24S-
OHC levels in CSF, previously determined in our lab group (Simpson et al., 2016). 
This study found that no significant correlations between cholesterol biosynthetic 
gene relative concentration in astrocytes and neurons and HMGCR immunoreactivity 















Figure 3.16. HMGCR, ABCA1 and SREBP2 gene relative concentration in neurons does 
correlate with AT8 immunoreactivity: Spearmen’s rank correlation test was carried 
out to determine any correlations between relative concentration values for 
cholesterol biosynthetic genes from astrocytes (A) and neurons (B) with Aβ and AT8 
immunoreactivity. Where r is the correlation coefficient and p is the significance value. 
Scatter plots showing the neuronal relative concentration (y-axis) for HMGCR, 
ABCA1 and SREBP2 respectively against AT8 immunoreactivity (x-axis) (C-E). 
Relative concentration values for each gene were calculated relative to Braak and 





















































Figure 3.17. HMGCR gene relative concentration in neurons correlates to markers of DNA 
damage in neurons: Spearmen’s rank correlation test was carried out to determine any 
correlations between relative concentration values for cholesterol biosynthetic genes from 
astrocytes (A) and neurons (B) with markers of oxidative stress (MDA protein levels and 8-
OHdG immunoreactivity) and markers of DNA damage (H2AX immunoreactivity). Where r is 
the correlation coefficient and p is the significance value. Scatter plots showing the neuronal 
relative concentration (y-axis) for HMGCR against H2AX immunoreactivity in neurons (x-axis) 
(C). Relative concentration values for each gene were calculated relative to Braak and Braak 























































Figure 3.18. HMGCR gene relative concentration in neurons correlates to markers 
of neuroinflammation: Spearmen’s rank correlation test was carried out to 
determine any correlations between relative concentration values for cholesterol 
biosynthetic genes from astrocytes (A) and neurons (B) with markers of 
neuroinflammation (MHCII and CD68 immunoreactivity) and gliosis (GFAP 
immunoreactivity). Where r is the correlation coefficient and p is the significance 
value. Scatter plots showing the neuronal relative concentration (y-axis) for 
HMGCR against MHCII immunoreactivity in neurons (x-axis) (C). Relative 
concentration values for each gene were calculated relative to Braak and Braak 





3.4.15 Removal of outliers to confirm significant results 
Outlying data points were removed to ensure significant data was not a result of 
statistical artefacts from extreme data points. Outliers were identified based on 
distribution displayed on a histogram and box plots and extreme data points with a 
relative gene concentration value (relative to Braak and Braak group 1 and Thal 
phase 1) greater than 3 and one standard deviation from the upper quartile. Outliers 
met all conditions to be removed from subsequent reanalysis. The outlier’s removed 
were: RH43 from HMGCR in astrocytes (RC=4.37); RH40 and RH76 from HMGCR 
in neurons (RC=3.23 and RC=5.87, respectively); RH41 from CYP46A1 in neurons 
(RC=6.94); RH43 from ABCA1 in astrocytes (RC=4.50); RH68 and RH20 from 
SREBP2 in neurons (RC=14.61 and RC=11.07, respectively).  Exclusion of outlier’s 
led to the loss of significance for some variable and added significance for other 
variables (Table 3.6). Significant increase in SREBP2 expression in neurons with 
Braak and Braak group was lost (including outlier’s KW, p=0.040; excluding outlier’s 
KW, p=0.174). A trend to decrease with tangle pathology and HMGCR expression in 
neurons (including outlier’s JT, p=0.022; excluding outlier’s JT, p=0.057). Significant 
decrease in HMGCR expression in neurons and plaque pathology was also lost 
(including outlier’s KW, p=0.040; excluding outlier’s KW, p=0.174). Significant 
correlations were also lost in neuronal HMGCR expression and AT8 and neuronal 
γH2AX immunoreactivity (including outlier’s r=-0.458, p=0.032; r=0.419, p=0.046; 
excluding outlier’s r=-0.284, p=0.224; r=0.335, p=0.138, respectively). New 
significant correlations also emerged following the removal of outlier’s: HMGCR 
expression in neurons showed significant correlations with Aβ immunoreactivity and 
24S-OHC levels in CSF (including outlier’s r=-0.351, p=0.101; r=0.454, p=0.089; 
excluding outlier’s r=-0.443, p=0.044; r=0.567, p=0.022, respectively); CYP46A1 
expression in neurons showed significant correlations with astrocytic γH2AX 































































Table 3.5. Correlation matrix between cholesterol biosynthetic 
gene expression in astrocytes and neurons with HMGCR and 
24S-OHC: Spearmen’s rank correlation test was carried out to 
determine any correlations between relative concentration 
values for cholesterol biosynthetic genes from astrocytes (A) 
and neurons (B) with HMGCR immunoreactivity and 24S-OHC 
CSF levels. Where r is the correlation coefficient and p is the 
significance value. Relative concentration values for each gene 





















































Table 3.6. Changes to significance following outlier exclusion: The 
significance of data changed following exclusion of outliers. The table 
shows changes in differences and trends with AD pathology (A). The table 
shows changes in correlations with AD pathology and markers of oxidative 





3.4.16 Tissue cholesterol concentration not normally distributed in temporal 
cortex 
Temporal cortex tissue cholesterol concentration was determined using the Amplex 
red cholesterol assay. Distribution of tissue cholesterol concentration was tested for 
normality using a Kolmogorov-Smirnov (KS) test. A histogram was plotted to 
visualise the distribution of tissue cholesterol concentration in post-mortem human 
temporal cortex tissue (Figure 3.19). A non-parametric approach was used because 
although the KS values were not significant indicating a normal distribution however, 
inspection of histograms suggests that the data was not normally distributed. As a 
quality control measure, the effects of pH and post-mortem delay (PMD) on tissue 
cholesterol concentration were assessed using Spearman’s rank correlation test. 
Only weak correlations between tissue cholesterol concentration with pH (r=0.262, 
p=0.041) and PMD (r=-0.278, p=0.033) were found (Figure 3.20 A). Plotting scatter 
graphs of tissue cholesterol concentration against pH (Figure 3.20 B) and PMD 
(Figure 3.20 C) showed that the correlation between these two variables was very 
weak and skewed by a few data points.  
3.4.17 Tissue cholesterol concentration does not change with Braak and Braak 
stage 
To determine how tissue cholesterol concentration related to NFT progression, we 
examined the relationship to Braak and Braak groups. No significant differences or 
trends were observed between tissue cholesterol concentrations with Braak and 
Braak groups (Figure 3.21). 
3.4.18 Tissue cholesterol concentration does not change with Thal Aβ phase. 
To determine whether tissue cholesterol concentration relates to Aβ progression, we 
examined the relationship to Thal Aβ phases. No significant differences or trends 
were observed between tissue cholesterol concentrations with Thal Aβ groups 
(Figure 3.22). 
3.4.19 Tissue cholesterol concentration does not correlate with Aβ and AT8 
immunoreactivity in temporal cortex 
To assess whether tissue cholesterol concentration was related to local AD 
pathology we examined the relationship of two classical markers of AD pathology; 
Aβ and AT8 immunoreactivity, previously determined in our lab group (J E Simpson 
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et al., 2010). No significant correlations between tissue cholesterol concentration and 
markers of classical AD pathology were observed (Table 3.7).  
3.4.20 Tissue cholesterol concentration does not correlate with markers of 
cholesterol biosynthesis and metabolism.  
To assess whether tissue cholesterol concentration was related to markers of 
cholesterol biosynthesis and metabolism, we examined the relationship of HMGCR 
immunoreactivity and 24S-OHC levels in CSF, previously determined in our lab 
group (Simpson et al., 2016). This study found that no significant correlations 
between tissue cholesterol concentration and HMGCR immunoreactivity and 24S-
OHC CSF levels (Table 3.8). 
3.4.21 Tissue cholesterol concentration does not correlate with relative gene 
expression of genes involved in cholesterol biosynthesis and metabolism.  
To assess whether tissue cholesterol concentration was related to relative gene 
expression of genes involved in cholesterol biosynthesis and metabolism, we 
examined the relationship between gene expression of HMGCR, CYP6A1, ABCA1 
and SREBP2 isolated from astrocytes and neurons from post-mortem temporal 
cortex tissue. This study found that no significant correlations between tissue 
cholesterol concentration and genes involved in cholesterol biosynthesis and 
metabolism (Table 3.9). 
3.4.22 Tissue cholesterol concentration does not correlate with markers of 
oxidative stress and DNA damage 
To assess whether the tissue cholesterol concentration was related to markers of 
oxidative stress and DNA damage, we examined the relationship of oxidative stress 
markers (Malondialdehyde [MDA], thioredoxin-2 [Trx2] and peroxiredoxin-3 [Prx3]) 
and DNA damage markers (γH2AX), previously determined in our lab group (J. E. 
Simpson et al., 2010). This study found that no significant correlations between 
tissue cholesterol concentration and MDA protein expression and γH2AX 
immunoreactivity in astrocytes and neurons (Figure 3.23 A). No significant 
differences or trends were observed between tissue cholesterol concentrations with 



























































Figure 3.19. Distribution of tissue cholesterol concentration across 
cohort: The table shows the descriptive statistical values for cholesterol 
concentration per mg of tissue across the cohort (A). Data was tested 
for normality using Kolmogorov-Smirnov (KS). The distribution of tissue 

























































Figure 3.20. Tissue cholesterol concentration correlates with pH and 
PMD: Spearmen’s rank correlation test was carried out to determine 
any correlations between tissue cholesterol concentration with pH and 
post-mortem delay (PMD). Where r is the correlation coefficient and p 
is the significance value. Scatter plots showing tissue cholesterol 























































Figure 3.21.  Tissue cholesterol concentration does not change with 
Braak and Braak groups: The table shows the descriptive statistical 
values for cholesterol concentration in each Braak and Braak group. 
The table also shows the p values for KW and JT tests to assess 
differences between tissue cholesterol concentration and Braak and 
Braak groups (A). Box plots show the distribution of tissue cholesterol 
concentration (y-axis) across Braak and Braak groups (x-axis) (B). No 
significant differences between tissue cholesterol concentration and 























































Figure 3.22. Tissue cholesterol concentration does not change with 
Thal groups: The table shows the descriptive statistical values for 
cholesterol concentration in each Thal group. The table also shows 
the p values for KW and JT tests to assess differences between 
tissue cholesterol concentration and Thal groups (A). Box plots 
show the distribution of tissue cholesterol concentration (y-axis) 
across Thal groups (x-axis) (B). No significant differences between 





















































Table 3.7. Tissue cholesterol concentration does not correlate with Aβ and AT8 
immunoreactivity: Spearmen’s rank correlation test was carried out to determine any 
correlations between tissue cholesterol concentration with Aβ and AT8 immunoreactivity. 
Where r is the correlation coefficient and p is the significance value. 
Table 3.8. Correlation matrix between tissue cholesterol concentration with HMGCR and 
24S-OHC: Spearmen’s rank correlation test was carried out to determine any correlations 
between tissue cholesterol concentration with HMGCR immunoreactivity and 24S-OHC 
CSF levels. Where r is the correlation coefficient and p is the significance value.  
Table 3.9. Correlation matrix between tissue cholesterol concentration and cholesterol 
biosynthetic gene expression in astrocytes and neurons: Spearmen’s rank correlation 
test was carried out to determine any correlations between tissue cholesterol 
concentration with relative concentration values for cholesterol biosynthetic genes from 
























































Figure 3.23. Tissue cholesterol concentration does not correlate to markers of 
oxidative stress: Spearmen’s rank correlation test was carried out to determine 
any correlations between tissue cholesterol concentration with markers of 
oxidative stress (MDA protein levels) and markers of DNA damage (H2AX 
immunoreactivity) (A). Where r is the correlation coefficient and p is the 
significance value. The table also shows the p values for KW and JT tests to 
assess differences between tissue cholesterol concentration and Trx2 and Prx3 
immunoreactivity (B). Box plots show the distribution of tissue cholesterol 
concentration (y-axis) across Trx2 immunoreactivity (C-D) and Prx3 
immunoreactivity (E-F) (x-axis).  
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3.4.23 Tissue cholesterol concentration does not correlate with markers of 
neuroinflammation and gliosis 
To assess whether tissue cholesterol concentration was related to markers of 
neuroinflammation and gliosis, we examined the relationship of neuroinflammation 
markers (MHC class 2 and CD68) and gliosis markers (GFAP), previously 
determined in our lab group (J. E. Simpson et al., 2010). This study found that no 
significant correlations between tissue cholesterol concentration and MHCII, CD68 
and GFAP immunoreactivity (Table 3.10). 
3.4.24 Tissue cholesterol concentration does not change with markers of 
vascular pathology 
To assess whether tissue cholesterol concentration was related to markers of 
vascular pathology, we examined the relationship of vascular pathology markers 
(cortical micro-infarct stage and CAA pathology) previously determined (Ince, 2001; 
Matthews et al., 2009a). No significant differences or trends were observed between 
tissue cholesterol concentrations with cortical micro-infarct stage (Figure 3.24) and 
CAA pathology (Figure 3.25). 
3.4.25 Tissue cholesterol concentration does not associate with various AD 
pathologies 
Statistical analyses of various markers of contributors to AD pathology such as 
oxidative stress, neuroinflammation and vascular pathology. A summary of findings 







































































Table 3.10. Tissue cholesterol concentration does not correlate to markers of 
neuroinflammation: Spearmen’s rank correlation test was carried out to determine 
any correlations between tissue cholesterol concentration with markers of 
neuroinflammation (MHCII and CD68 immunoreactivity) and gliosis (GFAP 
























































Figure 3.24.  Tissue cholesterol concentration does not change with cortical micro infarct 
stage: The table also shows the p values for KW and JT tests to assess differences 
between tissue cholesterol concentration and cortical micro infarct stage (A). Box plots 
show the distribution of tissue cholesterol concentration (y-axis) across cortical micro 
infarct stage (x-axis) (B). No significant differences between tissue cholesterol 























































Figure 3.25.  Tissue cholesterol concentration does not change with CAA pathology: 
The table also shows the p values for Mann-Whitney U (MW) test to assess 
differences between tissue cholesterol concentration and CAA pathology (A). 
Histogram shows the distribution of tissue cholesterol concentration (y-axis) in the 
absence (0-blue) and presence (1-red) of CAA pathology (B). No significant 




































Table 3.11. Tissue cholesterol concentration does not associate with AD pathologies:  A summary of the various measures carried 
to determine relationships of tissue cholesterol concentration with various AD pathologies. Where r is the Spearmen’s rank 
correlation coefficient and p is the significance value. The table also shows the p values for KW (Kruskal-Wallis), JT (Jonckheere-
Terpstra) and MW (Mann-Whitney U) tests. All tests were two tailed and the p<0.05 was set as the level for significance. 
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3.4.26 Moderate and high tissue cholesterol concentration is associated with 
dementia status 
To determine if the variation in brain tissue cholesterol concentration associated with 
dementia status a Mann-Whitney U test was carried out. From the cases that 
cholesterol was measured (n=63), 40 cases had a dementia diagnosis before death 
(median=14.08, IQR= 9.06-21.76) and 21 cases had no dementia (median=12.84, 
IQR= 8.37-20.14) (Figure 3.26 A). The test showed that there was no significant 
difference between tissue cholesterol concentration and dementia status (MW, 
p=0.95). The distribution of tissue cholesterol concentration by dementia status 
across specific Braak and Braak stages and Thal phases was determined (Figure 
3.26 B and C). A pairwise comparison of means using Tukey’s adjustment found no 
significant difference between tissue cholesterol concentration and dementia status 
at specific Braak and Braak stages and Thal phases. The effect of tissue cholesterol 
concentration on risk of dementia was analysed using logistic regression (Figure 
3.26 D). A univariate model adjusted for only age at death and sex as covariates, as 
well as a multivariate model adjusted for Braak and Braak, Thal and CAA pathology 
was produced. Tissue cholesterol concentration was analysed as continuous scales 
and categorically divided into tertiles. When modelled continuously no effect was 
seen in tissue cholesterol concentration. However, when tissue cholesterol was 
divided into tertiles, point estimates showed increased risk of dementia in moderate 
(univariate OR:1.58, 95% CI: 0.39-6.43; multivariate OR: 1.43 95% CI: 0.31-6.53) 
and high cholesterol groups (univariate OR:1.44, 95% CI: 0.35-5.85; multivariate OR: 
1.21 95% CI: 0.29-5.08). In contrast the estimate for continuous cholesterol measure 
shows no effect with a more precise 95% CI (OR: 0.98, 95% CI: 0.93-1.03). 
Statistical analysis in relation to dementia status was carried out by Connor 




























































Figure 3.26. Moderate and high tissue cholesterol concentration is associated with 
dementia status: Tissue cholesterol concentration was compared to dementia status. 
Box and violin plots displaying the distribution and probability density of tissue 
cholesterol concentration by dementia status (A). Box plots show median, IQR and 
range, area around the box displays the probability density. Wider sections of the violin 
plots represent a higher probability that members of the population will take on the given 
value; narrower sections represent a lower probability. Violin plots showing the 
distribution of tissue cholesterol concentration by dementia status at specific Braak and 
Braak stage (C) and Thal phase (D). No significant difference between tissue 
cholesterol concentration and dementia status was found. Table D shows the output 
from logistic regression modelling (D). A univariate model adjusted for age at death and 
sex, multivariate models adjusted for Braak and Braak, Thal and CAA pathology. Tissue 
cholesterol concentration was modeled on a continuous scale and categorically by 
tertiles. Results are presented as odd ratios (OR) with 95% confidence intervals (CI) 
and p values. Statistical analysis and violin plots courtesy of Connor Richardson, 







In this chapter, the relative expression of four key genes (HMGCR, CYP46A1, 
ABCA1 and SREBP2) involved in the cholesterol biosynthesis pathway and 
cholesterol metabolism were characterised using qPCR. In this study, we found that 
the relative expression of HMGCR in neuronal populations was decreased with 
tangle and plaque scores suggesting a decrease in expression as AD pathology 
progresses. This was supported by the negative correlation between percentage tau 
area-immunoreactivity and HMGCR expression in neurons. There were also positive 
correlations with neuronal HMGCR expression and markers of DNA damage (γH2AX) 
and neuroinflammation (MHCII). Furthermore, this study also found that SREBP2 
expression in enriched neuronal RNA was significantly increased with AD 
progression and pathology specifically with tau tangle pathology where an increase 
in relative expression is observed. We also found a significant moderate positive 
correlation between neuronal ABCA1 expression and tau immunoreactivity. In 
astrocytic cell enrichment samples, we found a significant trend to decrease with 
SREBP2 and Braak and Braak stages. No other statistically significant associations 
or correlations were observed in astrocyte isolations and markers of AD 
neuropathology progression, oxidative stress and neuroinflammatory markers. In this 
chapter, the total cholesterol concentration per mg of tissue from frozen human post-
mortem temporal cortex was determined using the Amplex red cholesterol assay. 
This study found that there were no significant changes or trends with tissue 
cholesterol concentration and tangle and plaque progression. No significant 
correlations between local AD pathology, oxidative stress markers, 
neuroinflammation markers and markers of vascular pathology. Interestingly, no 
significant correlations were observed between tissue cholesterol concentration with 
HMGCR immunoreactivity and relative gene concentration of HMGCR and SREBP2. 
No significant correlations were found between tissue cholesterol concentration and 
CSF 24-OHC levels and relative gene concentration of ABCA1 and CYP46A1.  Data 
from this current study also showed that there was no significant association 
between temporal cortex cholesterol concentration and dementia status. However, 
when tissue cholesterol concentration was categorically divided into tertiles and 
modelled using logistic regression analysis, moderate and high tissue cholesterol 
concentration was associated with dementia. 
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3.5.1 LCM of immune-positive cells from post-mortem temporal cortex can 
produce an RNA sample enriched for neuronal and glial RNA. 
LCM was used to isolate neurons and astrocytes from frozen temporal cortex 
sections from the CFAS Cambridge cohort. Once isolated, RNA was extracted from 
the cells and quality of RNA was assessed using Agilent RNA 6000 Pico Chip 
analysis which assigns the sample a RIN value. A RIN value was also obtained 
before carrying out LCM. This degradation between the RNA samples was expected 
as the first sample was extracted from an entire section of tissue so more high-
quality RNA is expected and post-LCM an enriched but not homogenous cell 
population was obtained. Previous work within our lab group has found that following 
LCM the RIN value decreased by 1.5, however this remained of sufficient quality for 
downstream analysis (Waller et al., 2012).       
There are limitations to the use of post-mortem tissue, especially when extracting 
RNA from tissue. Conditions experienced at the time of death have an impact on 
RNA quality. Brain pH is a good indicator of levels of mRNA degradation, as a low 
pH (<6.5) indicates a slow death and a prolonged period within the agonal phase of 
donor prior to death (Kingsbury et al., 1995). Nevertheless, the pH values obtained 
from human post-mortem brain tissue are sufficiently good for molecular 
investigations (Monoranu et al., 2009). Hypoxia, pyrexia and terminal coma also lead 
to a decrease in mRNA stability (Harrison et al., 1991; Waller et al., 2012). Hence, 
for this study the criteria for inclusion within the sub-cohort was based on brain pH, 
PMD as well Braak and Braak stage.   
The peaks at 28s and 18s from the Picochip analysis are used to determine the 
quality of RNA and help determine how much degradation has occurred. These 
peaks represent the level of RNA digestion that has occurred; if no peaks are 
present this indicates that all the RNA has been digested (Ogura et al., 1998). A 
small level of degradation is expected due to the fact that RNA degradation may 
occur during the brief freeze thaw process that occurs during sectioning and the 
LCM process such as duration of capture and immunolabelling of sections may also 
contribute to RNA degradation (Waller et al., 2012). However, despite the 
degradation in RNA, the RNA extracts are sufficient for downstream expression 
analysis as demonstrated by previous work undertaken within our lab (Simpson et al., 
2011, 2015, 2016).   
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Due to the intimate microarchitecture found within the brain, the LCM method helps 
isolate an enriched cell sample. To confirm neuronal enrichment, RNA from neuronal 
cell isolations was amplified to detect NeuN. NeuN is a neuronal nuclear protein, 
which is localised to the nucleus and is a marker for post-mitotic neurons and is 
expressed by most types of neurons except; Cajal-Retzius cells, inferior olive 
neurons, γ-motor neurons and Purkinje cells  (Gusel’nikova and Korzhevskiy, 2015). 
Presence of a band in within the NeuN well, confirmed neuronal cell enrichment. 
Astrocytic enrichment was confirmed by amplification of RNA to detect GFAP. GFAP 
is a component of intermediate filaments found within astrocytes and is 
overexpressed in reactive astrocytes (Carter et al., 2019). Presence of a band in 
within the GFAP well, confirmed astrocyte cell enrichment.  
The use of FFPE tissue could help eliminate factors leading to RNA degradation that 
are associated with frozen brain tissue. One advantage of using FFPE would be the 
preserved morphology of the tissue, making isolation easier as specific cells can be 
identified using morphology in addition to immunostaining, leading to a more 
enriched population of single cell type (S. Shi et al., 2008). However, during the 
fixation process both RNA and DNA are degraded making nucleic acid extraction 
challenging although transcription expression studies have been carried out on RNA 
extracted from FFPE tissue using LCM (Joseph and Gnanapragasam, 2011).  
Another method that could potentially be used to isolate specific cell populations 
from a section of tissue is flow-cytometry. A novel method has been developed by 
Martin et al (2017) in which they are able to sort cells from murine brains that have 
been fixed in formalin, they were also able to extract mRNA from the sections and 
perform qPCR after isolating cells and they found that they had high purity of isolated 
cell populations (Martin et al., 2017).  
3.5.2 HMGCR expression in neurons decreases with increasing AD pathology 
HMGCR is an enzyme involved in the cholesterol biosynthesis pathway and the 
activity of this enzyme determines the rate of cholesterol production (Sharpe and 
Brown, 2013b). Immunohistochemical investigation in this study shows that HMGCR 
is expressed in the pyramidal neurons of the temporal cortex and the expression of 
HMGCR at a protein level, HMGCR immunoreactivity was also observed in glial 
population within the cortex and white matter boundary (2.4.3). The gene expression 
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studies confirm HMGCR expression at an mRNA level in astrocytes and neuron 
populations isolated from the temporal cortex at all Braak and Braak stages. 
The data from this current study showed that neuronal HMGCR expression showed 
a trend to decrease with increasing tangle pathology and a significant moderate 
negative correlation with AT8 immunoreactivity. One study investigated the effects of 
different splice variants of the HMGCR gene in post-mortem tissue from AD patients 
(Leduc et al., 2016). HMGCR gene has two possible alleles G and A, alternative 
splicing leads to full length and a variant containing a single nucleotide 
polymorphism (SNP) at locus rs3846662 which results in alternative splicing of exon 
13. The skipping of exon 13 (Δ13) is more common in A allele rather than the G 
allele. The exact effect of the SNP remains unknown but it is suggested that it may 
result in a reduced or lack of enzymatic activity (Johnson et al., 2003; Burkhardt et 
al., 2008; Medina and Krauss, 2009; Yu et al., 2014).  The study by Leduc et al, 
(2016) found that Δ13 mRNA levels in the frontal cortex positively correlate with NFT 
and within the cerebellum Δ13 mRNA levels negatively correlate with Aβ, suggesting 
a link between HMGCR gene expression and AD pathology (Leduc et al., 2016). 
However, these differences in brain regions could be accounted for by the varying 
cell populations as the frontal cortex has a higher ratio of glial cells compared to 
neuronal cells and vice versa within the cerebellum. So this would suggest that 
within the frontal cortex glial expression of Δ13 mRNA positively correlates with NFT 
and within the cerebellum neuronal expression of Δ13 mRNA negatively correlates 
with Aβ (Leduc et al., 2016). Additionally, Δ13 splice variant did not have an impact 
on HMGCR protein levels and no significant correlations were observed with full 
length HMGCR mRNA levels in both frontal and cerebellar cortices and NFT and Aβ.  
In this current study, we found that the expression of HMGCR within neurons 
decreased with increasing plaque pathology. One study investigated the effects of 
lovastatin in vitro on Aβ production and APP processing (Mendoza-Oliva et al., 2015). 
Treating human neuroblastoma cells with lovastatin reduced the protein expression 
of HMGCR and increased levels of degraded HMGCR. Furthermore, APP levels 
were increased but secretion of Aβ1-40 and Aβ1-42 was significantly reduced; 
however, prolonged exposure to lovastatin induced cell death (Mendoza-Oliva et al., 
2015). This suggests that the initial degradation in HMGCR expression could be a 
protective effect to reduce the production of Aβ. However this sustained reduction 
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may later lead to neuronal cell death as HMGCR is crucial for other cellular functions 
such a protein prenylation and isoprenoid synthesis (Cahoy et al., 2008b; Zhang et 
al., 2014; Moutinho, Nunes and Rodrigues, 2017). 
3.5.3 HMGCR expression in neurons correlates with markers of DNA damage 
Data from this current study shows that the relative concentration of HMGCR in 
neurons showed a moderate positive correlation with γH2AX immunoreactivity in 
neurons. This suggests oxidative DNA damage in the form of double stranded DNA 
breaks in neurons alters HMGCR expression in neurons. A microarray study in which 
human neuroblastoma cells were exposed to xanthine/xanthine oxidase (X-XOD) 
which induces oxidative stress found overexpression of cholesterol biosynthetic 
genes and a fold change of 1.8 in HMGCR gene expression in cells treated with X-
XOD (Recuero et al., 2009). Previous microarray analysis from our lab group also 
found overexpression of HMGCR in neurons isolated from frontal cortex of low Braak 
and Braak cases that had high DNA damage response as a result of oxidative stress 
(Simpson et al., 2016). Both these studies suggest a link between DNA damage as a 
result of oxidative stress and an increase in HMGCR expression as a protective 
mechanism to combat a decline in membrane cholesterol levels as a result of ROS 
damage, the data from this current study supports these findings. However, the data 
from this study showed no significant correlation with HMGCR expression and other 
markers of oxidative stress such as MDA and 8-OHdG.  
3.5.4 HMGCR expression in neurons correlates with markers of 
neuroinflammation  
The data from this current study found that the relative concentration of HMGCR in 
neurons showed a moderate positive correlation with MHCII immunoreactivity, but no 
significant correlation was observed with CD68 and GFAP immunoreactivity. Major 
MHCII is a molecule which is expressed by activated microglia which occurs during 
neuronal injury (Neumann, 2001). This suggests that an increase in HMGCR 
expression in neurons correlates with an increase in microglial activation. A study by 
Chen et al (2018) investigated the effect of a high cholesterol diet in young and aged 
mice and found that the protein expression of CD68 was significantly increased in 
aged mice fed on a high cholesterol diet compared to control young mice.  A similar 
increase in CD68 protein expression was also observed in young mice fed on a high 
cholesterol diet compared to control young mice suggesting that a high cholesterol 
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diet may induce neuroinflammation by activating microglia (Chen et al., 2018). This 
study also found an up regulation in both pro- and anti-inflammatory cytokines at 
mRNA level in aged mice on a high cholesterol diet; this suggests that there may be 
a more complex interplay between cholesterol biosynthesis and regulation of a 
neuroinflammatory response.  
3.5.5 HMGCR expression in neurons does not correlate with markers of 
cholesterol biosynthesis 
Data from this current study shows that the expression of HMGCR in astrocytes and 
neurons isolated from the temporal cortex does not have any significant correlations 
with HMGCR immunoreactivity. The lack of significant correlation highlights the 
limitations of IHC as a method to determine protein levels as opposed to protein 
localisation. Furthermore, the IHC method does not provide a liner assessment of 
protein concentration this makes it difficult to assess HMGCR protein levels based 
solely on percentage immunoreactivity as this method only takes into account the 
number of pixels that contain the chromogen and not the absolute amount of 
chromogen present (Matkowskyj et al., 2003).  
3.5.6 SREBP2 expression in neurons is associated with markers of AD pathology 
SREBP2 is a major regulatory transcription factor for cholesterol biosynthesis 
pathway (Zhang and Liu, 2015). Immunohistochemistry showed that SREBP2 is 
localised to astrocytes and neurons in the human temporal cortex (2.4.6). Gene 
expression analysis now confirmed SREBP2 mRNA expression in both astrocyte 
and neuron isolations from the temporal cortex at all Braak and Braak stages, with 
an increase of SREBP2 expression in neurons with Braak and Braak stage, tangle 
pathology and AT8 percentage area immunoreactivity.  Although, a significant trend 
to decrease was observed in SREBP2 expression in astrocytes with increasing 
Braak and Braak stage, it is difficult to make any biological conclusions due to the 
small number of valid cases within this data set.  
Other studies have shown that SREBP2 alters with classical markers of AD 
pathology.  One study in which SREBP2 was overexpressed in APP/PS1 mice found 
that Aβ accumulation was accelerated in the triple transgenic mice compared to 
APP/PS1 mice (Barbero-Camps et al., 2013). Another study demonstrated that in 
high fat diet rats, activation of SREBP2 was observed and an increase in BACE1 
was correlated with activation of SREBP2 (Mastrocola et al., 2011). This data 
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suggests that activation of SREPB2 is associated with promoting the formation of Aβ. 
However, contradictory evidence has also been found in several other studies. One 
study found that Aβ inhibits the activation of SREBP2, in this study primary rat 
neurons were treated with oligomeric Aβ and found reduced levels of SREBP2 as 
well as decreased activated SREBP2 (Mohamed et al., 2018b). Furthermore, in AD 
patient derived fibroblasts, astrocytoma and hepatic cells cleavage of APP with α-
secretase stimulated SREBP2 signalling whereas β-secretase cleavage had an 
inhibitory effect (Mastrocola et al., 2011). This data suggests that both APP and 
SREBP2 are involved in a physiological feedback loop regulating growth via 
cholesterol homeostasis. However, the data from this current study found no 
significant differences or correlations with Aβ or plaque pathology. 
Wang et al, (2019) found that the N-terminal of SREBP2 was localised in the 
cytoplasm of pyramidal neurons from the hippocampus in AD brains, compared to 
age-matched control brains where the N-terminal of SREBP2 was localised to the 
nucleus. Furthermore, a significant reduction in neuronal nuclear locaisation in the N-
terminal of SREBP2 was observed in AT8 immunopositive cases (Wang et al., 2019). 
In vivo studies in triple transgenic mice models, which develop tau pathology, found 
that once NFT pathology starts to manifest a reduction in the neuronal nuclear 
locaisation in the N-terminal of SREBP2 was observed, this was further validated in 
another mouse model which overexpressed mutant tau where SREBP2 N-terminal 
was localised to the cytoplasm (Wang et al., 2019).  Therefore, this study suggests 
that there is a negative association between phosphorylated tau and nuclear 
localisation of SREBP2 is observed in pyramidal neurons of the hippocampus in AD 
brains suggesting that cholesterol biosynthesis is not being induced. Our study 
demonstrates a positive correlation between SREBP2 expression in neurons and 
AT8 immunoreactivity and tangle pathology and evidence from the study by Wang et 
al, (2019) validates this finding as they found the C-terminal fragment expression 
increased significantly in AD patients. The primer used in our study was specific for 
exons 15-16 which is located within the central portion of the gene which forms part 
of the cytoplasmic fragment.  
3.5.7 ABCA1 expression in neurons correlates with tau immunoreactivity 
ATP binding cassette transporter A1 (ABCA1) is a membrane bound protein which 
plays a role in regulating cellular cholesterol homeostasis (Phillips, 2018). ABCA1 is 
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ubiquitous and localised to the plasma membrane of cells and has also been 
observed to traffic between the plasma membrane, intracellular vesicles and early 
and late endosomes (Neufeld et al., 2001). In the brain ABCA1 is mainly expressed 
in the endothelial cell membranes, playing a role in cholesterol efflux and 
redistributing phospholipids in the membrane and via apoE (Schinkel and Jonker, 
2003; Bartels, 2011).   
Cholesterol efflux mechanisms differ in expression and activity in both neurons and 
astrocytes. One study demonstrated an increased mRNA expression of ABCA1 in rat 
primary cortical neurons compared to rat primary cortical astrocytes however, when 
the cells were treated with ethanol there was increased cholesterol efflux in 
astrocytes compared to neurons (Chen et al., 2013). ABCA1 protein is expressed in 
neurons however, the exact physiological function of the transporter in neurons is yet 
to be elucidated. A study by Matsuda et al (2013) suggests that ABCA1 may play a 
role in 24S-OHC removal from neurons. The study found that the treatment of SH-
SY5Y cells with 24S-OHC induced ABCA1 gene expression and cholesterol efflux 
within the neurons was HDL- dependent (Matsuda et al., 2013).  Although, this study 
does not help ascertain the physiological function of ABCA1 as SH-SY5Y cells do 
not endogenously express it. Furthermore, 24S-OHC generates free radicals which 
induce apoptosis within neurons, making it neurotoxic, hence the action of ABCA1 in 
removing 24S-OHC may be a survival mechanism rather than a normal physiological 
mechanism (Kölsch et al., 2001b).  ABCA1 plays a crucial role in cholesterol 
transport within astrocytes. In one study, ABCA1 gene knockout in primary mouse 
astrocytes showed an overall decrease in cholesterol efflux and a significant 
reduction in cholesterol efflux to apoE4 was observed (Hirsch-Reinshagen et al., 
2004). Furthermore, silencing of ABCA1 in astrocytes, showed a decrease in apoE 
secretion and consequently intracellular cholesterol accumulation was also observed. 
This data suggests that ABCA1 plays a role in transporting cholesterol out of 
astrocytes and into apoE in vitro and lack of ABCA1 may impact apoE dependent 
cholesterol transport to neurons.  
The data from this study showed a moderate positive correlation with AT8 
immunoreactivity and ABCA1 expression in neurons, suggesting that an increase in 
AT8 immunoreactivity correlates with an increase in ABCA1 expression. ABCA1 
expression has been shown to alter tau pathology. In one study, transgenic mice 
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expressing both human apoE3 and apoE4 were treated with a peptide (CS-6253) 
which directly increased ABCA1 activity. The study found that treatment with CS-
6253 significantly decreased the AT8 immunoreactivity in murine hippocampal 
neurons compared to apoE3 treated and apoE4 untreated mice. Localisation of the 
peptide was found to accumulate in astrocytes within the hippocampus and 
treatment increased the lipidation of apoE4 and a significant reversal in cognitive 
decline was also observed (Boehm-Cagan et al., 2016). This suggests that ABCA1 
activation in astrocytes may play a role in the reversal of AD pathology, however the 
data from our study showed a significant correlation with neuronal ABCA1 
expression rather than astrocytic expression.  
Studies have demonstrated a link between Aβ and ABCA1. One study treated 
primary mouse cortical neurons with oligomeric Aβ and microarray analysis showed 
an increase in ABCA1 by a fold change of 4 (Malik et al., 2012). In APP23 mice the 
knockout of ABCA1 resulted in an increase in Aβ deposition within the brain 
(Koldamova, Staufenbiel and Lefterov, 2005). Overexpressing of ABCA1 has been 
shown to reduce Aβ deposition. A study by Wahrle et al (2008) overexpressed 
ABCA1 in an AD mouse model which overexpressed mutant human APP gene and 
found that there was a significant reduction in Aβ deposition (Wahrle et al., 2008). 
Activation of liver X receptors in murine neuroblastoma cells expressing the Swedish 
mutant of APP showed an increase in ABCA1 protein expression leading to a 
decrease in Aβ formation (Sun et al., 2003). Additionally, when apoE was added a 
profound decrease in Aβ was observed and a decrease in γ-secretase activity was 
also observed (Sun et al., 2003). These studies suggest that ABCA1 may have a 
role to play in the formation of Aβ depositions the exact mechanism in which this is 
regulated is currently unknown. One possible way in which Aβ formation may be 
regulated by ABCA1 is preventing γ-secretase activity which in turn prevents APP 
cleavage from forming the amyloidogenic Aβ42 fragment. Another possibility is the 
activity of ABCA1 changes the cholesterol composition of the membrane, which 
favours the non-amyloidogenic processing of APP. However, in our study we found 
that there was no significant correlation with ABCA1 expression in neurons and 
astrocyte isolations from temporal cortex with Aβ immunoreactivity, plaque and 
tangle pathology in the temporal cortex.    
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3.5.8 Tissue cholesterol concentration does not change with AD progression 
and does not correlate to markers of classical AD neuropathology 
This study found that there were no significant changes in brain tissue cholesterol 
concentration in relation to AD neuropathology progression. One study found that in 
AD transgenic mice brains (Tg2576 and 3xTg-AD) cholesterol accumulates in 
hippocampal regions undergoing Aβ deposition compared to wild-type mice, which 
displayed a more homogeneous distribution of cholesterol. The cholesterol granules 
were not intimately associated with single Aβ deposits but spread over regions 
where Aβ accumulates (Solé-Domènech et al., 2013). Another study found that 
cholesterol co-localised with fibrillar Aβ plaques but not diffuse plaques in mutant 
APP and PS1 transgenic mice (Burns et al., 2003). Studies in transgenic mice 
expressing the human isoform of tau and APOE knockout mice found that neurons 
affected by tau had higher levels of unesterified cellular cholesterol compared 
neurons without tau pathology (Glöckner and Ohm, 2014). These studies 
demonstrate a clear link between cellular cholesterol concentration and classical AD 
pathology, whereas this current study found no significant changes in tissue 
cholesterol concentration with AD pathology and progression. One possible 
explanation for this difference is whole tissue cholesterol concentration does not 
consider changes occurring at an intracellular level. Furthermore, these studies 
mainly focused on mouse hippocampal regions where AD pathology has a more 
pronounced effect compared to temporal regions (Belfiore et al., 2019).   
3.5.9 Tissue cholesterol concentration does not correlate with markers of 
cholesterol biosynthesis  
This study found that there were no significant correlations in brain tissue cholesterol 
concentration and markers of cholesterol biosynthesis. Correlations to cholesterol 
biosynthesis was assessed by comparing tissue cholesterol concentration with 
percentage immunoreactivity of HMGCR (2.4.1) and relative gene expression of 
HMGCR and SREBP2 in neurons and astrocytes. The lack of correlation could be 
explained by the limitations of IHC quantification mentioned previously (2.5.7). Briefly, 
the number of pixels containing the chromogen is not directly proportional to the 
amount of protein and the detection system used by the program is not linear 
(Matkowskyj et al., 2003). Another possible explanation as to why HMGCR 
immunoreactivity and gene expression does not correlate with tissue cholesterol 
concentration is that the mevalonate arm of the cholesterol biosynthesis pathway is 
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also used by neurons to synthesis isoprenoids rather than cholesterol (Cahoy et al., 
2008b; Zhang et al., 2014; Moutinho, Nunes and Rodrigues, 2017).  
3.5.10 Tissue cholesterol concentration does not correlate with markers of 
cholesterol metabolism  
This study found that there were no significant correlations in brain tissue cholesterol 
concentration and markers of cholesterol metabolism. Correlations to cholesterol 
metabolism was assessed by comparing tissue cholesterol concentration with CSF 
24-OHC levels (Simpson et al., 2016) and relative gene expression of ABCA1 and 
CYP46A1 in neurons and astrocytes. Studies in human volunteers have found that 
24-OHC flux into CSF and then into the jugular vein is calculated to be <1% this 
suggests that 99% of 24-OHC flux occurs via the BBB (Lütjohann et al., 1996b; 
Lütjohann, 2006). Thus, measuring plasma 24-OHC levels may be providing a more 
accurate assessment of cholesterol metabolism within the brain.  
3.5.11 Tissue cholesterol concentration does not correlate with markers of 
oxidative stress 
This study found that there were no significant correlations in brain tissue cholesterol 
concentration and markers of oxidative stress. DNA damage was assessed by 
γH2AX immunoreactivity (J. E. Simpson et al., 2010), H2AX is a core histone 
molecule, and is recruited at sites of double stranded breaks where it is 
phosphorylated on the 139th serine residue to form γH2AX foci (Kuo and Yang, 
2008). Oxidative stress was assessed by MDA protein levels and immunoreactivity 
of thioredoxin2 (Trx2) and peroxiredoxin3 (Prx3). MDA is the product of lipid 
peroxidation caused by free radicals in cells and is commonly used as a marker of 
oxidative stress (Torun et al., 2009). Trx2 and Prx2 are involved in the reduction of 
H2O2 into H2O to maintain mitochondrial redox status and thus a marker ROS 
induced oxidative stress (Yin et al., 2016). Studies have shown that in AD brains the 
expression of Prx3 is significantly lower compared to normal brains and Trx2 
expression is significantly reduced in the hippocampus of AD brains (Kim et al., 2001; 
Arodin et al., 2014). One study found that excitatory neurotransmission mechanisms 
were linked to cholesterol loss in ageing. In primary rat hippocampal neurons 
excitatory neurotransmission via N-methyl-D-aspartate (NMDA) lead to the 
generation of ROS and membrane cholesterol loss (Sodero et al., 2011). This study 
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suggests that a link between oxidative stress via ROS and cholesterol concentration, 
however in this current study no correlation was observed.   
3.5.12 Tissue cholesterol concentration does not correlate with markers of 
neuroinflammation  
This study found that there were no significant correlations in brain tissue cholesterol 
concentration and markers of neuroinflammation. To measure neuroinflammation the 
immunoreactivity of CD68, GFAP and MHCII from previous studies was used (J. E. 
Simpson et al., 2010). CD68 is a glycosylated type 1 transmembrane glycoprotein 
localised to endosomal/lysosomal compartments and is expressed on the surface of 
macrophages (Chistiakov et al., 2017). Major histocompatibility complex class 2 
(MHCII) is a molecule which is expressed by activated microglia which occurs during 
neuronal injury (Neumann, 2001). GFAP is a protein, which makes up the 
intermediate filaments of the astrocytic cytoskeletal, in reactive astrocytes this 
protein is overexpressed (Carter et al., 2019). A study in high cholesterol-fed rabbits 
found an increase in activated microglia and astrocytes alongside neuropathological 
features of AD (Zatta et al., 2002). A more recent study investigated the effect of a 
high cholesterol diet in young and old mice and found that in aged mice on a normal 
diet microglial activation was observed and in mice fed with a high cholesterol diet 
showed a further increase in microglial activation and secretion of inflammatory 
cytokines such a IL-1β, IL-6 and TNF-α (Chen et al., 2018). These studies suggest a 
relationship between high cholesterol diet and neuroinflammation via microglial 
activation, however the data from this study does not demonstrate this relationship.  
3.5.13 Tissue cholesterol concentration does not correlate with markers of 
vascular pathology 
This study found that there were no significant changes or trends in brain tissue 
cholesterol concentration and markers of vascular pathology. Vascular pathology 
was assessed by comparing tissue cholesterol concentration with the presence of 
cortical micro-infarcts and cerebra amyloid angiopathy (CAA) (Ince, 2001; Matthews 
et al., 2009a).  Early studies have shown a decrease in white matter cholesterol 
levels in brains diagnosed with AD and vascular dementia (Wallin et al., 1989). A 
more recent population based study has found no significant differences between 
late life plasma HDL levels and presence of vascular pathologies such as CAA and 
cerebral microinfarcts (Bettcher et al., 2017). This supports the findings from this 
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current study, however it is important to note that Bettcher et al (2017) measured 
blood plasma cholesterol levels in two ways: the first way was to predict the 
cholesterol level at age 70; and the second was to predict cholesterol levels 10 years 
prior to death (Bettcher et al., 2017). Whereas in this current study brain tissue 
cholesterol concentration was directly measured. 
3.5.14 Moderate and high tissue cholesterol concentration is associated with 
dementia status 
Data from this current study showed that there was no significant association 
between temporal cortex cholesterol concentration and dementia status. However, 
when tissue cholesterol concentration was categorically divided into tertiles and 
modelled using logistic regression analysis moderate and high tissue cholesterol 
concentration was associated with dementia. A high degree of uncertainty surrounds 
this estimate due to the wide 95% confidence intervals which suggest that the 
current sample size is small, and a larger sample size would provide greater 
certainty.   A longitudinal nationwide population study in Korea (Korean National 
Health insurance Service- Health Screening Cohort) measured the total cholesterol 
levels in blood of patients in the cohort during health examinations and the total 
cholesterol variability was determined from at least three measurements. They found 
that visit-to-visit total cholesterol variability was a risk factor for the development of 
all types of dementia (Chung et al., 2019). In another large case-control study in 
China which measured total blood cholesterol from patients. This study found that a 
higher serum total cholesterol level was positively associated with the risk of 
dementia (Chen et al., 2019). In a separate ageing population study in USA 
measured the total plasma cholesterol levels and then used these values to predict 
cholesterol levels in later life (Bettcher et al., 2017). In this study, blood plasma 
cholesterol levels were predicted in two ways: the first way was to predict the 
cholesterol level at age 70; and the second was to predict cholesterol levels 10 years 
prior to death. This study found no significant associations between blood cholesterol 
in late life and AD neuropathology (Bettcher et al., 2017). These studies show the 
that there is a complicated relationship blood plasma cholesterol levels and dementia 
however, it is worth noting that these studies investigated blood plasma cholesterol 




3.5.15 Limitations of qPCR 
There are limitations to the use of qPCR as a reliable method to study changes in 
gene expression. The qPCR data can be quantified by either absolute quantification 
or relative quantification (Rao et al., 2013). Absolute quantification was calculated 
against a standard curve whereas relative quantification is when gene expression is 
calculated relative to a reference sample. In this study we used relative quantification 
to analyse our qPCR data using the 2-ΔΔCt method, which determines relative 
concentration of gene by determining the number of PCR cycles that occur at which 
fluorescence levels reach a threshold level and is then normalised to reference gene 
expression and then further normalised to the control sample gene expression and 
raised to the power of two to give a liner value. In this study the relative 
concentration values for each gene were calculated relative to the mean ΔCt 
expression for Braak and Braak group 1 or Thal group 1 for each cell type. The 
reference gene selected for this study was β-actin, as this was the same 
housekeeping gene used in the preceding microarray study from which this study is 
derived from (Simpson et al., 2016). However, in a study by Chen et al (2013), the 
expression of ABCA1 in both astrocytes and neurons was normalised to the 
expression of hypoxanthine phosphoribosyl transferase 1 (HPRT1). This was 
because β-actin expression in primary rat cortical neurons was 0.475 fold of the 
expression in primary rat cortical astrocytes, whereas HPRT1 expression in neurons 
was 0.92 fold of astrocytic expression, this allowed for a better comparison in 
expression of cholesterol transporters between the two cell types (Chen et al., 2013). 
When carrying out relative quantification it is based on two main assumptions; first of 
which is that the PCR amplification efficiency is 100% across all samples and genes; 
and secondly background fluorescence from probes is consistent across all primers 
(Rao et al., 2013).   
3.5.16 Limitations of cholesterol assay 
There are some limitations associated with the cholesterol assay which need to be 
considered. The aim of the study was to determine the cholesterol concentration in 
temporal cortex tissue however, due to the nature of the frozen blocks that were 
available it was difficult to isolate the cortical regions. Therefore, the cholesterol 
concentration values also include cholesterol from white matter regions. Furthermore, 
according to the manufacturers protocol the assay is designed to detect cholesterol 
concentrations between 0 μM-20 μM (Amundson and Zhou, 1999). However, during 
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optimisation of this assay, we found that the fluorescent plate reader would 
oversaturate at 10 μM and so to maintain accuracy and reproducibility, tissue 
cholesterol extracts were diluted 500 fold to ensure they were within the standard 
curve range and a standard curve ranging from 0 μM-7.5 μM was used to determine 
cholesterol concentration.  
3.6 Conclusion 
In this current study, we confirmed the expression of four key genes (HMGCR, 
CYP46A1, ABCA1 and SREBP2) involved in the cholesterol biosynthesis pathway 
and cholesterol metabolism in neurons and astrocyte populations isolated from the 
temporal cortex. This suggests that neurons possess the machinery to carry out de 
novo cholesterol biosynthesis. Neuronal HMGCR relative gene expression was 
found to have a trend to decrease with increasing tangle pathology and a significant 
moderate negative correlation with AT8 immunoreactivity. Furthermore, SREBP2 
relative gene expression in enriched neuronal populations isolated from human 
temporal cortex was found to increase with Braak and Braak stage, tangle pathology 
and AT8 immunoreactivity. A significant moderate positive correlation between 
neuronal ABCA1 expression and tau immunoreactivity was also observed. This data 
suggests that the gene expression of key regulators of the cholesterol biosynthesis 
pathway in neurons may be altered by NFT pathology. However, these changes in 
cholesterol biosynthetic gene expression were not translated to a change in 
cholesterol concentration and no significant correlation was observed with tissue 
cholesterol concentration and NFT tangle progression and AT8 immunoreactivity. 
Although NFT pathology is altering cholesterol biosynthetic gene expression in 
neurons, it is not having an impact on overall temporal cortex tissue cholesterol 
concentration suggesting that NFT pathology may be redirecting the cholesterol 
biosynthesis pathway to provide a different product. In astrocytes we found a 
significant trend to decrease with SREBP2 relative concentration and Braak and 
Braak stages. Furthermore, no significant correlations were observed between tissue 
cholesterol concentration with HMGCR immunoreactivity and relative gene 
concentration of HMGCR and SREBP2. Data from this current study also showed 
that there was no significant association between temporal cortex cholesterol 
concentration and dementia status. However, when tissue cholesterol concentration 
was categorically divided into tertiles and modelled using logistic regression analysis, 
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moderate and high tissue cholesterol concentration was associated with dementia. 
This suggests that the accumulation of cholesterol within the brain could increase the 





















4.0 In vitro characterisation of the effects of oxidative stress on the 
cholesterol biosynthesis pathway in human neurons and astrocytes   
4.1 Introduction  
Oxidative stress is a feature of brain ageing and may contribute to the pathogenesis 
of AD. It is defined as the imbalance between biochemical processes leading to 
reactive oxygen species (ROS) being produced and those processes responsible for 
the removal of ROS (Harman, 1981; Recuero et al., 2009). Studies have shown that 
within the CNS there are many contributors to ROS production (Tönnies and 
Trushina, 2017). One of the main contributors to ROS production in the brain is from 
mitochondria during oxidative phosphorylation (Ray, Huang and Tsuji, 2012; 
Holmström and Finkel, 2014). The accumulation of ROS within the brain can have a 
detrimental impact on several cellular components and functions such as: protein 
oxidation, lipid peroxidation, membrane destabilisation, ER stress, calcium 
homeostasis and nuclear DNA damage (Tönnies and Trushina, 2017).   
Aβ can also lead to the formation of ROS and contribute to oxidative stress within the 
brain (Hensley et al., 1994; Varadarajan et al., 2000). The literature suggests that Aβ 
can accumulate inside neurons and target mitochondria. Hansson Peterson et al 
(2008) showed that incubating human neuroblastoma cells with extracellular Aβ, lead 
to Aβ being internalised and localised to the inner mitochondrial membrane 
(Hansson Petersen et al., 2008). This same study also found that Aβ accumulated in 
mitochondrial specimens obtained from biopsies from living patients undergoing 
neurosurgery for suspected normal pressure hydrocephalus. Studies using a 
Drosophila model of AD showed that Aβ42 induced mitochondrial mis-localisation 
with accumulation of mitochondria within the soma and a reduction in axons and 
dendrites of neurons (Iijima-Ando et al., 2009). Together these studies suggest that 
Aβ may play a role in mitochondrial dysregulation, which may play a role in ROS 
accumulation and AD pathogenesis.   
Accumulation of ROS within the brain can lead to the oxidation of nucleic acids 
resulting in DNA damage (oxidative DNA damage) (Halliwell and Cross, 1994).  Aβ 
can directly cause oxidative DNA damage. Human NT2 teratocarcinoma cells  
incubated with Aβ showed an up-regulation of a gene implicated in DNA excision 
repair mechanisms (growth arrest and DNA damage-inducible gene- gadd45), 
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suggesting that Aβ may cause rapid DNA strand breaks (Santiard-Baron et al., 
1999). Oxidative DNA damage is higher in the temporal lobes of both AD and control 
brains compared to other brain regions (Lyras et al., 1997).  
Build-up of oxidative DNA damage within neurons can trigger neuronal death, and 
the failure of DNA damage repair mechanisms also contribute to neuronal death 
(Coppede and Migliore, 2009). The base excision repair (BER) system is a 
mechanism responsible for repairing DNA damage caused by oxidative stress 
(Kwiatkowski et al., 2016). Patients with AD showed an increase in the level of DNA 
damage compared to control patients, and polymorphisms in genes involved in the 
BER response which may contribute to the increase in DNA damage were also 
observed (Kwiatkowski et al., 2016). Reactivation of the cell cycle within neurons has 
been suggested to be an attempt to repair damaged DNA (Krantic et al., 2005; 
Coppede and Migliore, 2009). Breast cancer type 1 susceptibility protein (BRCA1) is 
involved with both DNA damage response and cell cycle regulation (Wezyk and 
Zekanowski, 2018). The promoter region for BRCA1 was hypomethylated in post-
mortem brain tissue from AD patients, resulting in upregulation and mis-localisation 
of the BRCA1 protein (Mano et al., 2017).  
Previous studies from our lab have shown that at low Braak and Braak stages there 
is an increase in oxidative stress markers such as; γH2AX, 8-OHdG and DNA-
dependent protein kinase compared to high Braak and Braak stages in the temporal 
cortex. Furthermore, high levels of oxidative stress were associated with a DNA 
damage response (DDR) (J. E. Simpson et al., 2010).  Microarray analysis on 
neurons isolated from frontal cortex sections from the CFAS population-derived 
neuropathology cohort with low and high DDR was utilised to investigate neuronal 
changes associated with the DDR (Simpson et al., 2016). This study had included 
only low Braak and Braak stage (I-II) cases (n=39) from the cohort, so that 
confounding effects of AD pathology were not included, and the effects of AD were 
not examined by the paper. Up-regulation of HMGCR (fold change of 4.5, p=0.0008) 
and down-regulation in SREBF2 (fold change of -1.1, p=0.001) was associated with 
a high DDR. Further work identified that there was an overexpression of HMGCR in 
cases with high neuronal DDR suggesting that there is a link with oxidative DNA 
damage and cholesterol biosynthesis (Simpson et al., 2016). As a result, for this 
study four key genes involved in cholesterol homeostasis were investigated to 
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assess changes in relative gene expression following exposure to oxidative stress. 
The genes selected were HMGCR, SREBP2, ABCA1 and APOE.  
The involvement of HMGCR, SREBP2 and ABCA1 in AD and cholesterol 
homeostasis are discussed previously (3.1).  Apolipoprotein E (APOE) is found on 
chromosome 19 and has 3 alleles- ε2, ε3 and ε4- of which ε2 is said to be protective 
and ε4 increases the risk of AD(Corder et al. 1993; Strittmatter et al. 1993; Rosenthal 
& Kamboh 2014; Karch & Goate 2015). APOE codes for a glycoprotein which is 299 
amino acids long and is involved in cholesterol transport, neuroplasticity and 
inflammation within the CNS (Kim, Basak and Holtzman, 2009; Karch and Goate, 
2015). APOE is mainly expressed in astrocytes and microglia however, neurons are 
also able to express this gene during AD, although at a lower level than astrocytes 
(Metzger et al., 1996; Xu et al., 2006; Kim, Basak and Holtzman, 2009). ApoE 
interacts with Aβ and is involved in the clearance, aggregation and metabolism of 
Aβ, although the exact mechanisms are yet to be elucidated (Kim, Basak and 
Holtzman, 2009; Karch and Goate, 2015). ApoE is involved in the transport of 
cholesterol produced in astrocytes to neurons (Pfrieger, 2003). ABCA1 activity in 
astrocytes is critical to apoE protein lipidation to form the apoE HDL (Vance and 
Hayashi, 2010). The lack of lipidation of apoE4 makes it more prone to forming 
aggregates and developing AD pathology (Hatters et al., 2006; Raulin et al., 2019). 
Once the apoE HDL is formed it delivers cholesterol to neurons by binding to low-
density lipoprotein receptors (LDLR) (Herz and Bock, 2002; Belloy, Napolioni and 
Greicius, 2019). 
To investigate the effects of acute and chronic oxidative stress in neurons and 
astrocytes in vitro, a double stress model, previously optimised in our lab group was 
used (Irina Vázquez-Villaseñor, unpublished data). This model used Lund human 
mesencephalic cells (LUHMES), a conditionally immortalised human dopaminergic 
neuronal precursor cell line. The double stress model has shown to induce double 
stranded breaks in DNA which can been detected 96 hrs following the stress (Irina 
Vázquez-Villaseñor, unpublished data). This model can induce a more persistent 
oxidative DNA damage in cells, by the addition of H2O2 to the culture media. This 
same stress model was applied to primary human foetal astrocytes, to investigate 
the effects of acute and chronic oxidative stress. The use of this model allows the 
170 
 
characterisation of changes that occur in neurons and astrocytes when exposed to 

























4.2 Aims and Objectives 
The aim of this study is to examine the effects of acute and chronic oxidative stress 
on the expression of genes involved in cholesterol biosynthesis and metabolism in 
neurons and glia. 
We hypothesise that exposure to acute and chronic oxidative stress leads to 
cholesterol dysregulation in neurons and astrocytes, whereby an initial 
compensatory mechanism occurs, which then fails following chronic oxidative stress. 
The objectives of this chapter are: 
• Characterise LUHMES differentiation and expression of genes involved in 
cholesterol biosynthesis and metabolism. 
• Determine the expression of HMGCR, SREBP2, ABCA1 and APOE following 
a single and double exposure to H2O2 in LUHMES and primary human foetal 
astrocytes. 
• Visualise the effects of single and double exposure to H2O2 on DNA damage 
in LUHMES and primary human foetal astrocytes. 
• Determine the effect on cell viability on primary human foetal astrocytes 























List of materials can be found in Appendix 6.1.2 
 
4.3.1 LUHMES cell culture 
Lund human mesencephalic (LUHMES) cells, a conditionally immortalised human 
dopaminergic neuronal precursor cell line, possess the ability to differentiate into 
post-mitotic neurons following a strict differentiation protocol. LUHMES were derived 
from an 8-week old human embryonic ventral mesencephalic tissue and 
immortalised using a LINX v-myc retroviral vector containing a tetracycline-controlled 
transactivator (tTA). Therefore, in the absence of tetracycline (tet) v-myc gene 
transcription is activated by tTA continuing the cell cycle and maintaining the cells in 
a proliferative state. The addition of tet to culture media causes binding of tet to tTA 
which inhibits vmyc expression arresting the cell cycle and initiating differentiation so 
that after five days the LUHMES will be post-mitotic (Hoshimaru et al., 1996; 
Lotharius et al., 2002; Lotharius, 2005). A two-step differentiation protocol, by re-
plating the LUHMES following two days of differentiation, allows for a homogeneous 
and synchronised population of post-mitotic cells following five days of differentiation. 
LUHMES have been shown to be maintain electrophysiological activity for a further 
five-six days after achieving the post-mitotic state (Scholz et al., 2011).      
During the proliferation phase, the LUHMES were grown in Advanced DMEM/F12 
(advanced Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12, Gibco) with 1% 
(v/v) N2-supplement (Gibco); 1% (v/v) L-glutamine (Lonza group Ltd); 1% (v/v) 
Penicillin/Streptomycin (P/S) (Lonza group Ltd) and supplemented with 40 ng/ml 
basic fibroblast growth factor (bFGF) (Peprotech EC Ltd, USA). Fresh media was 
added replacing bFGF with 1 µg/ml of tetracycline (Sigma-Aldrich) to induce 
differentiation and over five days the LUHMES differentiated and become post-
mitotic, with a re-plating step being performed on the third day after adding the 
differentiation media. LUHMES were grown in T75 flasks coated with 50 µg/ml Poly-
L-ornithine hydrobromide (pLo) (Sigma-Aldrich) and 1 µg/ml fibronectin (Sigma-
Aldrich) in sterilised distilled water (d.H2O). The flasks were coated for a minimum of 
3 hrs at 37°C and washed with sterile 1x phosphate buffered saline (PBS), prior to 
seeding. LUHMES were maintained in T75 flasks or plates at 37°C with 5% CO2. 
LUHMES were passaged when they reached an 80% confluency, they were 
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dissociated using 1x trypsin versene (Lonza Group Ltd) at 37°C for 5 minutes and 
centrifuged at 550 rpm for 5 minutes to form a pellet which was then re-suspended in 
5 ml of fresh media and re-plated accordingly (Table 4.1).  
Plate or Flask Proliferating cell density 
(cells/well or flask) 
Differentiating cell density 
(cells/well or flask) 
T75 flask 7.0x105 4.0x106 
6-well plate 5.5x105 1.5x106 
12-well plate 3.0x105 4.5x105 
24-well plate 1.0x105 3.5x105 
Table 4.1: LUHMES seeding densities 
 
4.3.2 Cryopreservation of LUHMES 
LUHMES were dissociated from the flask as previously described in 4.4.1, pelleted 
and re-suspended in cryopreservation media consisting of 70% advanced 
DMEM/F12 (Gibco) supplemented with bFGF (40ng/ml) (Gibco) , 10% (v/v) Foetal 
Bovine Serum (FBS) (Biosera) and 20% (v/v) Dimethyl Sulphoxide (DMSO) (Gibco). 
The LUHMES were stored in labelled sterile cryogenic vials at a cell density of 1x106 
cells/ml and stored at -80°C for 24 hrs in CoolCell® SV2 (Biocision) before 
transferring to liquid nitrogen for long term storage.  
4.3.3 Astrocyte cell culture 
Primary human astrocytes isolated from human foetal cerebral cortex, were 
purchased from ScienceCell Research Laboratories (USA). Astrocytes were 
maintained in T75 flasks in Astrocyte media, supplemented with 2% (v/v) Foetal 
Bovine Serum (FBS), 1% (v/v) Astrocyte Growth Supplement (AGS) and 1% (v/v) 
Penicillin/Streptomycin (P/S) (all ScienceCell Research Laboratories, USA). 
Astrocytes were cultured at 37°C and 5% CO2. Astrocyte media was changed every 
3-4 days and astrocytes were passaged when cells reached 90% confluency. 
Astrocytes were dissociated from the flasks using 1x trypsin versene (Lonza Group 
Ltd) at 37°C for 5 minutes and centrifuged at 550 rpm for 5 minutes to form a pellet 
which was then re-suspended in 3 ml of fresh astrocyte media and re-plated 
according to the experiments.      
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4.3.4 H2O2 treatments  
Both LUHMES and astrocytes were subjected to single and double stress 
experiments (Figure 4.1). For single stress experiments fully differentiated LUHMES 
or primary human astrocytes were treated with a single dose of 50µM H2O2 (Sigma-
Aldrich, USA). This dose was chosen, as no significant impact on cell viability was 
detected after 2 hrs and a 27.1% reduction in cell viability after 24 hrs. This dose 
induced a DNA damage response in LUHMES which could be detected after 24 hrs 
after a single stress and 96 hrs after a double stress (Irina Vázquez-Villaseñor, 
unpublished data). An equal volume of sterile PBS was used as a control. The 
effects of single dose were assessed at 1 hr, 3 hr, 6 hr and 24 hrs (n=3). For double 
stress experiments a second dose of 50 µM H2O2 was added to the cells 6 hrs 
following the first dose. The effects of a double dose were assessed at 1 hr, 3 hrs, 6 



















































































Figure 4.1. Double stress model.  A diagram to illustrate the single (A) and double (B) 
dose of 50 µM H2O2 used in LUHMES and astrocytes to model the effects of acute and 
chronic oxidative stress on cholesterol biosynthesis.  
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4.3.5 RNA extraction from cells using TRIzol  
For single and double stress in both astrocytes and neurons RNA was extracted 
from a combination of 4 wells, each condition yielding a final volume of 600 μl and 
800 μl (astrocyte and neurons, respectively) of TRIzol extract per condition. Cells 
were scraped from the surface of the well and the TRIzol extracts were stored in 
labelled sterile tubes at -80°C. RNA extraction was carried out using the Direct-zol 
RNA MiniPrep extraction kit (Zymo Research, USA) according to the manufacturer’s 
protocol. Briefly, TRIzol extracts were defrosted and mixed with equal volumes of 
100% ethanol (LUHMES = 800 µl and astrocytes = 600 µl) and transferred to a 
Zymo-Spin IIC Column and centrifuged at 13,000g for 30 seconds at RT. The flow-
through was discarded and the column was washed with Direct-Zol RNA PreWash 
and centrifuged at 13,000g for 30 seconds at RT twice followed by a wash with 
Direct-Zol RNA Wash Buffer and centrifuged at 13,000g for 2 minutes at RT. 
Following the washes, RNA was eluted from the columns using 50 µl of RNase free 
water and centrifuged at 13,000g for 30 seconds at RT into a sterile tube. The RNA 
was stored in a labelled sterile tube at -80°C. RNA concentration was determined by 
placing 1µl of RNA sample in the NanoDrop Spectrophotometer (ThermoFisher 
Scientific, USA). This also allowed determination of the purity of the RNA sample as 
a ratio was also measured. RNA integrity and degradation were determined using 
the Agilent RNA 6000 Nano Chip (Agilent Technologies, USA). Both methods helped 
determined the quality of the RNA that was used and would aid in downstream gene 
expression analysis via qPCR.    
Following RNA extraction, cDNA synthesis, validation and q RT-PCR was carried out 
as outlined in previous chapter please refer to sections 3.3.7, 3.3.8 and 3.3.9. The 
PrimeTime qPCR assays (Integrated DNA Technologies) (Table 4.2) were used. 
Quantification of qPCR data was carried out using the ΔΔCt method relative to 
expression of control cells at the corresponding time points. Statistical analysis was 











Table 4.2: List of all Prime Time® qPCR Assays used for cholesterol biosynthetic gene expression investigation 
Gene Prime Time® Assay ID Reference Exon Primer Sequence Probe Sequence 
HMG Co Reductase 
(HMGCR) Hs.PT.58.4048748 NM_001130996 15-16 
1) 5’-CCTTTATATCCGTTTCCAGTCCA-3’ 
2) 5’-CCACTAACGGCTAGAATCTGC-3’ 5’-/56-FAM/ATGTTCATC/ZEN/CCCATGGCATCCCC/3IABkFQ/-3’ 
Cytochrome P450 46A1 
(CYP46A1) Hs.PT.58.26445892 NM_006668 12-13 
1) 5’-AAGAGTCGCTGAGGCTGTA-3’ 
2) 5’-CCTCAAAGTATGTGTCCATCCG-3’ 5’-/56-FAM/CTCCTCTTC/ZEN/CAGCAGGCGAAAGG/3IABkFQ/-3’ 
ATP Binding Cassette A1 
(ABCA1) Hs.PT.58.11955 NM_005502 49-50 
1) 5’-TGCTACAATACCAGCTTCCATC-3’ 




Hs.PT.56a.22489703 NM_000019 11-12 1) 5’-CTGTTTCTCTGGGACATCCAA-3’ 2) 5’-GAATTAGCATGGCAGAAGCAC-3’ 5’-56-FAM/TCAAATGAC/ZEN/CAACAATCCTGGCTCCA/3IABkFQ/-3’ 
Sterol regulatory 
element binding 
transcription factor 2 
(SREBF2) 
Hs.PT.58.39417166 NM_004599 16-17 1) 5’-TTCCTTCTGCCATTGCGA-3’ 2) 5’-ACAGTAGCAGGTCACAGGT-3’ 5’-56-FAM/CTATGGAGC/ZEN/AGCCTCAACGTCAGT/3IABkFQ/-3’ 
SREBF chaperone (SCAP) Hs.PT.58.1056408 NM_012235 18-19 1) 5’-CAGCAGCGAGGAGGTCT-3’ 2) 5’-GAGAAGAAATCAAGGGAACCGT-3’ 5’-56-FAM/CGTGCAGGCC/ZEN/ACAATCCTTTTGTCC/3IABkFQ/-3’ 
HMG Co Synthase 1 
(HMGCS1) Hs.PT.58.26937768.g NM_002130 9-10 
1) 5’-ATTCAAGAACTGGTGTGGCA-3’ 
2) 5’-AGTACCACGTTCCTTCAAAGAG-3’ 5’-56-FAM/AACATGAAG/ZEN/CTCAGAGAGGACACCC/3IABkFQ/-3’ 
Mevalonate kinase 
(MVK) Hs.PT.58.40379926 NM_001114185 8-10 
1) 5’-CTGCTCAAGTTCCCAGAGAT-3’ 








Hs.PT.58.40218739 NM_004462 7-8 1) 5’-GGGCAAGCAGTGACCCT-3’ 2) 5’-TGGTGGAGATGATCTGCCT-3’ 5’-56-FAM/AGATTTATC/ZEN/ATAGAATCCCCGACTCAGACCC/3IABkFQ/-3’ 
Beta-Actin (ACTB) Hs.PT.39a.22214847 NM_001101 1-2 1) 5’-ACAGAGCCTCGCCTTTG-3’ 2) 5’-CCTTGCACATGCCGGAG-3’ 5’-56-FAM/TCATCCATG/ZEN/GTGAGCTGGCGG/3IABkFQ/-3’ 




Cells were washed once with PBS followed by fixation in 4% paraformaldehyde 
(PFA) (Sigma-Aldrich) for 5 minutes at 37°C. Cells were gently washed 3 times with 
PBS and permeabilised in 0.3% Triton-X-100 (Sigma-Aldrich) for 3 minutes at RT, 
washed again in PBS and coverslips were blocked in ICC blocking solution (3% (w/v) 
BSA diluted in PBS-T) for 30 minutes at RT. Coverslips were incubated with the 
primary antibodies diluted in ICC blocking solution, antibody details and incubation 
conditions are provided in table 4.3. Following primary antibody incubation, the 
coverslips were washed 3 times with PBS and then incubated with the appropriate 
species of secondary antibody diluted in ICC blocking solution (Table 4.4) for 1hr at 
RT followed by further washes in PBS. Nuclei were stained with Hoechst 33342 dye 
(Sigma-Aldrich) before mounting in ClearMountTM Mounting solution (Invitrogen). 
Rabbit and mouse isotype controls and omission of primary antibody (negative 
controls) were included to confirm antibody specificity. Cells were examined and 
imaged using a DsRi1 Eclipse microscope and camera (Nikon instruments, Japan).     
Dual labelling immunocytochemistry was performed to determine the presence of 
γH2Ax foci within neuronal and astrocytic nuclei. Cells were fixed, permeabilised and 
non-specific binding blocked as described above. Cells were then incubated with a 
primary antibody against γH2AX (Table 4.3) washed in PBS and incubated with an 
anti-mouse secondary antibody (Table 4.4) at RT. From this point onwards, the 
remainder of the protocol was carried out in the absence of light. After removing the 
secondary antibody and washing in PBS, coverslips were again incubated in ICC 
blocking solution prior to an overnight incubation in the second primary antibody, 
which was cell specific; for LUHMES this was anti-β-III-tubulin and astrocytes anti-
CD44 (Table 4.3). Coverslips were washed in PBS, incubated with the appropriate 
species of secondary antibody (Table 4.4) and nuclei were stained as outlined 
above. Negative and isotype controls were carried out as outlined above. Coverslips 







Table 4.3: Primary antibodies used for immunocytochemistry experiments 
 
Antibody Species Dilution and incubation conditions Source 
488 Alexa Flour anti-chicken Goat 1:1000 (1hr, RT) Thermo Fisher Scientific, USA 
568 Alexa Flour anti-mouse Goat 1:1000 (1hr, RT) Thermo Fisher Scientific, USA 
568 Alexa Fluor anti-rabbit Donkey 1:1000 (1hr, RT) Thermo Fisher Scientific, USA 
 
Table 4.4: Fluorescent secondary antibodies used for immunocytochemistry 
experiments 
 
4.3.7 Lactate Dehydrogenase Assay 
Lactate dehydrogenase (LDH) assay was carried out to assess cytotoxicity and cell 
viability in astrocytes after single and double exposure to 50 µM H2O2. This assay 
works on the principle that the LDH enzyme, a stable enzyme found in the cytoplasm 
of all cells, is released into the cell culture media following cell lysis. To quantify 
enzyme activity, NADH levels are measured through a coupled reaction where a 
yellow tetrazolium salt is converted into a red formazan product in the presence of 
NADH. Formazan levels are directly proportional to LDH levels, which is directly 
proportional to the number of damaged cells. Formazan levels are determined by 
measuring the absorbance of samples at 492 nm wavelength using a colorimetric 
plate reader (Kumar, Nagarajan and Uchil, 2018).      
Antibody Species Specificity Dilutions and incubation conditions Source 






polyclonal Β-III tubulin peptide 1:1000 (1hr, RT) 
Merck Millipore, 
Germany 
Ki67 Mouse monoclonal Ki67 Cell cycling antigen 1:50 (overnight, 4°C) 
Leica microsystems, 
Germany 
Map2 Rabbit polyclonal 
Microtubule associated 
protein 1:100 (1hr, RT) Sigma-Aldrich, USA 
CD44 Rabbit polyclonal CD44 Peptide 1:500 (overnight, 4°C) Abcam, UK 
γH2AX Mouse monoclonal 
Phosphorylated histone 
H2A.X at Ser139. 
1:500 
LUHMES (1hr, RT) 





LDH cytotoxicity assay was purchased from Promega, USA and was carried out 
according to manufacturer’s protocol. Astrocytes were grown in phenol red free 
astrocyte media in 12-well plates and stressed as outlined above (4.3.4). Following 
stresses, 3x 50 µl samples of media were transferred into a 96 well plate. The 
remaining media was collected, and the volume was measured. 150 µl of 1x lysis 
solution (provided in the kit) was added to each well and incubated at 37°C for 45 
minutes. Following incubation, 850 µl of culture media was added to each well 
containing lysed astrocyte and 3 x 25 µl of lysed cell suspension was transferred into 
a 96 well plate and was made up to 50 µl using culture media. 50 µl of reaction mix 
was added to each well and was incubated for 30 minutes at RT in the dark. The 
assay was terminated by adding 50 µl of the stop solution (provided in the kit) into 
each well and the absorbance at 490 nm was measured using the PHERAStar 
spectrophotometer. The absorbance was normalised to positive controls and media 
controls on each plate and percentage cell death was calculated by working out the 
ratio of the absorbance at 490 nm of the media before and after lysis.  
4.3.8 Statistical Analysis 
Data obtained within this study was analysed with GraphPad Prism 8.0 (GraphPad 
Software, Inc., USA). All data was presented as mean ± standard error of the mean 
(SEM). One-way ANOVA was used to determine statistical significance of the data 
obtained from cholesterol biosynthesis gene expression in LUHMES during 
differentiation and cell viability experiments from astrocytes experiments. Post-hoc 










4.4.1 Characterisation of LUHMES during proliferation and differentiation  
To characterise LUHMES differentiation and confirm that the 2-step differentiation 
protocol outlined by Scholz et al, (2011) leads to post-mitotic neurons, 
immunocytochemistry for neuronal and cell cycle markers was carried out. NeuN 
expression in LUHMES was localised to the nucleus of the cells (Figure 4.2). During 
proliferation, NeuN expression was weak and was localised to the nucleus and 
cytoplasm as differentiation was initiated expression of NeuN was not detected 
during day 1 to day 2. Weak cytoplasmic staining was present on day 3 whilst on day 
4 and 5 NeuN expression was detected in the nuclei of cells.  During differentiation, 
the morphology of the nuclei within LUHMES was also altered, during proliferation 
nuclei appear to have a more ovoid morphology, whereas by day 5 LUHMES nuclei 
appear to have an oblong morphology. Microtubule-associated protein 2 (MAP2) is a 
protein involved in microtubule assembly and is abundantly expressed within the 
brain and is localised to somatodendritic compartments of neurons helping to 
stabilise dendrites (Harada et al., 2002). MAP2 expression in LUHMES was detected 
during all stages of differentiation and proliferation. During proliferation, MAP2 
staining was weak and near the nucleus, as the LUHMES differentiated expression 
of MAP2 was localised to small neurites structures which eventually formed longer 
neurites at days 4 and 5.  
To characterise cell cycle status, Ki67 expression was determined in LUHMES. 
Antigen Ki67 is expressed in mammalian cells undergoing cell cycle, it is a nuclear 
protein which has been shown to be involved in heterochromatin organisation and is 
used as a cell proliferation marker (Sobecki et al., 2016). When LUHMES are 
undergoing proliferation, the expression of Ki67 was localised to cell nuclei with most 
cells showing positive staining. Once differentiation had been initiated, the number of 
Ki67 positive nuclei decreased from day 1 to day 3 and after day 4 no Ki67 positive 
nuclei were observed. Staining for β-III-tubulin was also carried out to visualise 
morphological changes as β-III-tubulin is localised to the cytoskeleton. Within 
proliferating, day 1 and day 2, cells β-III-tubulin expression was present and 
displayed a change in morphology as small neurites formed. From day 3 onwards, 
neurites could be easily identified and were longer, a reduction in cell body size was 
also observed as differentiation took place.  
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4.4.2 Cholesterol biosynthetic gene expression in LUHMES during 
differentiation 
To assess cholesterol biosynthesis in LUHMES during differentiation, expression of 
key genes involved in cholesterol homeostasis was determined as LUHMES 
differentiated. LUHMES were cultured and RNA was extracted at the same time 
point for each day and qPCR analysis for nine key genes was carried out and 
quantified using the ΔΔCt calculation relative to the mean expression in proliferating 
LUHMES (Figure 4.3). Between the samples, a lot of variation in relative gene 
expression was observed. HMGCR expression was observed at all stages of 
differentiation and remained consistent during differentiation with a small increase in 
expression seen on day 2 and day 5, no significant difference between HMGCR 
expression during differentiation and proliferation was observed (ANOVA, p=0.461). 
ABCA1 expression increased during the first two days of differentiation followed by a 
sudden decrease in expression on day 3, followed by an increase in expression on 
day 4 and day 5, however the changes in ABCA1 expression were not statistically 
significant (ANOVA, p=0.553). The expression of ACAT1 shows a decrease in 
expression as LUHMES differentiate however, this decrease was not statistically 
significant (ANOVA, p=0.095). SREBP2 expression increased during the first two 
days of differentiation followed by a sudden decrease in expression on day 3, 
followed by an increase in expression on day 4 and day 5, however the changes in 
SREBP2 expression were not statistically significant (ANOVA, p=0.698). SCAP 
expression was significantly decreased in differentiating LUHMES compared to 
proliferating LUHMES (ANOVA, p=0.018), Tukey multiple comparisons showed that 
day 3, day 4 and day 5 were significantly decreased compared to proliferating cells 
(p=0.018, p=0.022, p=0.048 respectively). HMGSC1 showed an initial decrease in 
expression and then following day 3 expression increased however, the changes 
were not statistically significant (ANOVA, p=0.103). The expression of both MVK and 
MVD had a similar profile with an initial decrease in expression until day 3 and then a 
plateau in expression, however these changes were not statistically significant 
(p=0.179, p=0.193 respectively). FDFT1 expression decreased as LUHMES 
differentiated, the expression decreased until day 3 after which the expression 
stayed constant. This decrease was statistically significant (ANOVA, p=0.040) and 
Tukey’s multiple comparisons showed that the expression at day 3 was significantly 



































Figure 4.2. Characterisation of proliferating and differentiating LUHMES.  Tetracycline was added to LUHMES to inactivate the v-myc 
transgene and induce terminal differentiation and the expression of key proliferative and neuronal markers was determined using 
immunocytochemistry. LUHMES were fixed with 4% PFA on each day of the differentiation process and immunolabelled with antibodies 
NeuN (green-top row), MAP2 (green-second row), Ki67 (green-third row) and β-III-tubulin (green-bottom row). Nuclei were stained with a 





















































Figure 4.3. Cholesterol biosynthetic gene expression during LUHMES differentiation: The 
relative expression of genes involved in cholesterol biosynthesis was determined during 
LUHMES differentiation. Relative concentration values were calculated using the ΔΔCt 
calculation relative to the mean expression in proliferating LUHMES. A significant decrease 
in expression was observed in SCAP and FDFT1.  N=3  
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4.4.3 Single and double exposure to H2O2 leads to the presence of γH2AX foci in 
post-mitotic LUHMES 
To investigate the effects of oxidative stress on cholesterol biosynthesis, LUHMES 
were cultured on glass coverslips and exposed to either a single or double dose of 
50 μM H2O2. Immunocytochemistry for γH2AX foci demonstrated that at all time 
points with both a single and double exposure to 50 μM H2O2, γH2AX foci was 
detected in the nuclei of LUHMES over 24 hrs and 96 hrs respectively (Figure 4.4).  
4.4.4 Single exposure to H2O2 shows no significant changes in cholesterol 
biosynthetic relative gene expression in post-mitotic LUHMES 
Post-mitotic LUHMES were exposed to a single dose of 50 μM H2O2 and the 
expression of four genes (HMGCR, ABCA1, SREBF2 and APOE) involved in 
cholesterol biosynthesis and metabolism was determined using qPCR over 24 hrs. 
Preliminary data shows that all four genes were expressed in control and treated 
cells at all time-points. The current data suggests that there was a reduction in 
ABCA1 expression and an increase in SREBP2 expression following treatment with 
H2O2. However, due to the COVID-19 pandemic and a lack of technical replicates we 
found that the data is inconclusive (Figure 4.5). 
4.4.5 Double exposure to H2O2 shows no significant changes in cholesterol 
biosynthetic relative gene expression in post-mitotic LUHMES 
Post-mitotic LUHMES were exposed to a single dose of 50 μM H2O2 followed by 
another dose of 50 μM H2O2 6 hrs later. The expression of four genes (HMGCR, 
ABCA1, SREBF2 and APOE) involved in cholesterol biosynthesis and metabolism 
was determined using qPCR over 96 hrs. Preliminary data shows that all four genes 
were expressed in control and treated cells at all time-points. The current data 
suggests that there is an increase in HMGCR expression with both a single and a 
double stress for the first 48 hrs, which stabilises at 96 hrs. However, due to the 
COVID-19 pandemic and a lack of technical replicates we found that the data is 








































Figure 4.4. γH2AX foci expression in single and double stressed post-mitotic LUHMES: Immunocytochemistry was used to localise 
γH2AX foci expression (white arrows) as a marker of DNA damage during a single exposure to 50 µM H2O2 over a 24 hrs time period 
(top row, SS) and during double exposure to 50 µM H2O2 over a 96 hrs time period (bottom row, DS). Cells were stained with γH2AX 
(red) and counterstained with β-III-tubulin (green). Nuclei were stained with nuclear dye Hoechst H3342 (blue). Scale bar represents 



































Figure 4.5. Expression of cholesterol biosynthetic genes in post-mitotic LUHMES after a single exposure to 
H2O2: The expression of four key genes (HMGCR, ABCA1, SREBP2 and APOE respectively) involved in 
cholesterol biosynthesis was determined during a single exposure to 50 µM H2O2 in post-mitotic LUHMES 
over a 6 hrs time period. Relative concentration values for each gene were calculated relative to the control. 





















































Figure 4.6. Expression of HMGCR in LUHMES after a single and double exposure to 
H2O2 over a 96 hrs time period: The expression of HMGCR was determined 
during single and double exposures to 50 µM H2O2 in LUHMES over a 96 hrs 
time period. RNA was extracted from LUHMES, cDNA was synthesised, and 
HMGCR expression was determined using qPCR. Each point on the graph 





















































Figure 4.7. Expression of ABCA1 in LUHMES after a single and double exposure 
to H2O2 over a 96 hrs time period: The expression of ABCA1 was determined 
during single and double exposures to 50 µM H2O2 in LUHMES over a 96 hrs 
time period. RNA was extracted from LUHMES, cDNA was synthesised, and 
ABCA1 expression was determined using qPCR. Each point on the graph 





















































Figure 4.8. Expression of SREBP2 in LUHMES after a single and double 
exposure to H2O2 over a 96 hrs time period: The expression of SREBP2 
was determined during single and double exposures to 50 µM H2O2 in 
LUHMES over a 96 hrs time period. RNA was extracted from LUHMES, 
cDNA was synthesised, and SREBP2 expression was determined using 






















































Figure 4.9. Expression of APOE in LUHMES after a single and double 
exposure to H2O2 over a 96 hrs time period: The expression of APOE 
was determined during single and double exposures to 50 µM H2O2 
in LUHMES over a 96 hrs time period. RNA was extracted from 
LUHMES, cDNA was synthesised, and APOE expression was 
determined using qPCR. Each point on the graph represents an 
individual biological replicate. 
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4.4.6 Single and double exposure to H2O2 leads to the presence of γH2AX foci in 
astrocytes 
To investigate the effects of oxidative stress on cholesterol biosynthesis a single and 
double stress model was previously developed within our lab group for LUHMES 
was adapted for use on primary human astrocytes. Astrocytes were cultured on 
glass coverslips and exposed to either a single or double dose of 50 μM H2O2 
Immunocytochemistry for γH2AX foci demonstrated that at all time points with both a 
single and double exposure to H2O2, γH2AX foci were detected in the nuclei of 
astrocytes over 24 hrs and 96 hrs respectively (Figure 4.10).  
4.4.7 Single and double exposure to H2O2 does not change the cell viability of 
astrocytes 
To determine the toxicity and effects of a single and double dose of 50 µM H2O2 on 
cell viability an LDH assay was performed. The data shows that there were no 
significant changes to astrocyte cell viability following a single and double exposure 
to 50 µM H2O2 over 24 hrs and 96 hrs respectively (ANOVA, single stress p=0.981; 
double stress p=0.945) (Figure 4.11).  
4.4.8 Single exposure to H2O2 shows no significant changes in cholesterol 
biosynthetic relative gene expression in astrocytes 
Astrocytes were exposed to a single dose of 50 μM H2O2 and the expression of four 
genes (HMGCR, ABCA1, SREBP2 and APOE) involved in cholesterol biosynthesis 
and metabolism was determined using qPCR over 24 hrs. Preliminary data shows 
that all four genes were expressed in control and treated cells at all time-points. The 
current data suggests that there are no changes in APOE expression following H2O2 
treatment in astrocytes over 24 hrs. However, due to the COVID-19 pandemic and a 
lack of technical replicates we found that the data is inconclusive (Figure 4.12). 
4.4.9 Double exposure to H2O2 shows no significant changes in cholesterol 
biosynthetic relative gene expression in astrocytes 
Astrocytes were exposed to a single dose of 50 μM H2O2 followed by another dose of 
50 μM H2O2 6 hrs later. The expression of four genes (HMGCR, ABCA1, SREBP2 
and APOE) involved in cholesterol biosynthesis and metabolism was determined 
using qPCR over 96 hrs. Preliminary data shows that all four genes were expressed 
in control and treated cells at all time-points. The current data suggests that SREBP2 
expression is consistent at 1 hr following single and double exposure to H2O2 and an 
increased expression at 3 hrs in single stressed and a further increased expression 
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following a double stress. At 6 hrs we see a decrease in SREBP2 expression in both 
single and double stresses astrocytes, where the double stressed cells had a larger 
decrease compared to controls. At 24 hrs an increase in SREBP2 expression was 
observed in both single and double stressed cells. Followed by a decrease in 
SREBP2 expression at 6 hrs in single and double stressed cells. At both 48 hrs and 
96 hrs an increase in SREBP2 expression was observed in single stressed cells, 
however in double stressed cells there was no change in SREBP2 expression 
compared to the controls. Due to the COVID-19 pandemic and a lack of technical 




































































Figure 4.10. γH2AX foci expression in single and double stressed astrocytes: Immunocytochemistry was used to localise γH2AX foci 
expression (white arrows) as a marker of DNA damage during a single exposure to 50 µM H2O2 over a 24 hrs time period (top row, 
SS) and during double exposure to 50 µM H2O2 over a 96 hrs time period (bottom row, DS). Cells were stained with γH2AX (red) and 





















































Figure 4.11. Cell viability in astrocytes following single and double exposure to H2O2: LDH 
assay was carried out to determine the effect on cell viability following a single and double 
exposure to 50 µM H2O2 in astrocytes. (A) Shows the percentage of LDH released h after 
a single exposure over a 24 hrs time period. (B) Shows the percentage of LDH released 
after a double exposure over a 96 hrs time period. Each point on the graph represents an 




































Figure 4.12. Expression of cholesterol biosynthetic genes in astrocytes after a single exposure to H2O2: The expression of four key 
genes (HMGCR, ABCA1, SREBP2 and APOE respectively) involved in cholesterol biosynthesis was determined during a single 
exposure to 50 µM H2O2 in astrocytes over a 24 hrs time period. Relative concentration values for each gene were calculated relative 






















































Figure 4.13. Expression of HMGCR in astrocytes after a single and double 
exposure to H2O2 over a 96 hrs time period: The expression of HMGCR was 
determined during single and double exposures to 50 µM H2O2 in 
astrocytes over a 96 hrs time period. RNA was extracted from astrocytes, 
cDNA was synthesised, and HMGCR expression was determined using 






















































Figure 4.14. Expression of ABCA1 in astrocytes after a single and 
double exposure to H2O2 over a 96 hrs time period: The expression of 
ABCA1 was determined during single and double exposures to 50 µM 
H2O2 in astrocytes over a 96 hrs time period. RNA was extracted from 
astrocytes, cDNA was synthesised, and ABCA1 expression was 
determined using qPCR. Each point on the graph represents an 






















































Figure 4.15. Expression of SREBP2 in astrocytes after a single and 
double exposure to H2O2 over a 96 hrs time period: The 
expression of SREBP2 was determined during single and 
double exposures to 50 µM H2O2 in astrocytes over a 96 hrs 
time period. RNA was extracted from astrocytes, cDNA was 
synthesised, and SREBP2 expression was determined using 
qPCR. Each point on the graph represents an individual 





















































Figure 4.16. Expression of APOE in astrocytes after a single and double 
exposure to H2O2 over a 96 hrs time period: The expression of APOE 
was determined during single and double exposures to 50 µM H2O2 in 
astrocytes over a 96 hrs time period. RNA was extracted from 
astrocytes, cDNA was synthesised, and APOE expression was 
determined using qPCR. Each point on the graph represents an 





In this chapter, the effects of acute and chronic oxidative stress on cholesterol 
biosynthesis in neurons and astrocytes in vitro were investigated. The expression of 
cholesterol biosynthetic genes was characterised in LUHMES during differentiation. 
We found that genes involved in cholesterol biosynthesis were expressed in 
LUHMES during differentiation. This study also found a significant decrease in SCAP 
and FDFT1 expression during differentiation. A single and double stress model was 
used to determine the changes in expression of four keys genes (HMGCR, APOE, 
ABCA1 and SREBP2) involved in the cholesterol biosynthesis pathway and 
cholesterol metabolism were characterised using qPCR. We found that the four key 
genes were expressed in both neurons and astrocytes following a single and a 
double dose of H2O2. This current study also found that a single and double exposure 
to oxidative stress, in the form of H2O2, can lead to the formation of double stranded 
breaks in neurons and astrocytes and persists for up to 24 hrs and 96 hrs 
respectively.  
4.5.1 Cholesterol biosynthetic genes are expressed in LUHMES during 
differentiation 
The expression of cholesterol biosynthetic genes was characterised for LUHMES 
cell line during differentiation. Lund human mesencephalic (LUHMES) cells, a 
conditionally immortalised human dopaminergic neuronal precursor cell line, possess 
the ability to differentiate into post-mitotic neurons (Hoshimaru et al., 1996; Lotharius 
et al., 2002; Lotharius, 2005). A two-step differentiation protocol, by re-plating the 
LUHMES following two days of differentiation, allows for a homogeneous and 
synchronised population of post-mitotic cells on completion of differentiation 
following five days of differentiation (Scholz et al., 2011). This study demonstrated 
that genes involved in cholesterol biosynthesis were expressed in neurons during 
neuronal differentiation, suggesting that neurons possess the machinery to carry out 
cholesterol biosynthesis. Murine cortical neurons have shown that during neuronal 
differentiation de novo cholesterol biosynthetic mechanisms are active. Primary mice 
cortical neurons grown in cholesterol free media showed accumulation of cholesterol 
within the cell and cholesterol is released into the media (Genaro-Mattos et al., 
2019b). This suggests that neurons in vitro are capable of synthesising cholesterol 
and supports the findings from this current study. The neuronal expression of 
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HMGCR in vitro further validates our finding from in vivo studies in post-mortem 
human temporal cortex tissue (Chapter 2 and 3).     
Cartocci et al (2016) found that during neuronal differentiation in mice neuroblastoma 
cell line a reduction in HMGCR activity and the down-regulation of the mevalonate 
arm of the cholesterol biosynthesis pathway was observed (Cartocci et al., 2016).  
However, the data from our study showed that there were no significant changes in 
the expression of genes within the mevalonate pathway (HMGCR, HMGCS1, 
ACAT1). Cartocci et al (2016) also found a reduction in the cleaved form of SREBP2 
protein, whereas the data from this study showed no significant change in total 
SREBP2 expression. However, a significant decrease in SCAP expression was 
observed in this study, suggesting that over a longer period this may translate to a 
decrease in total SREBP2 expression. These differences could be accounted for by 
the re-plating step that occurs on day 2 during LUHMES differentiation which may 
alter cholesterol biosynthesis gene expression. Furthermore, the mice 
neuroblastoma cells were observed over eight days compared to just five days with 
the LUHMES, therefore a reduction within the mevalonate pathway could potentially 
be observed on later days as gene expression changes in LUHMES have also been 
observed at day 10-12 following differentiation (Scholz et al., 2011). In the study by 
Cartocci et al (2016) the murine cell line N1E-115 was used and is an ideal model for 
studying neuronal differentiation but do not become post-mitotic, compared to 
LUHMES which become post-mitotic after five days which could also account for the 
differences observed in this study (Kranenburg et al., 1995; Shim et al., 2006; 
Cartocci et al., 2016).   
4.5.2 Acute and chronic stress models induced oxidative DNA damage in 
LUHMES  
In this study, we used a previously optimised model of inducing acute and chronic 
stress to investigate the effects of oxidative DNA damage on the expression of four 
key genes involved in cholesterol homeostasis (Irina Vázquez-Villaseñor, 
unpublished data). We found that this model induced oxidative DNA damage, which 
was visualised using γ-H2AX foci as a marker of double stranded DNA breaks, the 
DNA damage persisted for 24 hrs following an acute stress and 96 hrs following a 
more chronic stress. Preliminary gene expression results are inconclusive due to the 
lack of repeats because of limitation of laboratory access due to the COVID-19 
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pandemic.  The aim was to carry out three biological repeats with three technical 
repeats. For primary cells the biological repeats would require the experiments to be 
carried out on three different primary cell lines, however with immortalised cell lines 
biological repeats would be determined by carrying out the experiments at different 
passage numbers. Technical repeats would be carried out to remove the effects of 
errors caused by the protocols (Tsvetkov et al., 2019). 
Clement et al (2009) exposed cloned murine hippocampal cells to long-term 
treatment of sub-lethal doses of H2O2 to develop resistance to H2O2-induced 
oxidative stress. Compared to wild type cells, resistant cells showed an increase in 
cholesterol and cholesterol precursor levels; however, a decrease in ABCA1 and 
HMGCR mRNA levels was detected, suggesting a decrease in cholesterol efflux and 
synthesis. Cholesterol also accumulated within the lysosomes of resistant cells, 
suggesting that this could be a neuroprotective effect as it prevents changes to 
plasma membrane rigidity preventing cellular degeneration (Clement et al., 2009). In 
another study using LUHMES, the effect of oxidative stress induced by silver 
nanoparticles on cholesterol homeostasis was determined during both the 
proliferative and post-mitotic state. Zuberek et al (2018) found that ABCA1 mRNA 
expression increased during differentiation and treatment of proliferating cells with 
silver nanoparticles also showed an increase in ABCA1 mRNA expression (Zuberek 
et al., 2018). This data suggests that an increase in ABCA1 turnover may be a 
neuroprotective effect because of oxidative stress. If a similar response was 
observed in our experiments, then in our current study, we would also predict a 
decrease in expression of HMGCR, SREBP2 and ABCA1 when exposed to a more 
chronic stress. 
4.5.3 Acute and chronic stress models induced oxidative DNA damage in 
astrocytes 
In this study we found that a single and double stress model that had been 
previously optimised in LUHMES also induced oxidative DNA damage in primary 
human foetal astrocytes. The presence of γH2AX, a marker of DNA damage (Kuo 
and Yang, 2008), foci within the nuclei of astrocytes after 24 hrs and 96 hrs following 
a single and double exposure, respectively, suggests that method can be used to 
measure the effects of a DNA damage response following exposure to acute and 
chronic oxidative stress within astrocytes. Measuring cell viability following single 
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and double exposure showed that there were no significant changes to cell viability 
suggesting that 50 μM of H2O2 is not a lethal dose to the astrocytes but is strong 
enough to induce oxidative DNA damage. Preliminary gene expression results are 
inconclusive due to the lack of technical repeats as a result of the COVID-19 
pandemic.   
Prieto and Alonso (1999) investigated the effect of varying H2O2 concentration on 
immature (E-14 embryonic origin) and mature (10-day-old) rat cortical astrocytes. 
Mature astrocytes showed no significant changes in LDH release as H2O2 
concentration increased. However, in immature astrocytes low concentrations of 
H2O2 (30 μM and 50 μM) showed no significant changes in LDH release but higher 
concentrations of H2O2 (100 μM- 1000 μM) showed a significant increase in LDH 
release compared to controls (Prieto and Alonso, 1999). This data suggests that 
mature astrocytes can cope better with H2O2 induced oxidative stress, compared to 
immature astrocytes and at 50 μM of H2O2 no significant changes to cell viability are 
observed, supporting the findings from our study. 
Ito et al (2013), treated primary rat astrocytes with 100 μM and 300 μM H2O2 for 1 
and 4 hrs and showed a significant decrease in percentage LDH release after 4 hrs, 
suggesting a decrease in cell viability. However, treating the astrocytes with 100 μM 
H2O2 for 4 hrs showed no significant decrease in LDH release compared to no 
treatment suggesting that cell viability does not significantly decrease (Ito et al., 
2013). Furthermore, following a 10 minutes treatment of 100 μM H2O2, caused a 
significant decrease in cholesterol synthesis for the first 6 hrs following treatment, 
and cholesterol synthesis was restored approximately 24 hrs after the stress. This 
would suggest that within our study a decrease in expression of HMGCR and 
SREBP2 would be predicted. Further studies have shown that in rat astrocytes 
treating cells with 100 μM H2O2 leads to an increase in cholesterol released from the 
plasma membrane (Ito et al., 2015). Further evidence from THP-1 macrophage 
treatment with H2O2 has shown a decrease in ABCA1 mRNA  expression (Marcil et 
al., 2006). This suggests that in astrocytes, H2O2 treatment may lead to a decrease 




There are certain limitations that need to be considered when interpreting the data 
from this study. One limitation of the double stress model is that it is unclear as to 
how much oxidative stress is present over the time period investigated. Previous 
work carried out within our lab group had showed that in LUHMES  following a single 
stress only 5% of LUHMES were positive for γH2AX foci after 24 hrs and following a 
double stress 18% of LUHMES were positive for γH2AX foci after 96 hrs (Irina 
Vázquez-Villaseñor, unpublished data). These are very low percentages of cells 
which are positive for γH2AX foci and therefore any changes caused by persistent 
DNA damage could be masked by the fact that the sample would be enriched with 
LUHMES and astrocytes with no DNA damage present. The clearance of H2O2 
within foetal astrocytic cultures and the impact H2O2 doses have on the generation of 
double stranded breaks and γH2AX foci needs to be determined. This will then allow 
a better assessment of the impact of the double stress model on astrocytes.  
Another limitation of this study is that both cell lines are of embryonic origin making it 
difficult to assess the specific effects of ageing as well as oxidative stress on 
cholesterol biosynthesis. To study the effects of aging these experiments could be 
repeated in adult astrocytes and neurons. Another approach could involve the use of 
patient derived fibroblasts that are reprogrammed to form induced neuronal stem 
cells (iNSCs) which can be differentiated to form neurons and astrocytes or directly 
reprogrammed fibroblast cells to produce iNeurons and iAstrocytes. These 
reprogrammed cells (iNSCs, iNeurons, iAstrocytes) will contain specific age-
associated changes, such as accumulation of DNA damage, compared to induced 
pluripotent stem cells (iPSCs) which may lose some of the epigenetic changes 
associated with ageing. These directly reprogrammed cells will help give a better 
understanding to how cholesterol synthesis is impacted during oxidative stress and 
AD (Erharter et al., 2019; Traxler, Edenhofer and Mertens, 2019). However, one 
advantage of using foetal cells is that it allows a more thorough examination of the 
cholesterol biosynthesis pathway within neurons and astrocytes, as currently the 
process of de novo cholesterol biosynthesis within the CNS is yet to be fully 
elucidated (Pfrieger and Ungerer, 2011; Zhang and Liu, 2015).  
Most in vitro neuronal studies make use of human neuroblastoma or murine derived 
cortical neurons however, in this study we used LUHMES. The advantages of using 
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LUHMES are that they are of human origin and cells can survive in a proliferative 
and post-mitotic phase with a relatively simple and quick differentiation protocol 
allowing for a synchronous population of cells to develop. However, LUHMES are 
very vulnerable to stresses associated with cell culture such as cell density, pH and 
temperature and can alter proliferation and differentiation of LUHMES. Previous work 
has shown that sub-confluent cultures are more vulnerable to oxidative stress and 
reduced clearance of H2O2 (Irina Vázquez-Villaseñor, unpublished data). Many 
studies make use of rodent derived astrocytes, however data shows that human 
astrocytes are much more complex and can better address questions related to 
human disease (Oberheim et al., 2006).  
Besides the limitations of qPCR quantification methods previously mentioned 
(3.6.13). Briefly, qPCR was quantified using relative quantification, when gene 
expression is calculated relative to a reference sample using the 2-ΔΔCt method. In 
this study, the relative concentration values for each gene were calculated relative to 
the mean ΔCt expression for control wells at each time point. The reference gene 
selected for this study was β-actin, as this was the same housekeeping gene used in 
previous studies involving LUHMES and astrocytes (Ratcliffe et al., 2018). The 
efficiency and handling prior to qPCR can be further improved by making use of a 
novel “zero-step” RT-qPCR (Chovancova et al., 2017). This novel method does not 
require an RNA extraction step and allows qPCR reaction mix to be prepared directly 
from cell lysates. This method allows for quicker and easier determination of gene 
expression and enables a more accurate assessment of gene expression at shorter 
and longer time points.   
4.6 Future work 
Due to COVID-19 pandemic, the forced closure of labs prevented experiments from 
being repeated and completed. Repeating the single and double stress experiments 
in both LUHMES and astrocytes would be upmost priority to attain sufficient 
biological repeats. Followed by optimisation of the double stress model to simulate 
the effects of oxidative stress in a co-culture model previously developed in our lab 
(Ratcliffe et al., 2018). Further technical validation of the double stress model in 
foetal astrocytes would also be required such as determining the clearance of H2O2 
depending on cell density. Furthermore, determining the lasting effects of the double 
207 
 
stress model will help assess astrocyte recovery in relation to oxidative stress. To 
further validate gene expression data, determining the levels of cellular cholesterol 
within LUHMES and astrocyte cultures following single and double stress will enable 
us to determine if changes in cholesterol biosynthetic gene expression translated to 
a change in overall cellular cholesterol levels.   
The literature suggests that within the CNS neurons and astrocytes work together to 
ensure overall homeostasis. Some evidence is suggesting that impairment in 
cholesterol transport from astrocytes and astrocytic cholesterol synthesis impairment 
could be involved in neurodegeneration. We hypothesise that dysregulation of 
cholesterol biosynthesis in the neuron-astrocyte unit contributes to dementia by 
impairing neuronal function due to impaired cholesterol metabolism and through 
generation of pro-oxidative stress metabolites. This hypothesis could be investigated 
within the co-culture system by pre-treating astrocytes using statins thereby, 
impairing cholesterol synthesis, and investigating the effect on neuronal health when 
the system is exposed to oxidative stress.  
4.7 Conclusion 
In this study, we found that in vitro neurons express genes involved in cholesterol 
biosynthesis suggesting that they are capable of producing their own cholesterol. We 
also found that a single and double exposure to H2O2 lead to the formation of double 
stranded breaks leading of oxidative DNA damage in both neurons and astrocytes. 
The effects of a single exposure to H2O2 are detected 24 hrs after the dose and the 
effects of a double exposure to H2O2 are detected 96 hrs after the dose in both cell 
types. Preliminary data from stress experiments showed that the four key genes 
involved in cholesterol homeostasis (HMGCR, ABCA1, SREBP2 and APOE) were 
expressed at all-time points following a single and double exposure to H2O2 in both 
cell types. The expression of these cholesterol biosynthetic genes in neurons 
suggests that cholesterol biosynthesis may be directly affected by oxidative stress, 
highlighting the importance oxidative stress plays in neurodegeneration in particular 
its effect on cholesterol. In this study a double stress model was employed to model 
the effects of chronic oxidative stress, compared to other studies which model the 





5.0 General discussion and future work 
5.1 General Discussion 
The overall aim of this thesis was to characterise how cholesterol production and 
cholesterol metabolism changed during the progression of AD. The overall 
hypothesis is that cholesterol dysregulation in the brain contributes to dementia and 
to progression of AD. We found that NFT pathology correlates with changes in gene 
expression of genes involved in cholesterol biosynthesis however, these changes in 
gene expression were not translated to changes in tissue cholesterol concentration. 
Immunohistochemical characterisation of key regulators of the cholesterol 
biosynthesis pathway (HMGCR and SREBP2) were localised to the neurons and 
astrocytes within the temporal cortex. However, quantification of HMGCR 
immunoreactivity and subsequent statistical analysis found that there were no 
significant associations with AD neuropathology progression and dementia status. 
This study found that moderate and high levels of brain cholesterol are associated 
with dementia.  However, the confidence intervals were wide suggesting uncertainty 
around this association. Therefore, further studies with a larger sample size would be 
required in order to confirm a real association. If a real association is present, then 
this study suggests that the effect of brain cholesterol on dementia is small.  In 
conclusion, the findings of this study suggest that cholesterol biosynthesis and 
metabolism are dysregulated in the brain however, whether this dysregulation 
contributes to dementia or AD progression remains unknown. 
5.2 Neuronal expression of HMGCR 
One of the key findings of this study was the neuronal expression of the enzyme 
HMGCR. Immunohistochemical characterisation of HMGCR in human post-mortem 
temporal cortex and frontal cortex tissue showed positive immunolabelling in 
pyramidal neurons. This staining pattern was observed across a pan- Braak and 
Braak cohort and an ageing series, from young to old, this suggests that the staining 
pattern is not a consequence of aging or neurodegeneration. Furthermore, HMGCR 
expression was confirmed at protein level in whole tissue protein extracts and in 
protein lysates from LUHMES cells demonstrating that HMGCR is expressed in vivo 
and in vitro in neurons. HMGCR expression was also found at an mRNA level in 
isolated neuronal populations from the temporal cortex and LUHMES. This is a novel 
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finding in human brain, as many studies have shown glial cells tend to undertake the 
bulk of the cholesterol production within the brain, whereas this study suggests that 
neurons possess the mechanisms to synthesise cholesterol (Pfrieger, 2003; Nieweg, 
Schaller and Pfrieger, 2009; Pfrieger and Ungerer, 2011; Zhang and Liu, 2015). To 
investigate this suggestion, HMGCR immunoreactivity and HMGCR mRNA 
expression in the temporal cortex was compared to temporal cortex total tissue 
cholesterol concentration, but no significant correlations were observed. The lack of 
correlation could be due to the limitations of the methods used. As mentioned before, 
IHC detection is not linear and therefore positive immunolabelling does not represent 
exact amount of antigen present (Matkowskyj et al., 2003). Additionally, gene 
expression data was calculated relative to the expression of β-actin over Braak and 
Braak group 1 using the 2-ΔΔCt method which is not an absolute measurement of 
HMGCR expression (Rao et al., 2013). Furthermore, tissue cholesterol concentration 
was determined using frozen temporal cortex blocks rather than an enriched 
population of neurons, hence other cells within the temporal cortex and white matter 
regions contribute to the total cholesterol concentration.   
One possible biological explanation for the lack of correlation between HMGCR 
expression and cholesterol concentration, could be that HMGCR activity is used to 
produce isoprenoids rather than cholesterol (Eckert et al., 2009). Isoprenoids such 
as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) are 
involved in the prenylation of proteins, a post-translational modification, allowing 
insertion into membranes and determining their function and localisation. FPP is 
formed from the mevalonate arm of the cholesterol biosynthesis pathway and is a 
precursor for both cholesterol and GGPP (Eckert et al., 2009). Neurons have been 
shown to maintain and activate the mevalonate pathway to produce isoprenoids and 
protein prenylation (Moutinho, Nunes and Rodrigues, 2017). One study showed that 
a product of protein prenylation, Rho GTPases, are essential for neuronal 
development playing a key role in axonal and dendritic outgrowth and stabilisation 
and synapse formation (Govek, Newey and Van Aelst, 2005). Interestingly, levels of 
FPP and GGPP are higher in the brain compared to other organs and in aged mice a 
reduction in association of Rho GTPases in the membranes of aged mice (Hooff et 
al., 2010; Afshordel et al., 2014). These studies demonstrate the crucial role of 
isoprenoids in the brain. A study in aged mice found that levels of FPP and GGPP 
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protein levels were significantly increased in aged mice (23 months old) compared to 
young mice (3 months old) (Hooff et al., 2012). A separate study showed that FPP 
and GGPP levels were significantly increased in AD brains compared to age 
matched controls in the frontal cortex (Hooff et al., 2008).   
Changes in isoprenoids have been observed in ageing and neurodegeneration 
(Edlund, Söderberg and Kristensson, 1994). One study found that treating primary 
rat basal forebrain neurons  with oligomeric Aβ showed a significant reduction in Rab 
and Ras protein prenylation (Mohamed et al., 2012). A similar effect was also 
observed in cortical regions of a transgenic mouse model of AD compared to age-
matched wild type controls. The decrease in prenylation by Aβ was attributed to a 
reduction in GGPP supply and inhibition of protein prenylation has been suggested 
to be involved in the mechanisms of neuronal death (Mohamed et al., 2012). One 
study reported the involvement of GGPP in γ-secretase activity in SH-SY5Y 
neuroblastoma cells; and FPP and GGPP increase the Aβ levels in H4 neuroglioma 
cells by increasing γ-secretase activity (Kukar et al., 2005; Urano et al., 2005).   
5.3 Cholesterol biosynthesis gene expression is altered with tau pathology 
In this study, the variation in neuronal HMGCR immunoreactivity was not associated 
with dementia status and AD pathology.  However, HMGCR relative gene expression 
in enriched neuronal populations isolated from human temporal cortex tissue was 
found to decrease with increasing tangle pathology and there was a significant 
moderate negative correlation with AT8 immunoreactivity. Furthermore, SREBP2 
relative gene expression in enriched neuronal populations isolated from human 
temporal cortex was increased with Braak and Braak stage, local cortical tangle 
pathology and AT8 immunoreactivity. This data suggests that the gene expression of 
key regulators of the cholesterol biosynthesis pathway (HMGCR and SREBP2) may 
be altered by NFT pathology. A decrease in HMGCR expression suggests that 
cholesterol levels may be optimum or accumulating hence a reduced mRNA 
expression to prevent an accumulation of cholesterol. However, the increase in 
SREBP2 expression suggests that an increase in SREBP2 cleavage and turnover 
and so an increase in SREBP2 expression has occurred to maintain SREBP2 
homeostasis. Interestingly, the changes in gene expression in the enriched neuronal 
population were not translated to a change in cholesterol concentration. Another 
possible explanation for the changes in SREBP2 expression could be that this could 
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be a compensatory mechanism as cholesterol levels are not altered. However, 
considering the fact that SREBP2 expression shows a trend to increase it may later 
lead to an increase in expression of SREBP2 target genes such as HMGCR (Sharpe 
and Brown, 2013b). Therefore, from this data alone it is difficult to determine the 
specific impact of AD neuropathology and dementia on neuronal cholesterol 
biosynthesis as mRNA or protein expression of HMGCR alone does not determine 
cholesterol biosynthesis, as mentioned earlier, HMGCR activity has also been shown 
to be involved in the protein prenylation and isoprenoid synthesis (Eckert et al., 
2009).   
5.4 The impact of oxidative stress on cholesterol biosynthesis 
This current study also investigated the impact of oxidative stress on cholesterol 
biosynthesis. In post-mortem human temporal cortex tissue, we found that HMGCR 
immunoreactivity did not correlate to markers of oxidative DNA damage. However, in 
enriched neuronal populations isolated from the temporal cortex HMGCR expression 
showed a moderate positive correlation with oxidative DNA damage markers 
(γH2AX). Further work found that HMGCR mRNA expression was observed 
following exposure to acute and a more chronic oxidative stress in neuronal 
monocultures. This data suggests that oxidative stress may have an impact on 
cholesterol biosynthesis. Previous work from our lab has shown overexpression of 
HMGCR in neurons isolated from frontal cortex of low Braak and Braak cases that 
had high DNA damage response as a result of oxidative stress (Simpson et al., 
2016). Exposing human neuroblastoma cells to oxidative stress also found an 
increase in HMGCR expression (Recuero et al., 2009). These studies also show that 
oxidative stress induces expression of HMGCR in neurons. Studies have shown that 
cholesterol influences the processing of APP, cholesterol enriched regions of the 
membrane favour the production of amyloidogenic Aβ and APP has also been 
shown to inhibit cleavage of SREBP2, preventing the nuclear localisation of the 
transcription factor domain (Cordy et al., 2003; Grimm, Rothhaar and Hartmann, 
2012, Pierrot et al., 2013b). The deposition of Aβ plaques is a source of oxidative 
stress leading to DNA damage within neurons (Kwiatkowski et al., 2016). This 
suggests that APP prevents the expression of SREBP2 target genes however, the 
presence of Aβ plaques leads to the generation of ROS and oxidative stress, which 
may induce HMGCR expression. This may lead to the aberrant activation of 
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cholesterol biosynthesis and cholesterol accumulation in cells, which increases the 
generation of Aβ. 
5.5 High brain cholesterol is associated with dementia  
This study found that moderate and high brain cholesterol was associated with 
increased risk of dementia. In this study the association with dementia was assessed 
independently of any presumed pathological basis. This effect was observed in both 
a univariate analysis adjusted for age at death and sex as well as a multivariate 
analysis adjusted for AD pathologies such as Braak and Braak, Thal and CAA 
pathology. Given the wide confidence intervals it suggests a weak and uncertain 
relationship and if any significant effect was present the effect is likely to be small. 
This study does not provide sufficient evidence to suggest that brain cholesterol 
modification, such as statins, would be an important therapeutic target for treating 
dementia. This is because it is still unclear whether the accumulation of cholesterol is 
bad for the neuron or whether the accumulation is a result of secondary changes due 
to other pathologies. However, considering the potential downstream functions 
associated with the cholesterol biosynthesis pathway, would provide important 
avenues for further investigation for targeting dementia.  
5.6 Future work 
To determine whether the mevalonate arm of the cholesterol biosynthesis pathway is 
being diverted to isoprenoid synthesis rather than cholesterol synthesis, 
characterisation of isoprenoids such as FFP and GGPP should be carried out. 
Immunohistochemical characterisation will determine the expression and localisation 
of isoprenoids in the temporal cortex. Dual labelling of isoprenoids and HMGCR 
would help determine if neuronal HMGCR immunoreactivity is associated with the 
non-sterol pathway. Immunohistochemical characterisation using both the CFAS and 
Edinburgh ageing cases will help determine if changes in isoprenoid expression are 
associated with aging and dementia status and pathology. Furthermore, isolating 
neurons from temporal cortex tissue using laser capture microdissection will help 
determine the changes that occur within both the mevalonate pathway and the 
isoprenoid synthesis pathway at an mRNA level.  
The cholesterol biosynthetic gene expression in temporal cortex isolations should be 
further validated in temporal cortex using immunohistochemistry to determine the 
localisation of CYP46A1 and ABCA1. Extending gene expression studies to different 
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areas of the brain such as the hippocampus and frontal cortex will help elucidate the 
changes that occur in cholesterol biosynthesis in different brain regions during AD. 
This will also demonstrate the role of cholesterol homeostasis in different brain 
regions and may highlight similarities and differences between the regions. 
Measuring cholesterol concentration in an ageing cohort will help also determine the 
effects of aging on tissue cholesterol concentration in specific regions of the brain.  
Another approach could involve the use of AD patient derived fibroblasts that are 
reprogrammed to form induced neuronal stem cells (iNSCs) which can be 
differentiated to form neurons and astrocytes or directly reprogrammed fibroblast 
cells to produce iNeurons and iAstrocytes. These reprogrammed cells (iNSCs, 
iNeurons, iAstrocytes) will contain specific age-associated changes, such as 
accumulation of DNA damage, compared to induced pluripotent stem cells (iPSCs) 
which may lose some of the epigenetic changes associated with ageing. These 
directly reprogrammed cells will help give a better understanding to how cholesterol 
biosynthesis is impacted in response to Aβ, tau and other contributing AD 
pathologies such as oxidative stress and neuroinflammation (Erharter et al., 2019; 
Traxler, Edenhofer and Mertens, 2019).  
In vivo models of AD can also be used to determine changes in cholesterol 
biosynthesis alongside AD neuropathology progression, this can be achieved using 
transgenic mice models. Transgenic mice models of AD usually consist of 
overexpressing human forms of wild type or mutant genes that are known to be 
involved in the formation of plaques and tangles (APP, MAP2, APOE, PSN1) (Myers 
and McGonigle, 2019). These models will allow the assessment of AD pathology on 
the cholesterol biosynthesis within the brain as LCM or cell sorting can be used to 
isolate neurons and astrocytes and determine the gene expression and protein 
levels of key regulators of the cholesterol biosynthesis pathway. Furthermore, 
transgenic mice models can also be used to determine the changes in brain tissue 
cholesterol in response to AD neuropathology. Certain limitations and considerations 
need to be considered when using transgenic mice models. First and foremost are 
the ethical consideration surround in vivo animal work and whether a different model 
may be more appropriate. Furthermore, wild type mice do not develop AD and 
mouse homologs of AD associated protein differ from human homologs. Also the 
expression patterns and phenotypes of microglia differ between the two species 
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hence, transgenic mice do not necessarily have the disease and does not accurately 






















6.0 Appendix  
6.1 Materials 
All chemicals/solutions were stored at room temperature (RT) unless stated 
otherwise. 
All chemicals were purchased from Sigma-Aldrich Ltd, (UK), unless stated otherwise. 
6.1.1 Histology materials 
6.1.1.1 Immunohistochemistry 
1x Tris-buffered Saline (TBS) pH 7.6 was prepared using 6.05 g of Tris base (Fisher 
Scientific, New Jersey, US) and 8.50 g of Sodium Chloride (Alfa Aesar, USA) in 1 L 
of distilled water. 
Xylene (Fisher Scientific, UK)  
Ethanol (VWR Chemicals, France) 
pH 9.5 buffer for antigen retrieval (Menarini Diagnostics, UK)  
Endogenous peroxidase blocking solution 3% (v/v) H2O2/Methanol (Fisher Scientific 
UK)/ (Fisher Scientific UK)  
Vectastain elite ABC Rabbit IgG kit (Vector Laboratories, UK). The goat blocking 
serum was prepared in 10 ml of TBS with 150 μl of serum. The secondary 
biotinylated antibody was prepared in 10 ml of 1.5% (v/v) goat serum with 50 µl of 
antibody solution. The avidin biotinylated complex horseradish peroxidase (ABC-
HRP) solution was prepared in 10 ml of TBS with 100 µl of both reagent A and 
reagent B, at least 30 minutes before use.  
3,3’-diaminobenzidine (DAB) (Vector Laboratories, UK). The DAB solution was 
prepared in 2.5 ml of d.H2O in which 50 µl of DAB buffer, 50 µl H2O2 and 100 µl of 
DAB substrate were added.  
Harris haematoxylin (Cell Path, UK)  
Scotts Tap water was prepared using 3.5 M of Sodium bicarbonate (Fisher Scientific, 
UK) and 20 M of Magnesium Sulphate (Fisher Scientific, UK) in 1 L of tap water. 
DPX mountant (Cell Path, UK) 
Antibodies used for IHC can be found in Table 2.3 
216 
 
6.1.1.2 Frozen Immunohistochemistry 
Acetone (VWR chemicals, France) and stored at 4°C 
6.1.1.3 Dual labelling immunohistochemistry 
Vectastain ABC-AP kit, Vector Laboratories, UK. Alkaline phosphatase-conjugated 
avidin-biotin complex (ABC-AP) was prepared by adding 100 μl of reagent ‘A’ and 
100 μl of reagent ‘B’ into 5 ml 1x TBS, prepared at least 30 minutes prior to use. 
Vector Red Alkaline Phosphatase substrate kit, Vector Laboratories, UK. Alkaline 
phosphatase substrate was prepared by adding 100 μl of reagents 1, 2, and 3 into 5 
ml Tris-HCL, 100mM. 
6.1.1.4 Bicinchoninic acid assay (BCA) 
BCA protein assay kit was purchased from ThermoFisher Scientific, USA. 
Extra strong lysis buffer was prepared in ultrapure H2O using 10 mM Tris-HCL (pH 
7.5), 0.5% (w/v) sodium dodecyl sulphate (SDS), 0.5% (w/v) sodium deoxycholate, 1% 
(v/v) Triton X-100, 75 mM sodium chloride, 10 mM ethylenediaminetetraacetic acid, 
2 mM sodium orthovandate, 1.25 mM sodium fluoride. Protease inhibitor cocktail 
(Roche, Germany) for mammalian tissues, 1 tablet was used for 10 ml of extra 
strong lysis buffer.  
Bovine serum albumin (BSA) standard was purchased from Thermo 
Scientific™Pierce™ Albumin standard (Pierce Endogen, USA).  
6.1.1.5 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
30% Acrylamide solution (Bio-Rad Laboratories Ltd, UK). 
Ammonium Persulphate (APS). 
Tetramethylethylenediamine (TEMED) (Thermo Scientific, UK). 
Resolving buffer was prepared using 1.5 M Tris-HCL pH 8.8 and 4% (v/v) of 10% 
(v/v) SDS solution. 
Stacking buffer was prepared using 0.5 M Tris-HCL pH 6.8 and 4% (v/v) of 10% (v/v) 
SDS solution. 
Running buffer was prepared using 24.8 mM Tris base, pH 8.3 and 192 mM glycine. 
4x Lammeli sample buffer was prepared using 40 mM Tris, pH 6.8, 12% (w/v) SDS, 
47% (v/v) glycerol, 0.12% (v/v) beta-mercaptoethanol and 0.6 M DTT.  
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The Precision Plus Dual Colour Protein Standard was used as the standard for 
Western Blot analysis (Bio-Rad Laboratories Ltd, UK). 
6.1.1.6 Western Blotting 
1x Phosphate buffered Saline (PBS) pH 7.4 was prepared using 8 M sodium chloride, 
0.2 M potassium chloride, 1.44 M sodium phosphate dibasic and 0.24 M potassium 
phosphate monobasic diluted in ultrapure H2O.  
Western blotting transfer buffer was prepared using 25 mM Tris, 100 mM glycine and 
10% (v/v) methanol. 
Nitrocellulose membrane (GE Healthcare, UK) 
Milk-PBST blocking solution was prepared using 5% (w/v) marvel original dried 
skimmed milk and 0.01% (v/v) tween 20 in 1x PBS 
Ponceau red was prepared using 0.1% (w/v) Ponceau S in 5% (v/v) acetic acid 
diluted in ddH2O.  
PBS-T wash buffer was prepared using 0.01% (v/v) Tween-20 in 1x PBS. 
Enhanced chemiluminescent substrate (ECL) (EZ-ECL Biological Industries, Israel).   
6.1.1.7 RNA Extraction from Post-Mortem Tissue 
Trizol (Fisher Scientific, UK) and stored at 4°C. 
Chloroform (Sigma-Aldrich, UK).   
Isopropanol (Fisher Scientific, UK). 
Ethanol (VWR Chemicals, France). 
RNAase free water (Zymo research, US).  
6.1.1.8 Rapid Immunohistochemistry for laser capture microdissection 
Acetone (VWR chemicals, France) and stored at 4°C. 
6.1.1.9 Toluidine Blue staining for neurons 
Toluidine blue is prepared using 1 g/l of Toluidine blue (TCS Biosciences LTD, UK) 
in dH2O.  
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Diethylpyrocarbonate (EMD Biosciences, UK) add 1 ml of 0.1% (v/v) 
Diethylpyrocarbonate (DEPC) to 1 L dH2O and mix well.  Autoclave and cool to RT 
prior to use. 
6.1.1.10 Laser Capture Micro-dissection (LCM) 
LCM caps (Arcturus, life technology, US). 
Picopure RNA isolation kit (Thermo fisher scientific, UK). 
6.1.1.11 cDNA synthesis 
Q-script (Quanta biosciences, US) and stored at -20°C. 
6.1.1.12 Cell enrichment validation 
5x Green firepole PCR mix (Solis Biodyne, Estonia) and stored at -20°C. 
Validation primers (Eurofins Genomics, Germany) reconstituted and stored at -20°C. 
Primer sequences can be found in table 3.1.  
6.1.1.13 Agarose Gel Electrophoresis  
Agarose (Bioline, UK). 
1x TAE buffer is used which has 0.04 M Tris-Acetate and 0.001 M EDTA in triple red 
pure water.  
Hyperladder V (Bioline, UK) and stored at 4°C. 
Ethidium Bromide (Sigma-Aldrich, UK). 
6.1.1.14 Quantitative real time PCR (q RT-PCR) 
PrimeTime qPCR assays were purchased from Integrated DNA Technologies (USA). 
Standard qPCR assays were reconstituted in 500 μl 1x TE buffer, the primer probe 
sequence can be found in table 3.2. 
TE Buffer, pH8, was prepared using 10 mM Tris and 0.1 mM EDTA in triple red pure 
water. 
1x LUNA universal probe qPCR master mix (New England Biolabs, UK). 
6.1.1.15 Amplex Red cholesterol Assay 
Amplex Red cholesterol assay kit was purchased from (Thermo fisher scientific, UK). 




6.1.2 Cell culture materials 
6.1.2.1 LUHMES cell culture 
Poly-L-Ornithine (p-L-o) was prepared using 50 μg/ml p-L-o in 1x PBS. 
Fibronectin was prepared using 1 μg/ml fibronectin in 1x PBS. 
Proliferation media was prepared using Advanced Dulbecco’s Modified Eagle 
Medium/Nutrient Mixture F-12, (Gibco, Thermo Fisher Scientific, UK), 1% (v/v) N2-
supplement (Gibco, Thermo Fisher Scientific, UK), 1% (v/v) L-glutamine (Lonza 
group Ltd, Switzerland), 1% (v/v) Penicillin/streptomycin (Lonza group Ltd, 
Switzerland) and supplemented with 40 ng/ml basic fibroblast growth factor (bFGF) 
(Peprotech EC Ltd, USA).  
Differentiation media was prepared using Advanced Dulbecco’s Modified Eagle 
Medium/Nutrient Mixture F-12, (Gibco, Thermo Fisher Scientific, UK), 1% (v/v) N2-
supplement (Gibco, Thermo Fisher Scientific, UK), 1% (v/v) L-glutamine (Lonza 
group Ltd, Switzerland), 1% (v/v) Penicillin/streptomycin (Lonza group Ltd, 
Switzerland) and supplemented with 1 μg/ml tetracycline (Sigma-Aldrich, UK). 
Trypsin-versene (Lonza group Ltd, Switzerland). 
6.1.2.2 Cryopreservation of LUHMES 
Foetal Bovine Serum (FBS) (Biosera, France). 
Dimethyl sulphoxide (DMSO) (Sigma-Aldrich, UK). 
6.1.2.3 Astrocyte cell culture 
Astrocyte media was purchased from ScienceCell Research Laboratories (USA) and 
supplemented with 2% (v/v) FBS, 1% (v/v) astrocyte growth supplement (AGS) and 
1% (v/v) penicillin/streptomycin all purchased from ScienceCell Research 
Laboratories, USA.  
6.1.2.4 H2O2 treatments  
30% H2O2 (v/v) (Sigma-Aldrich, UK).  
6.1.2.5 RNA extraction from cells using Trizol extracts 




4% Paraformaldehyde was prepared using 4% (w/v) Paraformaldehyde (Sigma-
Aldrich, UK) in 1x PBS and sterile filtered through 0.45 μM filter. 
0.3% (v/v) Triton-X100 (Sigma-Aldrich, UK) in 1x PBS. 
Blocking solution was prepared using 3% (v/v) Albumin bovine fraction V (BSA) 
(Melford Laboratories Ltd, UK), 0.01% Tween20 (Sigma-Aldrich, UK) in 1x PBS. 
Hoechst (33342) 10 mg/ml bisbenzimide H 33342 trihydrochloride (Sigma-Aldrich, 
UK). 
ClearMountTM mounting solution (Invitrogen, UK). 
Primary and secondary antibodies used for ICC can be found in table 4.2 and 4.3 
respectively.  
6.1.2.7 Lactate Dehydrogenase Assay (LDH) 


























6.2 HMGCR antibody optimisation  
To study the protein expression and localisation of HMGCR, antigen retrieval and 
antibody dilution were optimised for human post-mortem formalin fixed paraffin 
embedded brain tissue from the CFAS Cambridge cohort. Weak specific 
immunolabelling of pyramidal neurons was observed at the 1:100 and 1:50 antibody 
dilutions with both pressure cooker antigen retrieval conditions. Immunolabelling was 
not observed with both antibody dilutions with either microwave antigen retrieval 
conditions. Overall, a 1 hr antibody incubation time at RT showed a weak 
immunoreactivity for the pressure cooker treated sections while no immunoreactivity 
was present with microwave treated sections (Figure 6.1), indicating the pressure 
cooker antigen retrieval with a longer antibody incubation time would be required. No 
specific immunoreactivity was observed in IgG and negative controls. 
After an overnight incubation at 4°C, HMGCR immunoreactivity was strong for the 
1:50 antibody dilution, although a high amount of non-specific background 
immunoreactivity was also present for both pH6 and pH9 antigen retrieval buffers 
(Figure 6.2 E & F). An antibody dilution of 1:100 gave a very similar level of 
immunoreactivity as the 1:50 dilution but there appeared to be less non-specific 
background staining for both pH6 and pH9 buffers (Figure 6.2 A and B). Thus, 
optimal conditions for HMGCR IHC were the use of a pressure cooker with an 
alkaline (pH9) buffer. Optimal antibody conditions were a 1:100 with a 24hr 



















































Figure 6.1. HMGCR antibody 
optimisation, 1hr incubation 
at room temperature. 
Pressure cooker antigen 
retrieval at pH9 , 1:100 (A), 
1;50 (E), pressure cooker 
antigen retrieval at pH6 1:100 
(B), 1:50 (F), microwave 
antigen retrieval using EDTA 
buffer (pH8) 1;100 (C), 1:50 
(G), and microwave antigen 
retrieval using tris sodium 
citrate buffer (pH6) 1:100 (D), 
1:50 (H). Weak specific 
immunolabelling of pyramidal 
neurons (as indicated by the 
black arrows) was observed 
at the 1:100 and 1:50 
antibody dilutions with both 
pressure cooker antigen 
retrieval conditions (A, B, E & 
F). Immunolabelling was not 
observed with both antibody 
dilutions with either 
microwave antigen retrieval 
condition (C, D, G, H) No 
specific immunostaining was 
observed in either IgG 
isotype control (I) or negative 






















































Figure 6.2. HMGCR antibody optimisation, overnight 
incubation at 4°C. The sections were incubated overnight at 
4°C with the primary antibody. Both pressure cooker antigen 
retrieval at pH6, 1:100 (A) and 1:50 (B) showed weak 
immunostaining (black arrows). Pressure cooker antigen 
retrieval at pH9, 1:100 (C) and 1:50 (D) showed strong 
punctate immunostaining in pyramidal neurons (black 
arrows). No specific immunostaining was observed with 
either rabbit IgG isotype control (E) or negative control (F). 
Scale bar represents 100μm.  
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demographics Men, n = 37 Women, n = 60 Total, n = 97 
Age at death/ years    
70-74 5 5 10 
75-79 5 5 10 
80-84 9 9 18 
85-89 10 18 28 
90+ 8 23 31 
Average age at 
death/ years 83 83 83 
Median post-
mortem delay / hrs 21 15 17 
Median brain pH 6.43 6.54 6.50 
Dementia status/ n    
No Dementia 16 21 37 
Dementia 19 39 58 
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Table 6.4.1: Edinburgh Medical Research Council sudden death prefrontal 









Cause of Death Neuropathology 
16-30 
20 F 6.5 71 Suspension by ligature None 
29 M 6.5 44 Suspension by ligature Focal Tau, no neuritic plaques 
30 M 6.4 71 Unascertained None 
31-45 





39 F 6.4 43 Suspension by ligature None 
42 M 6.4 61 IHD None 
46-60 
46 M 6.5 52 IHD None 
48 M 6.3 72 CAD None 
50 M 6.3 45 IHD/CAD None 
52 M 6.4 91 Road traffic collision None 
57 M 6.5 66 IHD/CAD None 
61-75 
63 F 6.3 35 IHD/CAD Mild amyloid tangles and plaques 
70 F 6.5 79 Ruptured aneurysm 
Large vessel arteriosclerosis 
and ischaemic white matter 
pathology. Mild tau threads 
and tangles. Mild vascular 
amyloid, tangles and plaques. 
71 F 6.5 41 IHD 
Mild and focal vascular tau. 
Mild amyloid tangles and 
plaques 
74 M 6.3 66 IHD/CAD White matter pallor, mild tau tangles, plaques and treads 
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